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 CB1 receptors (CB1R) mediate the psychoactive and therapeutic effects of cannabinoids 
including ∆9-tetrahydrocannabinol (THC), the main psychoactive constituent in marijuana. 
However, therapeutic use is limited by side effects and tolerance and dependence with chronic 
administration. Tolerance to cannabinoid-mediated effects is associated with CB1R adaptations, 
including desensitization (receptor-G-protein uncoupling) and downregulation (receptor 
degradation). The objectives of this thesis are to investigate the regional-specificity in CB1R 
function and regulation. Previous studies have investigated CB1Rs in a subset of regions 
involved in cannabinoid effects, but an inclusive regional comparison of the relative efficacies of 
different classes of cannabinoids to activate G-proteins has not been conducted. A novel 
unbiased whole-brain analysis was developed based on Statistical Parametric Mapping (SPM) 
xv 
 
for 3D-reconstructed mouse brain images derived from agonist-stimulated [35S]GTPγS 
autoradiography, which has not been described before. SPM demonstrated regional differences 
in the relative efficacies of cannabinoid agonists methanandamide (M-AEA), CP55,940 (CP), 
and WIN55,212-2 (WIN) in mouse brains. To assess potential contribution of novel sites, CB1R 
knockout (KO) mice were used. SPM analysis revealed that WIN, but not CP or M-AEA, 
stimulated [35S]GTPγS binding in regions that partially overlapped with the expression of 
CB1Rs. We then examined the role of the regulatory protein Beta-arrestin-2 (βarr2) in CB1R 
adaptations to chronic THC treatment. Deletion of βarr2 reduced CB1R 
desensitization/downregulation in the cerebellum, caudal periaqueductal gray (PAG), and spinal 
cord. However in hippocampus, amygdala and rostral PAG, similar desensitization was present 
in both genotypes. Interestingly, enhanced desensitization was found in the hypothalamus and 
cortex in βarr2 KO animals. Intra-regional differences in the magnitude of desensitization were 
noted in the caudal hippocampus, where βarr2 KO animals exhibited greater desensitization 
compared to WT. Regional differences in βarr2-mediated CB1R adaptation were associated with 
differential effects on tolerance, where THC-mediated antinociception, but not catalepsy or 
hypothermia, was attenuated in βarr2 KO mice. Overall, studies using SPM revealed intra- and 
inter-regional specificity in the function and regulation of CB1Rs and underscores an advantage 
of using a whole-brain unbiased approach. Understanding the regulation of CB1R signaling 
within different anatomical contexts represents an important fundamental prerequisite in the 
therapeutic exploitation of the cannabinoid system. 
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I. Introduction 
 
A. Cannabis use: past and present 
 Marijuana, also known as cannabis, is perhaps one of the oldest psychoactive plants 
known to civilization. Its cultivation and utility as an industrial fiber (hemp fiber) has been 
approximated by modern historians to have started 10,000 years ago, roughly around pottery 
making and before metal working (Herer, 2000). Americans began using hemp for the 
production of rope, sails, and clothing in the 17th century. In the 1920s, Mexican immigrants 
introduced the recreational use of marijuana leaves, which sparked the early anti-marijuana 
campaigns and initiated an era of 'Reefer Madness' or national propaganda efforts to campaign 
against the "dangerous weed" (Herer, 2000). This eventually led Congress to pass the Marijuana 
Tax Act in 1937, which essentially criminalized marijuana and restricted its possession for 
authorized medical and industrial uses. Despite the enactment of stricter sentencing laws in the 
mid 1950s, marijuana usage surged in the 1960s following a shifting political and cultural 
climate. In 1996, the medical use of marijuana was first legalized in the state of California under 
the successful passing of proposition 215, allowing for the sale and medicinal use of marijuana 
for patients with debilitating conditions such as AIDS and cancer (Herer, 2000). Presently, 14 
states have legalized the medical use of marijuana and two states have passed laws that, although 
favorable towards medicinal usage of marijuana, does not legalize its use (www.ProCon.org, 
2010). 
 Currently marijuana, including various other tetrahydrocannabinol constituents of the 
plant (i.e. Δ9-tetrahydrocannabinol (THC), Δ8-tetrahydrocannabinol, etc.), is classified as a 
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Schedule I drug, along with other drugs of abuse such as heroin, lysergic acid diethylamide 
(LSD), and psilocybin (constituent of "Magic Mushrooms") (www.justice.gov, 2010). THC is 
also the primary psychoactive constituent in marijuana. Under the Controlled Substances Act for 
the United States, Schedule I drugs or substances are classified by the DEA to have a high 
potential for abuse, have no currently accepted medical indication, and lack safe standards of use 
under medical supervision. However, the FDA has approved two cannabinoids for use as 
medical therapies. For example, Dronabinol (Marinol) or synthetic THC is currently used to treat 
nausea and vomiting associated with cancer chemotherapy and to treat anorexia associated with 
AIDS-related weight loss. In addition, Nabilone, a synthetic cannabinoid that mimics the effects 
of THC, is used as a last resort to treat nausea related to cancer chemotherapy for patients not 
responsive to other existing anti-emetics. More recently in March 2010, encouraging results from 
a large scale U.S. phase IIb trial reported better pain scores (indicitive of pain management) 
comparing Sativex (an oromucusol spray containing THC and cannabidiol) versus placebo in 
patients with advanced stages of cancer. Plans are now underway to commence Phase III trials 
for Sativex in managing cancer pain. 
 
B. The Endocannabinoid System 
 Pharmacological evidence of a cannabinoid receptor in brain was first suggested by 
Howlett and Fleming in their work demonstrating the inhibition of adenylate cyclase by 
cannabimimetic drugs (Howlett and Fleming, 1984). This work eventually led to the elucidation 
and characterization of a cannabinoid agonist binding site (Devane et al., 1988), and shortly 
thereafter, the CB1 receptor was cloned from rat cerebral cortex cDNA library (Matsuda et al., 
1990). A second cannabinoid receptor (CB2) with 44% structural homology to CB1, has also 
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been cloned from cDNA prepared from the human promyelocytic leukaemic line HL60 (Munro 
et al., 1993). Molecular characterization and identification of these receptors stimulated a search 
for their endogenous ligands. Several lipid-based compounds have since been isolated from brain 
and identified as endogenous ligands to the cannabinoid receptor. Of these, 
arachidonoylethanolamide (also known as anandamide; AEA) (Devane et al., 1992) and 2-
arachidonoylglycerol (2-AG) (Mechoulam et al., 1995; Sugiura et al., 1995) are best 
characterized. Unlike classical neurotransmitters, endocannabinoids are not stored in vesicles, 
but are synthesized on demand via membrane phospholipid precursors. Synthesis of AEA was 
previously thought to occur from the enzymatic hydrolysis of N-acyl-phosphatidylethanolamines 
(NAPE) by a NAPE selective phospholipase D (Schmid et al., 1990). However, studies using 
NAPE-PLD knockout mice demonstrated equivalent levels of AEA as in wild-type animals 
(Leung et al., 2006), suggesting existence of other biosynethic pathways. Alternative NAPE-
PLD independent pathways thought to contribute to the synthesis of AEA include for example 
the double-deacylation of NAPE by α/β-hydrolase 4 (ABH4) followed by posphodiesterase-
mediated cleavage by GDE1 (Simon and Cravatt, 2006). In addition, phospholipase C-catalyzed 
cleavage of NAPE and its subsequent dephosphorylation (Liu et al., 2006) represents another 
potential biosnythetic pathway. Interestingly, a recent report found unaltered levels of AEA in 
GDE1 knockout mice, as well as only partial disruption of N-acyl ethanolamine biosynthesis in 
GDE1/NAPE double knockout mice (Simon and Cravatt, 2010). Collectively, these reports 
suggest multiple biosynthetic pathways for AEA, which may be brain region-dependent. As for 
2-AG, the biosynthetic substrates are the sn-1-acyl-2-arachidonoylglycerols (DAGs) and requires 
DAG lipase (DAGL) (Bisogno et al., 2003). Recent studies using mice lacking either DAGL 
isotype (DAGLα or DAGLβ) suggest that DAGLα is the primary biosynethic enzyme for 2-AG 
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in the CNS as well as an important mediator of retrograde signaling (Gao et al., 2010; Tanimura 
et al., 2010). 
 The actions of endocannabinoids are relatively short lived and endocannabinoid tone is 
regulated by metabolic enzymes that are codistributed in most cannabinoid containing brain 
regions. Fatty acid amide hydrolase (FAAH) is primarily responsible for the metabolism of AEA 
(Cravatt et al., 1996) and other fatty acid amides, whereas monoacylglyceride lipase (MAGL) is 
the major metabolic enzyme of 2-AG (Dinh et al., 2002). The regional differences in the 
distribution of these two enzymes and their intricate cellular compartmentalization within the 
CNS (Dinh et al., 2002; Gulyas et al., 2004; Thomas et al., 1997), creates an elaborate metabolic 
machinery to modulate endocannabinoid signaling. Together, the cannabinoid receptors, 
endogenous ligands that bind these receptors, and degradative and synthetic enzymes, comprise 
the endogenous cannabinoid system. 
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A 
CB1 receptor antagonist 
SR141716A (Rimonabant) 
 
CB2 receptor antagonist 
SR144528 
 
B  
Phytocannabinoid 
Δ9-tetrahydrocannabinol 
 
Non-classical 
CP 55,940 
 
Aminoalkylindole 
WIN 55,212-2 
 
 
Figure 0.1. Chemical structures of CB1 and 
CB2 receptor selective antagonists (A) and 
different classes of cannabinoid receptor 
agonists (B). 
Eicosanoid 
(R)-(+) Methanandamide 
 
 
Arachidonoylethanolamide (Anandamide) 
 
2-Arachidonoylglycerol (2-AG) 
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C. Cannabinoid Pharmacology 
 The cannabis plant, Cannabis sativa, contains a mixture of cannabinoids (Elsohly and 
Slade, 2005) including ∆9-tetrahydrocannabinol (THC), the primary psychoactive constituent of 
marijuana. The structural elucidation of THC by Gaoni and Mechoulam in 1964 (Gaoni and 
Mechoulam, 1964) led to the development of more potent synthetic cannabinoid agonists, such 
as CP55,940 and WIN55,212-2 (Fig. 0.1), which has advanced our understanding of the 
cannabinoid system (Melvin and Johnson, 1987). CP55,940 ((-)-cis-3-[2-hydroxy-4-(1,1-
dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol), a bicyclic analog of THC, 
belongs to the class of nonclassical cannabinoids. It is a high efficacy partial agonist at the CB1 
receptor and is a full agonist at the CB2 receptor, with similar binding affinities to both CB1 and 
CB2 receptors (Howlett et al., 2002). CP55,940 is one of the most widely used radiolabeled 
cannabinoid ligands and has historical significance, as it was first used to demonstrate a specific 
cannabinoid binding site (Devane et al., 1988) and to anatomically map the distribution of 
cannabinoid receptors in rat brain tissue (Herkenham et al., 1991). WIN55,212-2 (R-(+)-[2,3-
Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-
naphthalenyl)methanone mesylate) is a full agonist at CB1 receptors, and the prototype of the 
aminoalkylindole family (Howlett et al., 2002). Synthesis of a CB1 selective antagonist 
SR141716A (N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazole-
carboxamide) helped establish the specificity of CB1 receptor-mediated effects, and demonstrate 
that most in vivo effects of cannabinoids are mediated by the CB1 receptor (Rinaldi-Carmona et 
al., 1994). SR141716A is a highly potent CB1 antagonist that effectively inhibits and reverses 
CB1-mediated effects both for in vitro and in vivo assays (Howlett et al., 2002). SR141716A has 
also been shown to act as an inverse agonist by reducing the constitutive activity (functional 
7 
 
coupling to effector mechanisms in the absence of an agonist) of CB1 receptors, although 
concentrations significantly greater than the normal dose range to antagonize CB1-mediated 
effects may be required in brain (Bouaboula et al., 1997; Landsman et al., 1997; Pertwee, 2005a; 
Sim-Selley et al., 2001). 
 The eicosanoid class of cannabinoids include the endocannabinoids AEA and 2-AG, 
which are derivatives of arachidonic acid and are the prototypic and most investigated members 
of this group. Although AEA and 2-AG have similar binding affinities, 2-AG exhibits higher 
efficacy than AEA at both CB1 and CB2 receptors (Pertwee, 2005b). Because AEA is highly 
susceptible to metabolism, synthetic derivates such as (R)-(+)-Methanandamide have been 
developed, which exhibit greater metabolic stability, affinity, and CB1 selectivity (Di Marzo et 
al., 2001; Lin et al., 1998).  
 
D. Cannabinoid receptor neuroanatomy 
 Cannabinoid receptors are among the most abundant G-protein coupled receptors 
(GPCR) in the brain. CB1 receptors represent the predominant subtype in the CNS, whereas CB2 
receptor expression is restricted mainly to the immune system with limited expression in the 
CNS (Onaivi et al., 2006; Van Sickle et al., 2005). CB1 receptors are highly expressed in brain 
areas, including the cortex, basal ganglia, hippocampus, amygdala, and cerebellum (Herkenham 
et al., 1991; Jansen et al., 1992; Tsou et al., 1998). This neuroanatomical distribution is 
consistent with in vivo effects of cannabinoids, including antinociception, cognitive and memory 
disruption, catalepsy, decreased motor activity, and hypothermia (Dewey, 1986; Hollister, 1998). 
Studies utilizing CB1 receptor knockout mice (Zimmer et al., 1999) and CB1 receptor selective 
antagonists (Rinaldi-Carmona et al., 1994) have also indicated that most of the in vivo effects of 
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THC and other cannabinoids are primarily mediated via the CB1 receptor. Development of 
agonist-stimulated [35S]GTPγS autoradiography in our laboratory (Sim et al., 1995) allowed for 
the initial demonstration of regional differences in desensitization (see Receptor Desensitization 
below) of cannabinoid-receptor mediated G-protein activity following chronic administration of 
THC (Sim-Selley and Martin, 2002; Sim et al., 1996a). Agonist-stimulated [35S]GTPγS 
autoradiography provides not only a measurement of receptor-mediated G-protein activation, but 
also its neuroanatomical distribution. Figure 0.2 illustrates the first 3D image reconstruction of 
cannabinoid-stimulated G-protein activity produced by the full CB1 receptor agonist 
WIN55,212-2 and was derived from the average of multiple naive mouse brain (n = 7) images 
(image reconstruction is described in Chapter 1). CB1 receptor-mediated G-protein activity was 
found highest in regions including the amygdala and basal ganglia output nuclei, such as the 
substantia nigra and globus pallidus. Moderate levels of agonist-stimulated [35S]GTPγS binding 
was noted in the hippocampus, deeper layers of cortex, and the cerebellum. In medullary nuclei 
important for mediating respiration, CB1 receptors are low in abundance and therefore have low 
probability of lethality from overdose. 
 Studies on the subcellular localization of CB1 receptors revealed that they are highly 
expressed on axon terminals and preterminal segments (Hajos et al., 2000; Katona et al., 2001). 
Double-label immunostaining experiments in the forebrain have also indicated that CB1 
receptors are primarily found on GABAergic interneurons (Tsou et al., 1999). Cannabinoid 
receptor modulation of other neurotransmitters have also been demonstrated. Interestingly, the 
synthethic cannabinoid WIN inhibited glutamatergic neurotransmission in the hippocampus of 
both CB1 receptor wild-type and knockout mice (Hajos et al., 2001), a brain area that has 
previously been reported to contain putative non-CB1 sites and exhibiting WIN-stimulated G-
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protein activity ((Breivogel et al., 2001; Nguyen et al., 2010) and see Chapter 2). As opposed to 
inhibition, systemic administration of WIN has been shown to result in the efflux of 
norepinephrine in the rat frontal cortex, which appears to be modulated by the presnyaptic 
localization of CB1 receptors on noradrenergic axon terminals (Oropeza et al., 2007; Oropeza et 
al., 2005; Reyes et al., 2009). The spatial localization of CB1 receptors thus suggests that the 
cannabinoid system plays an important neuromodulatory role in the CNS. 
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Figure 0.2. Image average (N = 7) of WIN55,212-2-stimulated [35S]GTPγS binding in the 3D 
reconstructed mouse brain produced by a maximally effective concentration of the full CB1 
receptor agonist WIN55,212-2 (10 µM). A coronal, sagittal, and transverse section are shown in 
the upper left, upper right, and bottom left corners, respectively. Stimulated [35S]GTPγS binding 
values (nCi/g) are shown in pseudocolor, demonstrating highest and lowest magnitudes of 
stimulated G-protein activation in red/orange and blue/black, respectively. White lines represent 
the level of each respective anatomical plane as shown in the figure. Highest WIN-stimulated G-
protein activity are shown in the basal ganglia output nuclei (substantia nigra (SN), globus 
pallidus (GP)), amygdala (Amyg), cerebellum (Cb), hypothalamus (Hypo), hippocampus (Hipp), 
caudate-putamen (CPu), and cortex (Ctx). Details of 3D image reconstruction is described in 
Chapter 1 
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E. CB1 receptor signal transduction pathways 
 Cannabinoid receptors belong to the superfamily of seven-transmembrane spanning G-
protein coupled receptors (Fig. 0.3). CB1 receptors are predominantly expressed presynaptically 
and inhibit neurotransmitter release (Ishac et al., 1996; Kathmann et al., 1999; Nakazi et al., 
2000; Shen et al., 1996; Szabo et al., 1999). Agonist binding activates the receptor, which 
promotes interaction with its cognate heterotrimeric G-protein. This facilitates exchange of GDP 
for GTP, which binds and activates the α subunit. The activated α subunit then dissociates from 
the [βγ] complex, and each can activate intracellular effectors (Hall et al., 1999; Wickman and 
Clapham, 1995). The α subunit inactivates via an intrinsic GTPase, thus increasing the affinity of 
α for βγ, and association of the subunits. G-protein activation is catalytic because each receptor 
can activate multiple G-proteins (Gierschik et al., 1991; Sim et al., 1996c). CB1 receptors 
primarily activate the pertussis toxin-sensitive Gi/Go family of G-proteins that inhibit adenylyl 
cyclase (Howlett et al., 1986; Pacheco et al., 1991). CB1 receptors inhibit several types of voltage 
gated calcium channels, such as N-type and Q-type currents, and activate G-protein-coupled 
inwardly rectifying potassium channels 1 and 2 (Howlett et al., 2002). In addition, CB1 receptor 
activation has been shown to regulate ceramide metabolism and activate various intracellular 
kinases such as mitogen-activated protein (MAP) kinases, phosphatidylinosital-3-kinase, focal 
adhesion kinase, protein kinase B/Akt, and c-Jun N-terminal kinase (JNK1 and JNK2) (Howlett 
et al., 2002).  
 The production and release of endocannabinoids is thought to occur through a number of 
mechanisms and has been recently reviewed (Mackie, 2008). Wilson, Nicoll, and colleagues 
were the first to report feedback mechanisms involving endogenous cannabinoids by which a 
depolarized post-synaptic neuron can modulate the pre-synaptic release of an inhibitory or 
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excitatory neurotransmitter (Wilson et al., 2001; Wilson and Nicoll, 2001, 2002). This retrograde 
modulation by endocannabinoids is also referred to as depolarization-induced suppression of 
inhibition (DSI) or excitation (DSE). The underlying mechanism is now understood to involve 
postsynaptic intracellular increases in calcium followed by retrograde inhibition of presynaptic 
terminals, which was first noted by Llano et al. (Llano et al., 1991). Further, a recent report 
found a loss of retrograde endocannabinoid signaling in mice lacking DAGLα, the biosynthetic 
enzyme of 2-AG, suggesting an important role for the endocannabinoid 2-AG in retrograde 
synaptic plasticity (Gao et al., 2010). Depolarization-induced release of endocannabinoids has 
also been demonstrated to occur through a Gq/11-dependent mechanism involving the activation 
of postsynaptic group I metabotropic glutamate receptors (Varma et al., 2001) or M1 and M3 
muscarinic receptors (Ohno-Shosaku et al., 2003). The actual underlying mechanism by which 
cannabinoid receptors modulate neurotransmitter release is unclear, however some evidence 
point to involvement of various ion channels, including K+ channels (Kreitzer et al., 2002), or N 
or P/Q type Ca2+ channels (Guo and Ikeda, 2004). 
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Figure 0.3. Two-dimensional structure of the human CB1 receptor. Three extracellular (E1-3) 
and three intracellular (C1-3) regions are represented along with highly conserved key residues 
shown in bold. Sequences in the third intracellular domain (C3) important for Gαi1 and Gαi2 and 
C-terminal residues important for Gαo and Gαi3 interactions are represented by shaded circles. 
Red colored amino acid letters illustrate proposed binding site residues within 2.5 Å of the bound 
non-classical cannabinoid CP55,940 (figure and caption adapted from Mukhopadhyay et al., 
Chem Phys Lipids 2002)  
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F. Acute effects of cannabinoids 
 At present, there is no evidence for structural changes in the brain following ether acute 
or chronic use of marijuana. Using magnetic resonance imaging (MRI), frequent marijuana users 
showed no evidence of cerebral atrophy or gross reductions in brain volume (Block et al., 2000). 
The in vivo effects of THC and other cannabinoids are well characterized. The most established 
behavioral model used to assess a wide array of cannabinoid-mediated effects in laboratory 
animals is the classical tetrad model, developed by Martin and colleagues (Compton et al., 1993). 
Acute administration of THC consistently produces hypothermia, catalepsy, antinociception, and 
decreased spontaneous motor activity. Porrino and colleagues (Freedland et al., 2002) have 
investigated the changes in cerebral metabolism using quantitative 2-[14C]deoxyglucose (2-DG) 
autoradiography following THC administration. When assessed 15 minutes after drug 
administration, the acute effects of THC dose-dependently decreased regional brain metabolism, 
as measured by the rate of local cerebral glucose utilization. Other prominent central effects of 
cannabinoids include memory and cognitive impairment, which has been demonstrated in a 
number of memory paradigms showing the disruptive effect of cannabinoids on memory related 
tasks (Ferrari et al., 1999; Varvel et al., 2001). Interestingly, endocannabinoids have been 
implicated in the extinction of aversive memories (Marsicano et al., 2002). In this study, elevated 
levels of endocannabinoids were found in the basolateral amygdala following tone presentation 
during extinction trials. In addition, the authors found that both CB1 knockout mice and CB1 
wild-type mice treated with the CB1 receptor antagonist SR141716A had impaired extinction of 
fear-conditioned tests.  
 Previous reports have demonstrated the effects of cannabinoids on synaptic plasticity, 
particularly long-term potentiation (LTP). Nowicky and colleagues first demonstrated the effects 
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of THC on modulating the duration of LTP of the CA1 evoked field potential in rat hippocampal 
slices (Nowicky et al., 1987), thus providing insight into the role of endocannabinoids in 
synaptic plasticity. Inhibition of long-term depression (LTD) by cannabinoids has also been 
demonstrated in the hippocampal CA1 field, induced by lower frequency stimulation (Misner 
and Sullivan, 1999).  
 One other notable effect of cannabinoids include its orexogenic effect. Hyperphagia 
generally follows THC administration (Williams et al., 1998), whereas CB1 receptor blockade 
results in a reduction in food intake (McLaughlin et al., 2003).  
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Figure 0.4. Regulatory mechanisms of G-protein coupled receptors. Following prolonged 
exposure to an agonist, GPCR signaling is attenuated through receptor desensitization (1), 
internalization (2), or downregulation where it is targeted for degradation (3). Resensitization or 
recycling of the receptor may also occur following internalization (from Luttrell et al, 2002). 
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G. Regulation of cannabinoid receptors: mechanisms of cannabinoid tolerance 
 Tolerance occurs when there is a reduction in the magnitude of a drug effect following 
chronic administration at a constant drug dose. Chronic administration of THC and other 
synthetic cannabinoid agonists produce tolerance to the behavioral effects of cannabinoids, 
which have been well characterized in laboratory animals. These include, for example, tolerance 
to cannabinoid-mediated antinociception, hypothermia, catalepsy, and reduction in spontaneous 
motor activity (Carlini, 1968; Gonzalez et al., 2005; Pertwee et al., 1993). Interestingly, tolerance 
to the memory impairment effects of cannabinoids does not appear to develop following 
prolonged administration (Barna et al., 2007; Boucher et al., 2009; Ferraro and Grilly, 1973). 
Studies in humans have been limited, however tolerance to the cardiovascular (Benowitz and 
Jones, 1975) and memory/cognitive impairment (D'Souza et al., 2008) effects of cannabinoids 
have been demonstrated. At the molecular level, chronic cannabinoid exposure results in the 
functional uncoupling of CB1 receptors from G-proteins (desensitization) (Sim et al., 1996a) and 
agonist-promoted internalization (Jin et al., 1999); followed by either receptor degradation in 
lysosomes (downregulation) or recycling to the cell membrane (resensitization) (Sim-Selley et 
al., 2006; Tappe-Theodor et al., 2007). These receptor adaptations are thought to contribute to 
the development of cannabinoid tolerance. 
 
Receptor downregulation 
 Adaptation to chronic administration of cannabinoids does not appear to be 
pharmacokinetic (Dewey et al., 1973; Martin et al., 1976), but rather pharmacodynamic in 
nature. It is also likely that these neuroadaptive changes are reversible. For example, chronically 
administering THC for 90 days in rats resulted in no changes in CB1 receptor levels in the 
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striatum, cerebral cortex, cerebellum, hippocampus, and brainstem/spinal cord, following a 60 
day recovery period (Westlake et al., 1991). However, studying CB1 receptor properties at earlier 
time points after chronic treatment can resolve characteristic CNS adaptations that have been 
implicated to contribute towards cannabinoid tolerance. 
 Agonist-activated GPCRs are rapidly phosphorylated by G protein-coupled receptor 
kinases (GRKs) and subsequently bound by arrestin proteins, which facilitate receptor 
uncoupling from G-proteins (see Fig. 0.4 and next section, Receptor Desensitization) and 
receptor internalization (Claing et al., 2002; Lefkowitz et al., 1990). These molecular events have 
been well characterized for the β2-adrenergic receptor (β2AR). Like the β2AR, CB1 receptors are 
internalized through clathrin-coated pits into early endosomes and this process requires the 
extreme carboxy tail of the receptor (Hsieh et al., 1999). Internalization occurs rapidly, and its 
rate correlates well with the relative efficacy of cannabinoid agonists to activate G-proteins. 
Recycling of internalized CB1 receptors back to the cell membrane also occurs rapidly following 
brief incubations with agonist. However, longer agonist incubation times (60 minutes) may result 
in irreversible internalization and receptor degradation (downregulation) via lysosomes. The 
targeting of CB1 receptors toward lysosomal degradation appears to require G-protein-associated 
sorting protein 1 (GASP1), a protein that has been shown to interact with CB1 receptors and was 
required for agonist-induced downregulation of CB1 receptors in spinal neurons (Tappe-Theodor 
et al., 2007). A recent report also demonstrated that GASP1 and CB1 receptors were colocalized 
in both GABAergic and glutamatergic cells of the thalamus (Martini et al., 2010). The authors of 
this study also found a loss in downregulation in both the spinal cord and cerebellum, as well as 
a lack of tolerance development to antinociception, motor incoordination, and locomotor 
hypoactivity, but not hypothermia, in GASP1 knockout mice treated chronically with WIN. In 
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other studies, prolonged agonist exposure times required new protein synthesis in order to 
normalize receptor levels (Hsieh et al., 1999). In fact, CB1 receptor protein levels, but not CB1 
receptor mRNA, matched the downregulation of CB1 receptors as well as its recovery after 
cessation of THC treatment, suggesting that regulation of CB1 receptors primarily occurs at the 
level of the protein (Sim-Selley et al., 2006). 
 Downregulation of CB1 receptors was first suggested by Oviedo et al. as one of the 
underlying receptor-mediated mechanisms of cannabinoid tolerance using quantitative 
[3H]CP55,940 binding autoradiography in rat forebrain sections (Oviedo et al., 1993). In that 
study, animals were injected once daily with intraperitoneal (i.p.) of THC (10 mg/kg), CP55,940 
(1, 3, or 10 mg/kg), or vehicle for 14 days. Behavioral assessment of a separate group of rats 
under the same drug paradigm demonstrated tolerance to the inhibitory effects of THC and 
CP55,940 on spontaneous motor activity. Tolerance to the motor effects of THC and CP55,940 
was associated with a reduction in [3H]CP55,940 binding (indicative of receptor levels) in THC 
treated compared to vehicle control rats in all brain areas examined including: olfactory tubercle, 
septum, caudate-putamen, and nucleus accumbens. These changes in receptor density also 
followed a dose-response relationship, with greatest reduction in the higher dose group (70-80% 
decrease) and lowest reduction in the lower dose group (40-50% decrease). Another study also 
found a positive association with the magnitude of CB1 receptor downregulation and dose of 
THC administration (McKinney et al., 2008). Interestingly, as depicted in Figure 0.5, the 
magnitude of receptor downregulation in that study appeared to vary not only as a function of 
dose, but brain region as well. 
 The degree of cannabinoid tolerance appears to vary based on the specific behavior 
assessed. Martin and colleagues found a high degree of tolerance to the pharmacological effects 
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of CP55,940 when dosing mice chronically (2 mg/kg) twice a day for 6.5 days (Fan et al., 1996). 
The ability of CP55,940 to decrease motor activity, produce hypothermia, and induce catalepsy 
was reduced by 163-, 97-, and 19-fold, respectively. One implication from this study is that the 
magnitude of tolerance does not develop proportionally for various cannabimimetic effects. 
Thus, differential tolerance may reflect the relative adaptability of different regions to chronic 
cannabinoids. The regional specificity in CB1 receptor downregulation has further been 
demonstrated by Sim-Selley and Martin (Sim-Selley and Martin, 2002) using [3H]SR141716A 
binding autoradiography to localize changes in CB1 receptor levels. In this study, mice were 
treated with escalating doses of THC, WIN-55,212-2, or vehicle subcutaneously (s.c.) twice 
daily for 15 days. Densitometry showed that downregulation occurred in all CB1 receptor-
containing brain regions, albeit at varying magnitudes of reduction. High levels of 
downregulation (55-70%) were found in prefrontal cortex, nucleus accumbens, hippocampus, 
amygdala, hypothalamus, thalamus, and entorhinal cortex, and intermediate levels (45-50%) in 
cerebral cortex, caudate-putamen, periaqueductal gray (PAG), and cerebellum. The lowest levels 
(10-25%) were found in basal ganglia output nuclei: globus pallidus, entopeduncular nucleus, 
and substantia nigra. These three regions are also highly dense in CB1 receptor levels; however it 
is unclear if this is related to the relative lower magnitudes of downregulation observed in these 
brain areas. 
 
Receptor desensitization 
 Different families of regulatory molecules are known to participate in desensitization of 
GPCRs: second messenger-dependent kinases (i.e. PKA, PKC, etc.), GPCR kinases (GRKs), and 
the arrestins (visual and non-visual) (Gainetdinov et al., 2004; Lefkowitz, 1998). GRKs 
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(Gainetdinov et al., 2004) selectively phosphorylate agonist-activated receptors, which leads to 
the recruitment and binding of an arrestin protein (Lefkowitz, 1993, 1998). The binding of 
arrestin sterically hinders and disrupts the ability of the receptor to initiate signal transduction by 
functionally uncoupling the receptor and G-protein, a process called homologous desensitization 
as only the activated receptor is affected (Gainetdinov et al., 2004). In the brain, the major 
isoforms are arrestins 2 (βar1) and 3 (βarr2), each having its unique distribution pattern in the 
CNS (Gurevich et al., 2002). β-arrestin is also involved in receptor internalization through its 
interactions with key proteins, including clathrin and adaptor protein-2 (Moore et al., 2007). 
There are seven known mammalian GRK isotypes. GRK2 and GRK3, also known as β-
adrenergic receptor kinase 1 and 2, respectively, are the predominant CNS isotypes and are 
widely distributed throughout synapses in the brain (Arriza et al., 1992). 
The role of GRK and β-arrestin in mediating CB1 receptor desensitization has been 
demonstrated in the Xenopus oocyte expression system (Jin et al., 1999). Anatomically, the brain 
distribution of βarr2 is ubiquitous and partially overlaps with CB1 receptors, suggesting that 
these two proteins may be co-distributed in similar neuronal populations (Attramadal et al., 
1992). However, the regional abundance of βarr2 varies; with highest levels in cortex, 
hypothalamus, amygdala, and hippocampus, and lower levels in striatum and cerebellum 
(Attramadal et al., 1992; Gurevich et al., 2002). Chronic THC treatment also increases the 
expression of specific isoforms of GRKs and β-arrestins at different extents by brain region; with 
GRK2, GRK4, and βarr1 predominantly in striatum, GRK4 and βarr2 in cerebellum, and GRK2 
and βarr2 in hippocampus (Rubino et al., 2006). This regional specificity suggests differential 
regulation between neuronal populations, which could account for the differences in the 
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regulation of CB1 receptors in distinct brain regions (Breivogel et al., 1997; Sim-Selley, 2003; 
Sim et al., 1996a). 
The development of functional binding assays such as cannabinoid-stimulated 
[35S]GTPγS binding in homogenized membrane preparations (Selley et al., 1996) and brain 
tissue sections (Sim et al., 1995) offered the ability to quantitate CB1 receptor-mediated G-
protein activation. Sim et al. (Sim et al., 1996a) first demonstrated desensitization of CB1 
receptors in brain tissue sections from rats chronically treated with THC (10 mg/kg for 21 days). 
In this paradigm, almost all sampled brain regions exhibited a profound decrease in WIN-
stimulated [35S]GTPγS binding. Large decreases (>50%) in receptor-mediated G-protein 
activation were found in hippocampus, cortex, caudate-putamen, and cerebellum. However, a 
number of regions exhibited lesser desensitization (20-30%), such as PAG, septum, globus 
pallidus, and substantia nigra. Further intra-regional differences in the magnitude of 
desensitization occurred within brain areas. For example, greater desensitization was found in the 
ventral aspects (60%) compared to dorsal aspects (34%) of entorhinal cortex. Other reports have 
found desensitization of CB1 receptor-mediated G-protein activation in similar brain regions 
chronically administering other cannabinoid agonists including THC (Breivogel et al., 1999; 
McKinney et al., 2008; Sim-Selley and Martin, 2002; Sim-Selley et al., 2006), CP55,940 
(Rubino et al., 1997), and WIN55,212-2 (Sim-Selley and Martin, 2002; Sim-Selley et al., 2006). 
In most of these reports, the cortex, hypothalamus, and hippocampus, exhibited the largest 
magnitude in desensitization (ranging 50-70%), while others were moderate, such as cerebellum, 
thalamus, and PAG (ranging 40-50%). Regions dense with CB1 receptors, such as globus 
pallidus, entopeduncular nucleus, and substantia nigra, tend to be least sensitive to 
desensitization.  
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Sim-Selley and Martin explored the possible ligand-specific differences in receptor 
adaptation in mice that were chronically treated with equally active and escalating doses of either 
THC or WIN55,212-2 for 15 days (Sim-Selley and Martin, 2002). In this report, desensitization 
had an inverse association with agonist efficacy, as the low efficacy partial agonist THC 
produced greater desensitization than the full CB1 agonist WIN55,212-2 in most brain regions 
examined. No differences however were detected between the two agonists in the magnitude of 
CB1 receptor downregulation. When comparing the regional differences in the magnitude of 
desensitization between the two agonists, THC produced approximately 2-fold greater 
desensitization than WIN55,212-2 in striatum, hippocampus, hypothalamus, PAG and amygdala. 
This finding is in agreement with a different study using the same treatment paradigm (Sim-
Selley et al., 2006). Further, the regional desensitization profile was: hypothalamus > cortex > 
hippocampus > striatum > PAG > thalamus > globus pallidus > substantia nigra > 
entopeduncular nucleus (Sim-Selley and Martin, 2002). Interestingly, the degree of tolerance that 
developed in this paradigm differed by the type of behavior assessed and also by the agonist 
used. THC demonstrated a tolerance profile of antinociception (119 fold) > hypothermia (53 
fold) > decreased spontaneous motor activity (6.3 fold). These data indicate that differential 
tolerance can occur during chronic THC treatment. 
McKinney et al. (McKinney et al., 2008) explored the regional differences in CB1 
receptor adaptation after administration of varying doses of THC and assessed tolerance 
produced by this chronic paradigm. Mice were treated twice daily for 6.5 days with either 
vehicle, or varying doses of THC: Low = 10 mg/kg, Medium = ramping dose of 10 to 20 to 30 
mg/kg, High = ramping dose of 10 to 30 to 60 mg/kg. This paradigm demonstrated differential 
tolerance to THC-mediated effects and regionally-specific CB1 receptor adaptations as a function 
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of THC dose (Fig. 0.6). For example, desensitization of the striatum and globus pallidus occurred 
only after medium and high doses of THC administration, whereas CB1 receptor downregulation 
occurred after the high dose, with an insignificant trend following the medium dose. This dose-
dependent trend was also observed for measures of motor function that may be related to these 
brain regions. Here, tolerance to THC-mediated decrease in spontaneous motor activity and 
catalepsy was detected only in medium and high doses of THC treatment. In contrast, tolerance 
to THC-mediated hypothermia and antinociception (associated with desensitization in PAG) was 
evident beginning with the low dose group. The regional specificity in CB1 receptor 
desensitization may have implications in the development of tolerance to various cannabinoid-
mediated behaviors, and suggests that different mechanisms may exist in regulating CB1 receptor 
function. 
 Recently, studies in mice lacking FAAH, the enzyme primarily responsible for the 
degradation of AEA, showed that repeated administration of AEA produced less adaptive 
changes at the CB1 receptor than THC (Falenski et al., 2010). Conversely, sustained elevation of 
the endocannabinoid 2-AG produced by chronic administration of JZL184 (Long et al., 2009), an 
inhibitor of MAGL (the enzyme primarily responsible for the degradation of 2-AG), resulted in 
region-specific desensitization of CB1 receptor-mediated G-protein activity (Appendix Fig. A1, 
Schlosberg et al., in press). Results from these studies suggest that FAAH inhibition may be a 
better therapeutic target versus inhibition of MAGL or chronic treatment with synthetic 
cannabinoids, which produce greater tolerance to their own effects. 
 Data on CB1 receptor localization, interaction with various proteins, and signal 
transduction pathways, are providing important insight into the physiological role of the 
endogenous cannabinoid system. However, a growing challenge is the translation of knowledge 
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gained from mechanistic studies in cellular systems into native anatomical contexts. An 
important matter is understanding how the signaling and regulation of CB1 receptors may vary in 
different neuronal populations, and how this contributes to the in vivo effects of cannabinoids. 
Studies in this dissertation will address these questions, and introduce novel approaches for the 
study of CB1 receptor function and regulation in the CNS. 
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Dose (%Vehicle Control) 
Brain Region Low Medium High 
Hippocampus 58.06 37.33 42.62 
Cerebellum 72.12 53.54 46.24 
Striatum/Globus Pallidus 87.39 65.98 54.54 
 
 
Figure 0.5. CB1 receptor downregulation following chronic THC administration as a function of 
THC dose and brain region. Bmax values were determined through [3H]SR141716A saturation 
binding in membrane preparations from various brain regions, and is represented as %Vehicle 
Control. A low (10 mg/kg), medium (escalating from 10 to 20 to 30 mg/kg), or high (escalating 
from 10 to 30 to 60 mg/kg) dose of THC was administered twice daily for 6.5 days. A 3D 
pseudocolored gradient is shown to highlight differences in the magnitude of CB1 receptor 
downregulation as a function of dose and region (adapted from McKinney et. al., 2008)  
27 
 
 
 
Dose (%Vehicle Control) 
Brain Region Low Medium High 
Hippocampus 54.59 48.35 39.05 
Cingulate cortex 61.64 64.82 43.79 
Preoptic area 83.13 66.46 21.06 
Nucleus accumbens 74.53 87.76 45.08 
Cerebellum 76.66 63.84 57.40 
Substantia nigra 83.64 82.75 80.85 
Caudate-putamen 90.65 91.18 60.64 
Entopeduncular nucleus 92.55 84.29 95.51 
Globus Pallidus 100.52 92.51 78.18 
 
Figure 0.6. CB1 receptor desensitization following chronic THC administration as a function of 
THC dose and brain region. A low (10 mg/kg), medium (escalating from 10 to 20 to 30 mg/kg), 
or high (escalating from 10 to 30 to 60 mg/kg) dose of THC was administered twice daily for 6.5 
days. WIN-stimulated [35S]GTPγS binding is represented as %Vehicle Control. A 3D 
pseudocolored gradient is shown to highlight differences in magnitude of CB1 receptor 
desensitization as a function of dose and region (adapted from McKinney et. al., 2008)  
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II. Rationale and Hypotheses 
 
 CB1 cannabinoid receptors belong to the superfamily of G-protein coupled receptors 
(GPCR) and are widespread throughout the CNS, with greatest abundance in the basal ganglia, 
hippocampus, and cerebellum. CB1 receptors also mediate the psychoactive and therapeutic 
effects of ∆9-tetrahydrocannabinol (THC), the primary psychoactive constituent of marijuana. 
Interestingly, the acute and chronic cellular actions of CB1 receptors vary by brain region, 
suggesting that specificity in CB1 receptor signaling may contribute to differential therapeutic 
versus side effects of cannabinoids as well as its chronic effects, including tolerance and physical 
dependence. Our laboratory and others have found regional differences in the regulation of CB1 
receptors by examining a subset of CB1 receptor containing regions that are likely to mediate 
various robust cannabimimetic effects, including memory disruption, antinociception, catalepsy, 
hypothermia, and reduction in spontaneous motor activity. However, the endocannabinoid 
system is implicated in diverse physiological functions, highlighting the importance of 
conducting an anatomically inclusive analysis. Yet, it has been difficult to conduct a 
comprehensive and thorough anatomical study of CB1 receptors due to limitations in 
autoradiographic analytical approaches and inherent challenges in defining anatomical 
boundaries for sampling pre-defined regions of interest; especially when the distribution of 
differences are not known a priori. 
 In the following studies in this thesis, we propose that the acute and chronic signaling and 
regulation of CB1 receptors occur in a region-specific manner. Furthermore, development of an 
unbiased whole-brain based approach will facilitate answering questions at the receptor level 
among anatomically distinct systems. This will be accomplished by using a novel voxel-based 
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image analysis approach, based on Statistical Parametric Mapping (SPM), to systematically 
investigate CB1 receptor signaling throughout the brain, which has previously not been 
described. In the first chapter, we establish an approach to reconstruct mouse brain images 
derived from agonist-stimulated [35S]GTPγS binding autoradiographic data into 3D volumetric 
images. In addition, various image processing techniques are implemented and assessed. This 
process lead to the development of a novel analytic approach for assessing autoradiographic data 
based on SPM that was subsequently applied in the following studies. 
 Ligand-dependent regulation of CB1 receptors has been demonstrated in cellular systems 
examining various adaptations such as receptor desensitization, internalization, and 
downregulation. CB1 receptors  have also been shown to exhibit domain selectivity for coupling 
to various subtypes of Gαi/o, and in various brain regions, activate different subtypes of G-
proteins with varying efficacy and potency following agonist stimulation. Few studies however 
have directly compared the relative efficacy of different classes of cannabinoids in relation to 
receptor-mediated G-protein activation as a function of region. In the second chapter, we 
hypothesize that cannabinoid-receptor mediated G-protein activity will differ by cannabinoid 
ligand and that relative efficacy of these ligands will vary by brain region. Regional differences 
in the relative efficacy of cannabinoid agonists may highlight unique signaling properties of the 
CB1 receptor, or suggest the existence of non-CB1 sites. In addition, these findings may have 
implications regarding the regulation of CB1 receptors following chronic administration of THC. 
For example, regional differences in the signaling of CB1 receptors may invoke different 
downstream regulatory pathways in a region-specific manner, which may contribute to 
differential tolerance to various cannabinoid-mediated effects. 
30 
 
 The regulation of cannabinoid receptors may potentially have important implications in 
regard to cannabinoid tolerance. Understanding the underlying mechanisms leading to 
cannabinoid tolerance not only is important from a therapeutic standpoint, but may also give 
insight into physical dependence or addiction to cannabinoids through potentially convergent 
regulatory pathways. This also has direct clinical relevance because THC and its synthetic 
derivatives are currently approved in the U.S. and indicated for treatment of adverse symptoms 
related to cancer chemotherapy and the anorexic effect of AIDS-related wasting syndrome. In 
addition, some states have permitted the medicinal use of marijuana. However, THC is the 
primary psychoactive constituent of marijuana, which is still the most commonly abused illicit 
drug in the U.S. Previously our laboratory demonstrated region-specific differences in the 
magnitude of CB1 receptor desensitization and downregulation following chronic THC 
treatment. Other reports have demonstrated the importance of various regulatory proteins, such 
as β-arrestin-2 (βarr2), and kinases, such as GPCR kinase, in the regulation of CB1 receptors in 
cellular systems. However, the in vivo physiological role of βarr2 in relation to the regulation of 
CB1 receptor function is unclear. The final chapter will test the hypothesis that βarr2 plays a role 
in the regulation of CB1 receptor desensitization and downregulation following chronic 
administration of THC. We predict that mice lacking βarr2 will exhibit a region-specific 
attenuation in the desensitization and downregulation of CB1 receptors to chronic THC 
treatment, for example, in particular CB1 receptor brain regions with high abundance of βarr2. 
Further, we propose that regional differences in βarr2-mediated regulation of CB1 receptors will 
impact the development of tolerance to THC-mediated effects. Specifically, region-specific 
regulation of CB1 receptor adaptation will result in a differential profile of tolerance to THC-
mediated effects in associated anatomical systems. 
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 Overall, we hypothesize that regional-differences in the acute and chronic signaling of 
CB1 receptors reflect differences in its regional regulation, and that this specificity will be 
revealed using a novel whole-brain unbiased approach. This will be important in understanding 
not only the differences in the regulation of CB1 receptors within various anatomical brain 
regions, but may also provide insight as to how this regional-specificity may contribute or play a 
role in the development of tolerance to various cannabinoid-mediated effects. As this novel 
approach is not restricted to predefined anatomical boundaries, we predict that it will extend our 
understanding of the function and regulation of the cannabinoid system with unprecedented 
anatomical precision. 
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III. Methods 
 
Subjects 
 Mice were generally housed four to six per cage and maintained on a 12-hr light/dark 
cycle in a temperature controlled environment (20-22°C), with free access to food and water. All 
experiments were performed with the approval of the Institutional Animal Care and Use 
Committee at Virginia Commonwealth University in accordance with the Guide for Care and 
Use of Laboratory Animals (National Research Council, 1996). 
 
Drug treatment and Behavioral Evaluation 
 Specific drug treatments are described within individual chapters. 
Antinociception. Antinociception is assessed using the tail warm water withdrawal assay at 
52°C. The intensity of the warm water stimulus is fixed to yield control latencies of 3-4 sec, and 
an automatic 8 sec cutoff is used to prevent tissue damage. Tail-flick response latencies are 
expressed as the percentage of the maximum possible effect (%MPE) calculated by: %MPE = 
[(test latency – control latency)/(cut-off time/control latency)]x100% 
Rectal Temperature. Core temperature to the nearest 1°C is measured by inserting a rectal probe 
connected to a Telethermometer (Yellow Springs Industries, Inc.) to a depth of 4.5 cm. Data are 
expressed as the difference in post- and pre-injection values from each animal expressed in units 
of °C. 
Catalepsy. The effect of chronic cannabinoid injection on catalepsy were assessed using the ring 
immobility test.  Each mouse was placed on a ring (5.5 cm in diameter) that is elevated 16 cm 
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above the tabletop for a 5 min session.  The amount of time the mouse remains motionless will 
be recorded to the nearest second.  Latencies of 100 sec or more will be considered cataleptic. 
 
Drugs and chemicals 
Guanosine 5'-O-[gamma-thio]triphosphate ([35S]GTPγS, 1250 Ci/mmol) and [3H]SR141716A 
(SA: 44.0 Ci/mmol) were purchased from PerkinElmer Life Sciences (Boston, MA). CP55,940, 
SR141716A, Δ9-THC and [3H]CP55,940 (88.3 Ci/mmol) were provided by the Drug Supply 
Program of the National Institute on Drug Abuse (Rockville, MD). Bovine serum albumin 
(BSA), GDP, GTPγS, and WIN55,212-2, WIN55,212-3 were purchased from Sigma-Aldrich (St. 
Louis, MO) and methanandamide (R-1) was purchased from Cayman Chemicals. All other 
chemicals were obtained from Sigma-Aldrich or Fisher Scientific.  
 
Agonist-Stimulated [35S]GTPγS Autoradiography 
 Mice were sacrificed by rapid decapitation, and brains were removed and immediately 
frozen in isopentane at -30°C and stored at -80°C. Autoradiographic assays were conducted as 
previously published from our laboratory (Sim et al., 1995). Briefly, coronal sections (20 µm) 
were cut on a cryostat maintained at -20°C, thaw-mounted onto gelatin-subbed slides, and stored 
desiccated at 4°C overnight. Slides were then stored desiccated at -80°C until use. To minimize 
variation in assay conditions, slides from each experimental condition within a single animal 
were processed concurrently. This allowed for identical assay conditions for basal and agonist 
incubated sections from each animal. For the [35S]GTPγS autoradiography assay, slides were 
brought to room temperature (~22°C) for 40 min, then equilibrated in 50 mM Tris-HCl buffer 
(pH 7.4) with 3 mM MgCl2, 0.2 mM EGTA, and 100 mM NaCl (Assay Buffer) for 10 min at 
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25°C. Next, slides were transferred to Assay Buffer + 0.5% BSA, with 2 mM GDP and 10 
mU/ml adenosine deaminase for 20 min at 25°C. Slides were then incubated in Assay Buffer + 
0.5% BSA containing 0.04 nM [35S]GTPγS in the presence or absence (basal) of appropriate 
drug(s) and/or vehicle for 2 hrs at 25°C. After final incubation, slides were rinsed twice in 50 
mM Tris buffer (pH 7.4) at 4°C, then in deionized water. Slides from each condition were then 
dried and loaded together in the same cassette with a [14C] standard, and exposed to Kodak 
BioMax MR film for 24-36 hrs. Films were digitized at 8-bits per pixel with a Sony XC-77 video 
camera. [35S]GTPγS binding data from autoradiography was generally expressed as Net 
Stimulation (nCi/g), which was calculated as: (agonist - basal). 
 
[3H]CP55,940 receptor binding autoradiography 
 [3H]CP55,940 receptor binding autoradiography was conducted as previously described 
(Herkenham et al., 1991; Moise et al., 2008), with slight modifications. Brain tissue sections 
were initially thawed to room temperature for 40 mins and incubated for 3 hrs in assay buffer 
containing 50 mM Tris-HCl (pH 7.4), 5% BSA, and 3 nM [3H]CP55,940 (88.3 Ci/mmol). Slides 
were then rinsed twice in wash buffer (50 mM Tris-HCl (pH 7.4), 1% BSA) maintained at 4°C 
for 2 hrs each. Sections were then briefly fixed in a solution containing 0.5% formalin in 50 mM 
Tris-HCl (pH 7.4) for 1 min and dried under a cool stream of air. Non-specific binding was 
assessed in the presence of 10 µM CP55,940. Slides from each subject (Total or Non-Specific) 
were loaded together in the same cassette with a [3H] standard, and exposed to Kodak BioMax 
MS film for 18 weeks. Films were digitized at 8-bits per pixel with a Sony XC-77 video camera. 
[3H]CP55,940 receptor binding data from autoradiography was generally expressed as Specific-
binding (nCi/mg), which was calculated as: (Total binding - Non-specific binding). 
35 
 
 
Agonist-Stimulated [35S]GTPγS binding for membrane homogenates 
 Membrane agonist-stimulated [35S]GTPγS binding experiments were conducted as 
previously published (Sim-Selley et al., 2006). Briefly, mice were sacrificed by decapitation and 
the whole spinal cord and brain were extracted, and individual brain regions dissected. Tissue 
was immediately frozen on dry ice and stored at -80°C until use. On the day of assay, tissue 
samples were homogenized in 5 ml of cold Assay Buffer (see Agonist-Stimulated [35S]GTPγS 
Autoradiography section above) and centrifuged at 50,000g at 4°C for 10 min. Supernatant was 
then discarded and tissue sample resuspended in 5 ml of Assay Buffer. Sample protein 
concentrations were determined by the Bradford method (Bradford, 1976). Tissue homogenates 
were then incubated with adenosine deaminase (3 mU/ml) in Assay Buffer for 15 min at 30°C. 
To generate concentration-effect curves, membrane protein (8 µg for whole brain, 10 µg for 
cerebellum or whole spinal cord) was incubated in Assay Buffer (0.5 mL total volume) 
containing 0.1 nM [35S]GTPγS, 0.125% BSA, 30 µM GDP, and varying concentrations of 
drug(s) for 2 hrs at 30°C. Non-specific binding was assessed in the presence of 20 µM unlabeled 
GTPγS. The reaction was terminated by vacuum filtration through Whatman GF/B glass fiber 
filters, and rinsed three times with cold Tris Buffer (50mM Tris-HCl, pH 7.4) at 4°C. Bound 
radioactivity was determined by liquid scintillation spectrophotometry following 15 hr extraction 
in Econo-Safe scintillation fluid. [35S]GTPγS binding data from membranes was generally 
expressed as %Net Stimulation, which was calculated as: [(agonist - basal)/basal] x 100%.  
 
[3H]SR141716A receptor binding for membrane homogenates 
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 Membrane and protein preparations were conducted as described above. Whole spinal 
cord membrane protein (30 µg) was incubated in buffer (pH 7.4) containing 50 mM Tris-HCl, 
0.2 mM EGTA, 3 mM MgCl2, 100 mM NaCl, 0.5% BSA and varying concentrations of 
[3H]SR141716A (0.1 - 2.5 nM) for 1.5 hrs at 30°C. Non-specific binding was assessed in the 
presence of 5 µM unlabeled [3H]SR141716A. The reaction was terminated by vacuum filtration 
through Whatman GF/B glass fiber filter paper soaked in Tris buffer (50mM Tris-HCl, pH 7.4) 
containing 0.5% BSA, and then rinsed three times with cold Tris buffer + 0.5 BSA at 4°C. 
Filtered samples were then placed in scintillation vials containing Econo-Safe scintillation fluid, 
shaken for 1 hr, and bound radioactivity was determined by liquid scintillation 
spectrophotometry. [3H]SR141716A receptor binding data from membranes was generally 
expressed as Specific-binding (pmol/mg), which was calculated as: (Total binding - Non-specific 
binding). 
 
[3H]CP55,940 receptor binding for membrane homogenates 
Membrane and protein preparations were conducted as described above. Whole 
cerebellar membrane protein (8 µg) was incubated in sodium-free buffer (pH 7.4) containing 50 
mM Tris-HCl, 0.2 mM EGTA, 3 mM MgCl2, 0.5% BSA and varying concentrations of 
[3H]CP55,940 (0.03 - 8.5 nM) for 1.5 hrs at 30°C. Non-specific binding was assessed in the 
presence of 10 µM unlabeled [3H]CP55,940. The reaction was terminated by vacuum filtration 
through Whatman GF/B glass fiber filter paper soaked in Tris buffer (50mM Tris-HCl, pH 7.4) 
containing 0.5% BSA, and then rinsed three times with cold Tris buffer + 0.5 BSA at 4°C. 
Filtered samples were then placed in scintillation vials containing Econo-Safe scintillation fluid, 
shaken for 1 hr, and bound radioactivity was determined by liquid scintillation 
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spectrophotometry. [3H]CP55,940 receptor binding data from membranes was generally 
expressed as Specific-binding (pmol/mg), which was calculated as: (Total binding - Non-specific 
binding). 
 
Thionin (Nissl) Staining 
 Unfixed brain tissue sections were initially placed in a 95% ethanol solution for 15 min 
and then hydrated in solutions of 70% ethanol, 50% ethanol, and then dH2O water each for 1 
min. Sections were then transferred to thionin working solution containing 93% buffer (7g Na-
acetate, 2 mL glacial acetic acid, 1 L dH2O) and 7% thionin stock (1 g thionin per 100 mL hot 
dH2O) for 2 min (sections requiring lighter or darker staining were left in solution shorter or 
longer, respectively). Sections were next dehydrated stepwise in the following solutions for 1 
min each: dH2O, 50% ethanol, 70% ethanol, 95% ethanol, 100% ethanol. Sections were finally 
rinsed twice in Xylene for 1 min and preserved with permount and cover slipped. 
 
3D image reconstruction and Statistical Parametric Mapping (SPM) analysis 
 Please see next chapter for complete methodology and assessment 
 
Region of Interest (ROI) analysis 
 To validate and compare regions found to be significant with SPM analyses, separate 
ROI analyses were performed. ROI measurements were conducted on the original unprocessed 
images, averaged bilaterally across hemispheres, and analyzed with GraphPad Prism Version 5 
using appropriate statistical tests and Tukey’s post-hoc analysis for ANOVA designs. ROI 
anatomical boundaries were defined by a mouse brain atlas (Franklin and Paxinos, 2008). The 
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following brain nuclei were included within each regional ROI measurement: amygdala 
(basomedial, basolateral, & medial, lateral, central nuclei), auditory cortex (primary, secondary), 
cerebellum (molecular layer), cingulate cortex (primary, secondary), hippocampus (CA1-3, 
dentate gyrus), hypothalamus (medial), motor cortex (primary, secondary), somatosensory cortex 
(primary, secondary), thalamus (central, ventral posteromedial & posterolateral, ventromedial, 
and ventrolateral thalamic nuclei), and visual cortex (primary, secondary). All other brain 
regions (i.e. caudate-putamen, globus-pallidus, periaqueductal gray, substantia nigra) were 
measured in entirety based on anatomical boundaries defined by a mouse atlas (Franklin and 
Paxinos, 2008). 
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IV. Chapter 1: Statistical Parametric Mapping (SPM) analysis of cannabinoid-mediated G-
protein activation in the 3D reconstructed mouse brain 
 
1.1 General overview of SPM analysis for reconstructed data sets 
 Previously our laboratory developed agonist-stimulated [35S]GTPγS autoradiography for 
the examination of receptor-activated G-proteins in brain tissue sections (Sim et al., 1995). This 
technique allows for both anatomical- and pharmacological-specific assessment of cannabinoid-
stimulated G-protein activity (Figures 1.1-1.2) in a quantitative manner. Analysis of these 
datasets generally involves manual measurements of pre-defined regions of interest (ROI). ROI-
based approaches therefore are limited by a priori selection of regions and subject to inter-rater 
bias. To avoid limitations in ROI-based approaches and investigate CB1 receptor signaling in an 
anatomically inclusive way, we adapted a novel whole-brain unbiased approach based on 
Statistical Parametric Mapping (SPM) to study CB1 receptor signaling in the 3D reconstructed 
mouse brain. The volumetric reconstruction of images derived from agonist-stimulated 
[35S]GTPγS autoradiography and procedure for SPM analysis is outlined in Figure 1.3. Briefly, 
coronal brain sections are collected throughout the neuroaxis, processed for agonist-stimulated 
[35S]GTPγS autoradiography, and digitized. Digitized images are then realigned to reestablish 
spatial consistency and stacked into a volumetric image array. SPM software is then used for 
further image manipulation and processing, including spatial normalization and image 
smoothing, which are required before implementation of voxel-based statistical analysis of data. 
Application of these methods are detailed in this chapter and further demonstrated with 
[3H]ligand autoradiographic data in Chapter 3, and Appendix Figure A3. The reference to 
“SPM” throughout this dissertation will refer to both the Statistical Parametric Maps generated 
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from SPM analysis as well as the collection of tools packaged with the SPM software, which is 
available in the public domain (http://www.fil.ion.ucl.ac.uk/spm/). All image processing, 
analyses, and display of data were done on a Windows-based 32-bit architecture PC, having 4 
gigabytes of RAM, a 3.2 Ghz Intel Pentium 4 processor, and a 256 MB 3D video card. 
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Figure 1.1. Overview of agonist-stimulated [35S]GTPγS binding assay. Binding of an agonist (1) 
to a G-protein coupled receptor (GPCR) results in a guanine nucleotide exchange reaction of 
GDP to GTP (2) and subsequent activation of the G-protein. Activation leads to the dissociation 
of the G-protein into both βγ and α subunits, which interact with specific effectors (3). 
Termination of signal transduction occurs via an intrinsic GTPase (4), hydrolyzing GTP back to 
GDP. A non-hydrolyzable radiolabeled GTP analogue, [35S]GTPγS (shown in bottom right, 3a), 
is used for quantification of receptor-mediated G-protein activity. This prevents the hydrolysis 
step and therefore leads to the accumulation of agonist-stimulated [35S]GTPγS binding (4a).
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Figure 1.2. Cannabinoid-stimulated [35S]GTPγS autoradiography. Agonist-stimulated 
[35S]GTPγS autoradiography was performed as described in Methods. Autoradiographs are 
shown in grayscale (top row) and pseudocolor (bottom row), where black or red/yellow pixels 
represent areas with the lowest and highest levels of stimulated [35S]GTPγS binding, 
respectively. Stimulated [35S]GTPγS binding is shown for the basal (no agonist, left column) 
condition, and after incubation with the full CB1 receptor agonist WIN55,212-2 alone (middle 
column) or in the presence of the CB1 receptor antagonist SR141716A. A histogram shows the 
distribution of CB1 receptor stimulated [35S]GTPγS binding by WIN55,212-2 alone.  
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1.2 Preparation of brain tissue sections and image pre-processing 
 Brain image reconstruction of autoradiographic data was conducted based on previously 
published methods (Holschneider et al., 2006; Nguyen et al., 2004), with modifications. For each 
study in this dissertation, reconstructed brain images from each condition (i.e. agonist or basal 
(absence of agonist)) were created from coronal sections collected throughout the neuroaxis from 
bregma 2.34 mm to -6.84 mm (Franklin and Paxinos, 2008) with an inter-slice distance of 200 
µm (Fig. 1.4). Volumetric reconstructions derived from coronal tissue sections produced the best 
results qualitatively compared to reconstructions from transverse sections (Fig. 1.5). Using an 
inter-slicing distance of 200 µm for transverse sections resulted in suboptimal slice realignment, 
likely due to rapid changes in anatomical structures as well as larger changes in overall surface 
area in this plane (see section 1.3 Slice registration and 3D image reconstruction). The larger 
perimeter in transverse versus coronal sections also presents a greater challenge in minimizing 
edge distortion that results from tears and folding of tissue during collection. Larger surface 
areas in transverse sections in addition increase the risk for trapping debris, condensed water 
droplets on the surface of the blade, or pockets of air, which can create bumps or bubbles in the 
mounted tissue section. Furthermore, the asymmetrical surface with respect to the cutting 
direction in transverse (shaped like an irregular ellipsoid) versus coronal (shaped like a regular 
ellipsoid) sections may lead to non-uniform adhesion of biological tissue onto the glass slide, 
which can be further perturbed by other environmental variables such as humidity or static 
electricity. Significant edge distortions can lead to uneven and serrated edges, which can best be 
visualized in the reconstructed coronal plane (Fig. 1.5A). 
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Figure 1.3. Flow chart of tissue preparation for autoradiography, 3D image reconstruction and 
SPM analysis (from Nguyen et. al., NeuroImage 2010). 
* 20 µm coronal sections are cut in a cryostat maintained at -20°C. C = condition; S = slice level; 
a & b = set 1 & 2 of duplicate sections 
† The section free from artifact (i.e. S1a or S1b) at each slice level is digitized at 8-bits per pixel 
and saved in TIFF format 
‡ Image reconstruction and slice registration described in Nguyen et al., NeuroImage 2004. 
Registered image stacks are quantitated and saved as 16-bit images in Analyze image format. 
§ Individual image reconstructions are spatially normalized to a study-specific brain template as 
described in Nguyen et al., NeuroImage 2004. Spatially normalized images are then smoothed 
with a Gaussian kernel (Full Width Half-Max = 3X the voxel value) 
♦ Statistical Parametric Mapping (SPM) software was used to setup experimental design and 
analysis of imaging data.   
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Figure 1.4. Brain sectioning strategy for 3D reconstruction. Volumetric reconstructions were 
derived from coronal sections (20 µm thick) collected throughout the neuroaxis from bregma 
2.34 mm to -6.84 mm (Franklin and Paxinos, 2008) with an inter-slice distance of 200 µm. (i-1) 
= second to last slice; i = last slice 
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Figure 1.5. Image reconstructions derived from coronal or transverse sectioning. Volumetric 
reconstructions of 10 µM DAMGO- (A) and 10 µM WIN55,212-2- (B) stimulated [35S]GTPγS 
binding autoradiographs in wild-type naive mice. Image reconstructions were derived from 200 
µm spaced transverse and coronal sections for DAMGO and WIN55,212-2 images, respectively. 
Crosshairs highlight the medial thalamus (A) and globus pallidus (B) in three orthogonal planes. 
Arrows represent the direction of sectioning in the cryostat with respect to the cutting plane. 
Agonist-stimulated [35S]GTPγS autoradiography was performed is described in Methods.  
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Figure 1.6. Image editing strategy for digitized autoradiographs having substantial artifact in one 
hemisphere. Missing tissue in one hemisphere is replaced by duplicating the missing tissue from 
the opposite intact hemisphere (A). The intact hemisphere is initially selected or image-masked, 
flipped horizontally, and duplicated as a new layer (B). The duplicated layer (layer 2 above) is 
placed behind the original layer (layer 1 above) and the two layers are manually aligned for 
spatial consistency. Replacement of the missing tissue area by the duplicated opposite 
hemisphere is represented as a shaded outline in the figure above (C). Both layers are then 
combined as a single layer or flattened image (D). 
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 Serial adjacent sections from a single brain were collected for different assay conditions 
in duplicate sets. This scheme allowed for duplicate sets of at most 4 different conditions 
(reconstructions) from a single mouse brain as outlined in Figure 1.3. For sections with extensive 
artifact(s) or missing tissue in one hemisphere, the intact opposite side was duplicated and 
reflected (flipped horizontally) either behind or over the damaged hemisphere in order to 
preserve original imaging data (Fig. 1.6). For severely damaged sections that made this strategy 
impossible, the other duplicate section was utilized. In these special cases, the true inter-slice 
distance varied between 100 to 260 µm. 
 Tissue sections free from artifact related to extraction of the brain, tissue sectioning, etc., 
were selected for image reconstruction. A mask was next created for each selected digitized 
autoradiographic section. Most standard mask creation tools select connected pixels whose data 
values are within a defined tolerance of neighboring reference pixels. The Quick Selection Tool 
in Adobe Photoshop CS3 (Version 10) was used in these studies as it is suitable for both agonist-
stimulated [35S]GTPγS binding and [3H]ligand binding autoradiographic data. Masked sections 
were then copied and pasted onto a new 8-bit grayscale image with a white background at 100 
dpi and size of 300 x 250 pixels (width x height), and saved in TIFF format. Pixel size was 
calculated by measuring the width of a brain section on film by a ruler (units in mm) and 
dividing by the captured image width (units in pixels). For example from studies in this 
dissertation, the average width of a mouse section at bregma -1.8 mm (Franklin and Paxinos, 
2008) is 10.6 mm and has an average corresponding pixel length of 266 pixels. This equates to a 
pixel dimension of about 40 µm/pixel. Thus for mouse brain sections captured at pixel 
dimensions of 40 x 40 µm2, a white background of image size 300 x 250 pixels allowed adequate 
space for rigid-body transformations during slice realignment (see next section). In addition, 
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masked sections were centered and rotated manually so that midline was approximately parallel 
to the vertical reference axis of the white background image (Fig. 1.7). This initial prealignment 
provided a good starting estimate for slice registration. 
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B  
 
  
Section dimension: 250x165 pixels 
White image dimension: 300x250 pixels 
 
 
 
 
 
Figure 1.7. Slice image editing of digitized autoradiographs. Raw mouse brain images are 
initially outlined with a selection mask, pasted onto a new image with a white background and 
rotated manually if the midline axis of the raw image is not parallel to the vertical axis of the 
new image. (A) An arrow shows the manual rotation used for prealignment. The raw image is 
then centered vertically and horizontally to complete section prealignment. (B) Section and total 
image dimensions (width x height) in pixels are shown with white and gray arrows, respectively. 
51 
 
1.3 Slice registration and 3D image reconstruction 
Image reconstructions were generated in ImageJ (version 1.42q, 
http://rsb.info.nih.gov/ij/) by importing coronal sections that were preprocessed as outlined in the 
previous section, and saving them as an image stack in Analyze format. The Analyze format 
(http://www.mayo.edu/bir/) is a common multidimensional biomedical imaging format that 
includes both a header (*.hdr) and data (*.img) file associated with each 3D image. The header 
file contains information such as voxel sizes, which must be defined prior to viewing and further 
processing within the SPM software. To make brain reconstructions spatially consistent in 3D, a 
section-to-section registration technique was used. Briefly, a section in the middle of the brain 
was chosen as the initial target to align adjacent sections in a stepwise fashion. Each registered 
section was then used as a new target to register the next adjacent section in either the anterior or 
posterior direction. A section in the middle of the brain was selected as the starting point to 1) 
allow for independent registration of slices in the anterior and posterior directions and 2) 
minimize the propagation of misregistration error that may occur in early slices if a section in the 
anterior-most pole was selected as the reference image. This registration algorithm utilizes the 
intensity of all image pixels for a section and searches for the transformation that maximizes a 
measure of intensity similarity between corresponding pixels of an adjacent section (Thévenaz et 
al., 1998). In other words the transformation is computed to minimize the mean-square 
difference between the target and source images. The registration algorithm is available as a 
plugin within the ImageJ environment called TurboReg 
(http://bigwww.epfl.ch/thevenaz/turboreg/). An auxiliary plugin, StackReg 
(http://bigwww.epfl.ch/thevenaz/stackreg/), was used for the recursive alignment of 
reconstructed image stacks in this dissertation. In order to preserve the original shape of tissue 
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sections, a non-warping rigid-body transformation was selected that consisted of only rotations 
and translations. It is important to note that the alignment algorithm performs optimally when the 
source and target images are comparable in size and have similar starting points (Nguyen, 
unpublished observations). Therefore, if the centers of two images are far apart, it is important to 
remove the translational offset manually (i.e. centering images) before proceeding with finer 
registration. StackReg offers an automatic and manual mode. In manual alignment, associated 
landmarks are defined on a source and target image to establish initial correspondence between 
them. All image registration in this dissertation used the automatic mode to minimize inter-rater 
variability. 
Header files of registered image stacks were opened and edited using MRIcro software, 
which is available in the public domain (http://www.cabiatl.com/mricro/mricro/index.html) from 
the Center for Advanced Brain Imaging, Atlanta, GA. Voxel sizes of mouse brain images in this 
dissertation were scaled up 10X their true size (40 x 40 x 200 μm3) and saved in the header files. 
This allowed for proper viewing within the SPM environment, which is originally designed for 
human brain imaging data having dimension sizes on the order of millimeters (Nguyen et al., 
2004). Gray level intensities of the raw image stack were then quantitated to activity values 
(nCi/g of tissue) as previously described (Sim et al., 1996b). Briefly, [35S] was incorporated into 
sections of frozen brain paste and sections were then weighed to obtain nCi/g of tissue. 
Radioactivity in each section was determined by liquid scintillation spectrophotometry. [14C] 
microscale standards and [35S] sections were then exposed to film and correction factors were 
calculated to convert [14C] values to [35S]. Raw optical density values (OD) are quantitated to 
radioactivity values (Y) using the following linear equation, where m is the slope and b is the 
intercept, as calculated from [14C] standards:  
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Y = m•OD + b 
Reconstructed stacks were quantitated using a macro created within ImageJ and its 
complete code is shown in Figure 1.8. This fully automated macro script opens a registered 
image stack and prompts the user to enter the slope (m) and intercept (b) coefficients, as 
calculated from standards, in order to globally quantitate raw voxel values to radioactivity units 
(nCi/g) and then save the image at a bit depth of 16-bits. Saving at a dynamic range of 16-bits 
allowed for a potential data range from 0 to (216-1), or 65,535 nCi/g. The StackReg utility 
normally introduces "registration artifact" or black edges to visually show the transformations 
that were applied to realign sections (see registration results in Figures 1.10-1.12). The above 
macro also includes functionality to automatically remove registration artifact. 
Although not required, volumetric images were reoriented in coordinate space to 
correspond to the standard viewing axis defined within the SPM software environment. In this 
standard coordinate space lateral, anterior-posterior, and dorsal-ventral correspond to the X, Y, 
and Z axes, respectively (Fig. 1.9). An automated macro script was written to reorient images 
using the To_AxialTP function (part of a suite of alignment plugins found at:  
http://www.med.harvard.edu/JPNM/ij/plugins/AlignStacks.html) within the ImageJ environment. 
The macro code and description is detailed in (Fig. 1.9). 
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Line # ImageJ macro for quantitation of [35S]GTPγS binding imaging data 
1 open(); 
2 run("Invert", "stack"); 
3 run("Duplicate...", "title=mask.img duplicate"); 
4 run("Invert", "stack"); 
5 run("Max...", "stack value=1"); 
6 run("Calculator Plus", "i1 i2=mask.img operation=[Multiply: i2 = (i1*i2) x k1 + k2] 
k1=1 k2=0 create"); 
7 run("Invert", "stack"); 
8 run("32-bit"); 
9 run("Multiply..."); 
10 run("Add..."); 
11 run("Min...", "stack value=0"); 
12 run("16-bit"); 
13 run("Analyze 7.5...", "save"); 
14 
15 
16 
close(); 
close(); 
close(); 
Description of macro code by line number: 
1:  prompts user for selecting image volume (analyze format, *.img) 
2-3:  inverts source image and creates a duplicate of itself 
4:  duplicate image is inverted 
5:  data values >1 are assigned a value of 1. This creates a binary (mask) image, so that areas 
 with registration artifact have a data value of 0 and all else have a value of 1. 
6: image array multiplication of source image and binary image  
7: image inversion reverts source image back to original state (without registration artifact) 
8: image bit depth increased to 32-bit to allow for the image quantitation 
9: prompts user to enter slope coefficient calculated from 14C standards using a linear fit 
10: prompts user to enter the intercept (of abscissa) calculated from 14C standards 
11: data values <  0 (i.e. negative numbers) are assigned a data value of 0 
12: quantitated images are saved at a dynamic range of 16-bit, to encompass the data range of 
 [35S]GTPγS binding imaging data, which typically ranges from 0 to 2,500 nCi/g 
13: prompts user to save quantitated stack image in analyze format 
14-16: closes all active windows 
Note: This macro removes slice alignment artifact generated from using the StackReg plugin for 
ImageJ. General requirements: ImageJ ver 1.36b (or later) and calculator plus. No other images 
should be open at time of use and "Scale when converting" must be disabled (under edit; 
options; conversions). 
 
 
 
 
 
Figure 1.8. ImageJ macro for removing slice registration artifact and quantitation of raw 
imaging data to radioactivity units (nCi/g). 
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Line # ImageJ macro for reorienting images to correspond to SPM standard axis 
1 open(); 
2 run("To AxialTP", "input=[Coronal (anterior-to-posterior)]"); 
3 run("Analyze 7.5...", "save"); 
4 close(); 
5 close(); 
 
Description of macro code by line number: 
1: prompts user for selecting image volume (analyze format, *.img) 
2: reorients image to correspond to the standard SPM axis (see image below) 
3: prompts user to save image in analyze format 
4-5: closes all active windows 
 
 
 
 
 
 
 
 
Figure 1.9. ImageJ macro for reorienting image volumes to correspond to the SPM standard 
axis: lateral left-right, anterior-posterior, and dorsal-ventral are the X, Y, and Z planes, 
respectively 
Y 
X 
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D 
Refined source 
landmarks (x, y) 
Target 
landmarks (x, y) 
A (164.99, 210.99) A' (150, 211) 
B (164.99, 124.99) B' (150, 125) 
C (164.99, 38.99) C' (150, 39) 
 
Length of B' to B = Bx - B'x = 164.99-150 = 14.99 pixels 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10. Image registration: translation simulation. (A) An image was duplicated and 
translated by 15 pixels. An outline of the translated slice is shown as an overlay on the original 
image. (B) An arrow and black area illustrates the applied transformation after image 
registration. (C) StackReg (TurboReg) utilizes landmarks on the target and source image to apply 
the transformation (D) Calculating the magnitude of translation can be done by vector 
subtraction of coordinate pairs. 
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D 
Refined source 
landmarks (x, y) 
Target 
landmarks (x, y) 
A' (134.88, 209.85) A (150, 211) 
B' (149.81, 125.16) B (150, 125) 
C' (164.75, 40.47) C (150, 39) 
 
θ = tan-1[(length A' to A)/(length A to B)] 
   = tan-1 [(Ax - A'x)/(Ay - By)] = tan-1[(150 - 134.88)/(211 - 125)] = tan-1 (15.12/86) = 9.97° 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11. Image registration: rotation simulation. (A) An image was duplicated and rotated by 
10 degrees. An outline of the rotated slice is shown as an overlay on the original image. (B) An 
arrow and black area illustrates the applied transformation after image registration. (C) StackReg 
(TurboReg) utilizes landmarks on the target and source image to apply the transformation. (D) 
Calculating the degree of rotation (θ) can be done trigonometrically. 
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A 
 
Slice A (target) 
 
Slice B (source) 
 
Slice B registered to A 
B 
 
Figure 1.12. Registration of two representative coronal images (A) and image correlation plots 
before (B, top) and after registration (B, bottom). Slice registration increased the image 
correlation coefficient (R2 value) to 0.97 (up from 0.45) 
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1.4 Assessment of registration algorithm: simulation studies 
The quality of brain reconstructions was assessed by visual inspection of internal 
structures viewed in different orthogonal angles and correspondence of brain areas across 
reconstructions of different conditions and/or subjects. The SPM software includes a utility, 
called CheckReg, to load and view multiple images of the same size. Spatial correspondence 
between images can be assessed by a crosshair or point of reference, which updates each 
orthogonal frame in all loaded images. To quantitatively assess the accuracy of the registration 
algorithm used for agonist-stimulated [35S]GTPγS autoradiographic data, simulation studies were 
done with representative brain tissue sections. A 2D image was registered to its duplicate that 
was either translated to the right by 15 pixels (Fig. 1.10) or rotated clockwise by 10° (Fig. 1.11). 
The calculated translation and rotation after applying image registration were 14.99 pixels and 
9.97°, respectively. The differences from actual values were 0.01 pixels (misregistration error of 
0.067% or about 0.4 µm) in the translation simulation and 0.03° (misregistration error of 0.3% or 
about 2.61 µm) in the rotation simulation.  
To further assess the registration algorithm, an image correlation plot was constructed for 
two different adjacent sections (spaced at 200 µm) before and after applying image registration 
(Fig. 1.12). Corresponding pixel values from both images (source and target) at each coordinate 
were graphed and correlated using a linear fit. The correlation coefficient (R2 value) was 0.45 
before image registration and increased to 0.97 after application of registration, suggesting an 
improvement in spatial correspondence between the two adjacent sections. These simulation 
studies thus demonstrate the robustness and viability of using the registration algorithm 
implemented in StackReg for the recursive alignment of images derived from agonist-stimulated 
[35S]GTPγS autoradiographic data. 
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1.5 Voxel-based Analysis using Statistical Parametric Mapping (SPM) 
 The SPM package exists as a collection of scripts written within the Matlab environment 
(http://www.mathworks.com/), which is a software program designed for numerical 
computation, creation of user-interfaces, implementation of algorithms, etc. SPM analyses 
(version SPM5, http://www.fil.ion.ucl.ac.uk/spm/) for reconstructed autoradiographs were 
conducted as previously published (Nguyen et al., 2004), with modifications. Prior to SPM 
analysis, all images from a study were spatially normalized into the same coordinate space 
(Ashburner J., 1999; Friston et al., 1995a) as defined by a study-specific brain template. This 
template was derived from brain reconstructions of the most efficacious agonist, due to its high 
structural information and contrast of anatomical boundaries, thus optimizing spatial 
normalization. Initially a subject’s reconstructed brain image from the most efficacious agonist 
was selected based on alignment quality and freedom from artifacts. This image was then 
smoothed by 3X its voxel size (see below for image smoothing rationale) to serve as the 
preliminary template. All reconstructions of the most efficacious agonist from different subjects 
were then spatially normalized to the preliminary template while retaining the original voxel 
sizes. These spatially normalized images were then averaged, using the SPM image average tool 
(spm_avg.m script in SPM directory), and smoothed by 3X its voxel size to become the study-
specific brain template.  
 Spatial normalization of reconstructions from multiple conditions (agonist(s) and basal) 
assayed from the same animal was performed by coregistering (using normalized mutual 
information option in SPM) these images to the most efficacious agonist. The coregistration 
technique allows within-subject registration of all reconstructions, so that they are aligned within 
the same coordinate space. This assumes that there are no gross differences among the shapes of 
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the reconstructed images, which is a reasonable assumption to make for images derived from the 
same animal. Intra-subject coregistration thus allows one to determine spatial normalization 
parameters from a single reconstruction (i.e. the most efficacious agonist) and subsequently 
apply them to all coregistered reconstructions from the same animal. Using this strategy has the 
dual advantage of reducing the number of spatial normalization routines as well as estimating the 
spatial normalization parameters from the set of images likely possessing the most structural 
information. Furthermore, this avoids spatial normalization challenges when basal images (no 
agonist) that have relatively low structural information/contrast are directly normalized to a 
template derived from an agonist (Nguyen, unpublished observations).  
A total of 16 iterations were used during the SPM spatial normalization routine, where a 
3D non-rigid transformation model was used to warp a source image to match the brain template. 
Image reconstructions of mouse brains may vary in shape and size due to intrinsic inter-subject 
differences in anatomical boundaries and/or from preparation of tissue. Therefore, the goal of 
spatial normalization is to warp, or deform, image reconstructions so that a given location in one 
subject (or reconstruction) corresponds to the same location in another subject’s image. It is 
important to note that the registration approaches for spatial normalization are different from the 
techniques in the previous section for individual sections, which employed rigid or non-warping 
transformations. Correspondence of brain regions are shown in Figure 1.13 before and after 
performing spatial normalization. Spatial normalization of these three images for example 
improved the spatial correspondence of the globus pallidus as depicted by the crosshair 
representing the same coordinate location across all subjects. The accuracy of spatial 
normalization is very important as it allows signal averaging across subjects and thus the 
possibility to perform univariate statistical tests at each voxel for the creation of a statistical 
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parametric map. In addition, it allows for creation of subtraction images, such as net-stimulated 
images derived from subtracting basal from agonist-stimulated images (see Chapter 3). Spatial 
normalization lastly serves as a diagnostic point to determine whether there are underlying 
problems with one's dataset. Unsuccessful spatial normalization of an image may infer 1) 
inadequate slice registration, 2) significant artifact related to preparation of tissue, or 3) 
insufficient structural information/contrast related to the autoradiographic assay 
 Image smoothing was referenced above at various processing steps, for example after 
averaging of images to create a study-specific brain template. Smoothing is also applied to 
spatially normalized brain images prior to SPM analysis. Image smoothing essentially convolves 
the data using a defined kernel or function. In other words, each data point in an image is 
averaged with its neighbors. Specific to studies in this dissertation, data points were smoothed or 
replaced by a weighted average of its surrounding neighbors in 3D space, where the closest 
neighboring voxels were given the greatest weights (Gaussian kernel). Image smoothing is 
illustrated in Figure 1.14A and demonstrates one benefit of smoothing, such as increasing signal 
to noise. Following the addition of randomly generated noise into an image in Figure 1.14A, 
smoothing effectively eliminates it, however at a cost of losing spatial resolution (Fig. 1.14A 
rightmost column). This is noted by the general “blurring of a smoothed image” and loss of 
discrete borders, such as the separation of hair in the example image.  The extent or magnitude of 
smoothing is defined by the width of the kernel, also referred as the full-width at half maximum 
(FWHM) of the Gaussian function. By the matched filter theorem, the optimum smoothing 
kernel corresponds to the size of the effect that one anticipates (Friston et al., 2007). However, 
this may be difficult to establish a priori especially for data sets studying receptor-mediated  
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Figure 1.13. Spatial normalization of reconstructed brain images. Three representative brain 
reconstructions are shown before (A) and after (B) application of spatial normalization. Yellow 
crosshairs in each column represent identical coordinate locations within each subject. Note the 
poor spatial correspondence of the globus pallidus in images before spatial normalization (red 
arrows) and its improvement after spatial normalization. 
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Figure 1.14. Image smoothing. (A) Smoothing with a Gaussian width equal to twice the pixel 
size is applied to a grayscale image after adding random noise (middle column). Note the 
removal of image noise after smoothing, but at the expense of spatial resolution (right column). 
(B) Application of image smoothing is shown for agonist-stimulated [35S]GTPγS binding 
autoradiography. Artifacts such as the smaller air bubbles and folds are removed, but relatively 
larger ones fail at this given magnitude of spatial smoothing.  
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 G-protein activity, because its magnitude may vary regionally based on the agonists intrinsic 
efficacy and receptor localization, or the size of the experimental effect may be unknown. Too 
little smoothing may result in artifactual differences, or “noisy SPMs”, whereas too much 
smoothing may potentially exclude the detection of smaller differences when signal is “diluted” 
or averaged out with its neighboring voxels. Therefore, a relatively moderate FWHM equal to 
3X the intrinsic voxel size (FWHM = 120 x 120 x 600 µm3) was used whenever smoothing was 
required, which was generally compatible with our estimate of misregistration error and 
anatomical variability between our data sets. As mentioned previously, image smoothing helps to 
increase the signal to noise ratio, but this has its limitations. In Figure 1.14B, smoothing of 
autoradiographic data can account for relatively minor artifacts related to tissue preparation (i.e. 
bubbles, folds), but has difficulty with more extensive artifacts such as tearing. Finally, 
smoothing the data renders the errors more normal in their distribution and ensures the validity 
of inferences based on statistical parametric tests (Friston et al., 2007).  
 To ensure that only voxels within the brain were included for SPM analysis, an image 
threshold was specified to create a mask image using the SPM software. The mask was visually 
inspected and overlayed onto brain images, and the threshold value was calculated such that 
voxels less than 10% of the mean voxel value within the brain were not included for SPM 
analysis. This calculated threshold value of 10% ensured that only voxels in the background and 
within the ventricles from all brain images (basal and agonist) were excluded. Figure 1.15 shows 
an image histogram of voxel values from a single reconstructed mouse brain. Note that the global 
mean has a value of 152.32 nCi/g, which is low due to the inclusion of voxels in the background. 
After thresholding, the corrected mean voxel value is 496.44 nCi/g and includes about one-third 
of the total number of voxels in the image.  
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Because amounts of radiolabeled [35S]GTPγS for in situ binding assays were kept 
constant, global normalization (Nguyen et al., 2004) in signal was omitted from SPM analysis. 
At each voxel, a general linear model was then used to describe the data in terms of experimental 
and confounding effects, and residual variability (Friston et al., 1995b). A voxel-by-voxel 
statistical analysis was performed to localize significant differences in receptor-mediated G-
protein activation. Because of the extensive number of univariate statistical tests performed by 
SPM, the multiple comparisons problem was addressed using gaussian random field theory 
(Worsley et al., 1992). This analysis results in inference based on corrected p-values (Friston et 
al., 1991; Friston et al., 1996; Friston et al., 1994). Each study in this dissertation used an 
appropriate parametric statistical test at each voxel to test the effect of drug in activating G-
proteins, and specific contrasts were evaluated. For all studies, significance (p < 0.05) was 
established at the voxel and/or cluster level (minimum cluster extent of 100 contiguous voxels) 
after correction for multiple comparisons. Statistical p-values were corrected using the false-
discovery rate and were adjusted for small search volume for each CB1 receptor containing 
region, including cortex, striatum, globus pallidus, substantia nigra, hippocampus, amygdala, 
hypothalamus, periaqueductal gray, and cerebellum. Small volume corrections used a sphere 
volume of interest to surround each CB1 receptor containing region. Significance for novel 
regions not considered a priori were corrected for multiple comparisons for the whole brain 
search volume or used an uncorrected threshold of p < 0.001 and minimum cluster extent size of 
100 contiguous voxels. Nissl staining of brain tissue sections from [35S]GTPγS autoradiographic 
studies was also conducted to identify subnuclei and discrete small nuclei in the brainstem. 
Significant clusters of voxels representing brain regions of interest were also verified to span at 
least 2-3 adjacent sections. To validate and compare regions found to be significant with SPM 
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analysis, a separate ROI analysis was performed. ROI measurements were generally conducted 
on the original unprocessed images, averaged bilaterally across hemispheres, and analyzed with 
GraphPad Prism Version 5. ROI anatomical boundaries were defined by a mouse brain atlas 
(Franklin and Paxinos, 2008). 
The overall assessment of image registration strategies for both 2D and 3D images 
derived from agonist-stimulated [35S]GTPγS autoradiography can be visualized in Figure 1.16, 
which represents a composite brain image created from the image average (n = 8) of WIN-
stimulated [35S]GTPγS binding images from CB1-/- mouse brains (dataset from Chapter 3). 
Spatial normalization resulted in correspondence between brain regions of all animals, therefore 
allowing successful averaging of voxel values. Success of spatial normalization can further be 
appreciated by the smooth cortical surface of the rendered composite brain image (Fig. 1.16A). 
This is further exemplified by the differentiation and contrast of anatomical boundaries of brain 
structures as illustrated in video sequences (download from http://catalog.library.vcu.edu) 
showing the anterior to posterior progression in the coronal plane, left to right lateral progression 
in the sagittal plane, and dorsal to ventral progression in the horizontal plane. 
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Figure 1.15. Image histogram of voxel values ([35S]GTPγS) from a single reconstructed mouse 
brain under basal (no agonist) conditions. The global image mean (includes background outside 
the brain) is illustrated by a dashed line and the corrected mean (not including background 
outside the brain) is shown as a dotted line. Note the closer proximity of the corrected global 
mean to central tendency after image thresholding.  
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Figure 1.16. Reconstructed brain images derived from agonist-stimulated [35S]GTPγS 
autoradiography provided 3D anatomical visualization in each orthogonal plane. A composite 
image created from the mean of eight reconstructed WIN-stimulated [35S]GTPγS binding images 
from CB1-/- mouse brains, was rendered in 3D (A) to demonstrate the result of slice registration 
and image reconstruction. Video sequences of slices are shown in the coronal (anterior to 
posterior) (B), sagittal (C), and transverse planes (dorsal to ventral) (D) to illustrate 3D spatial 
consistency of anatomical regions. The reader is referred to the web version of this dissertation to 
view/download video sequences in mpg format (search Peter Nguyen in 
http://catalog.library.vcu.edu). Video sequences can also be viewed/downloaded from the 
supplementary section of: Nguyen PT, Selley DE, Sim-Selley LJ. Statistical Parametric Mapping 
reveals ligand and region specific activation of G-proteins by CB(1) receptors and non-CB1 sites 
in the 3D reconstructed mouse brain. 2010. Neuroimage 52(4): 1243-1251. 
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1.6 Discussion: 3D reconstruction and analysis of cannabinoid-mediated G-protein activity 
 In this chapter we introduced the strategies used for reconstructing imaging data derived 
from agonist-stimulated [35S]GTPγS autoradiography and methods to analyze these data based 
on Statistical Parametric Mapping (SPM). The principle behind image reconstruction is similar 
to creating volumetric images using confocal microscopy. In the case of autoradiography, 
multiple planes of data are instead collected manually, subsequently assayed and prepared for 
autoradiography, and digitized. Unlike confocal microscopy where a “Z-stack” contains multiple 
planes of data that are intrinsically aligned by virtue of the acquisition method, reconstruction of 
autoradiographic data requires slice realignment or registration. Several registration methods and 
algorithms have been developed for the alignment of serial images derived from various imaging 
modality, which differ mainly in the features used to establish a measure of similarity between 
images and also the extent of required user-input. A review of some image registration 
approaches for autoradiographic data has previously been published (Hess et al., 1998). We 
determined that an intensity-based registration algorithm developed by Thévenaz et al. 
(Thévenaz et al., 1998) was robust for the recursive alignment of brain tissue sections from 
agonist-stimulated [35S]GTPγS autoradiography. The fully automated ImageJ plugin StackReg, 
which is based on this registration algorithm, successfully realigned 2D images with greater 
accuracy versus manual alignment in an unbiased fashion. 3D reconstruction offers the ability to 
visualize anatomical data in different orthogonal planes, as well as reslicing and visualization of 
data at virtually any angle. It is interesting to note that the reconstruction techniques in this 
chapter can possibly be adaptable and used to reconstruct data from different imaging modalities, 
such as immunohistochemistry or wherever multiple planes of data can be acquired. The 
application of these methods is extended to [3H]ligand receptor-binding autoradiography in 
75 
 
Chapter 3 and in a study comparing differences in CB1 receptor levels in the rat pilocarpine 
model of epilepsy versus controls (Appendix Fig. A3, Table A1). Important internet links for 
documentation related to analytical software is listed in the Appendix Table A2. 
 The high abundance and distribution of CB1 receptors in brain, as well as their 
neuromodulatory role in synaptic transmission, make them an attractive candidate for whole 
brain imaging. To date, most in vivo based imaging approaches utilize radiotracer compounds 
and modalities such as positron emission tomography (PET) or single photon emission computed 
tomography (SPECT) to study, for example, changes in receptor occupancy after chronic drug 
treatment or during various neurological diseases (Gifford et al., 2002). Most radiotracer 
compounds are developed using structural templates derived from pre-existing cannabinoid 
agonists or antagonists (Horti and Van Laere, 2008). However, some of the challenges that limit 
usage of candidate radiotracer compounds include their affinity and specificity for binding to the 
receptor, as well as their lipophilicity to penetrate the blood brain barrier (Gifford et al., 2002). 
These challenges in radiotracer design also influence the technical limitations and resolution of 
PET images from both human and small animals, which ranges from 2.5 mm to 6 mm and about 
1.5 mm, respectively (Cherry, 2006). Although in vivo studies offer the ability to study the 
biodistribution of radiolabeled cannabinoid compounds as a measure of receptor occupancy, it 
does not however give insight into the functional component of GPCR output at the receptor 
level. 
 We present the first attempt to functionally map and localize CB1 receptor-mediated G-
protein activity in 3D reconstructed mouse brains. Reconstructed brain images were analyzed by 
SPM, which is a well characterized approach for the analysis of human brain imaging data and 
has been previously adapted for autoradiographic datasets mapping cerebral blood flow (Nguyen 
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et al., 2004). However, the analysis of reconstructed datasets derived from agonist-stimulated 
[35S]GTPγS autoradiography has not been described. Data from this chapter demonstrate the 
feasibility of using SPM to perform various imaging manipulations on reconstructed datasets 
including coregistration, spatial normalization, and smoothing (Supplemental data using these 
methods are illustrated in the Appendix Figs. A2-A3, Table A1). The SPM image registration 
tools were robust and accurate for the spatial normalization of brains, showing satisfactory 
spatial correspondence of brain areas between subjects. These novel imaging approaches will 
further be explored in the next two chapters to study ligand- and region-specific activation of 
CB1 receptors (Chapter 2) and to determine the role of the protein beta-arrestin 2 in regulating 
CB1 receptor function following chronic administration of THC (Chapter 3). 
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V. Chapter 2: Statistical Parametric Mapping reveals ligand and region specific activation 
of G-proteins by CB1 receptors and non-CB1 sites in the 3D reconstructed mouse brain 
 The development of selective CB1 antagonists, such as SR141716A (Rinaldi-Carmona et 
al., 1994), and CB1 knockout mice (Valverde et al., 2005; Zimmer et al., 1999) has shown that 
most effects of THC are primarily mediated by the CB1 receptor. Our findings have 
demonstrated that CB1 receptor signaling varies by brain region, for example when examined 
following acute activation of CB1 receptors (Breivogel et al., 1997; Selley et al., 2001). 
However, the complete regional profile of CB1 receptor activity has not been elucidated due to 
limitations of current strategies for design and analysis of autoradiographic studies. In this 
chapter, we will thest the hypothesis that CB1 receptor-mediated G-protein activity will differ by 
cannabinoid ligand and that the relative efficacy of these ligands will vary by brain region.  
 
2.1 Cannabinoid-mediated G-protein activation is ligand and region specific  
Differences in the efficacy of various cannabinoid agonists to activate G-proteins have 
previously been studied using agonist-stimulated [35S]GTPγS binding in membranes prepared 
from various brain regions (Breivogel and Childers, 2000). However it is unclear whether the 
relative efficacy of cannabinoid agonists to activate G-proteins varies by region as determined 
autoradiographically in brain tissue sections. SPM was used to determine regional differences in 
cannabinoid-mediated G-protein activity in reconstructed wild-type C57/Bl6J mouse brains 
(N=5) using maximally effective concentrations of cannabinoid agonists differing in efficacy and 
structure, including the aminoalkylindole WIN55,212-2 (WIN), bicyclic CP55,940 (CP), and the 
metabolically stable endocannabinoid analogue methanandamide (M-AEA). Maximally effective 
concentrations of agonists were determined in concentration-effect curves, using 0.003-3 µM 
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CP, 0.01-10 µM WIN, or 0.1-30 µM M-AEA in membrane preparations from mouse whole brain 
(Fig. 2.1) or cerebellum (data not shown). Membrane agonist-stimulated [35S]GTPγS binding 
experiments were conducted as previously published (Sim-Selley et al., 2006). Results from 
whole brain and cerebellum membranes were similar, and thus concentrations used for agonist-
stimulated autoradiographic assays in all studies (CB1+/+ and CB1-/- animal studies) were: CP (3 
µM), WIN (10 µM), M-AEA (25 µM). The calculated Emax had a net stimulation (agonist-
stimulated minus basal [35S]GTPγS binding) of 89.6 ± 4.9%, 94.2 ± 3.6%, and 110.3 ± 1.8% over 
basal for M-AEA, CP, and WIN, respectively. The relative rank order in potency to activate G-
proteins was CP > WIN > M-AEA, with EC50 values of 5.7 nM, 35 nM, and 354 nM, 
respectively. Volumetric reconstructions of autoradiographic sections provided 3D anatomical 
visualization and localization of cannabinoid-mediated G-protein activity (Fig. 2.2). The spatial 
extent of cannabinoid-stimulated G-protein activity as illustrated in Fig. 2.2 is shown in red, and 
the surface of the brain is rendered in gray for the right hemisphere. All three cannabinoid 
agonists significantly stimulated greater [35S]GTPγS binding than basal (no agonist) in all CB1 
receptor containing regions (Fig. 2.3) as determined by SPM analysis. As shown for WIN (Fig. 
2.2), cannabinoid-stimulated G-protein activity was widespread in the cortex, densely distributed 
in the output nuclei of the basal ganglia (globus pallidus, substantia nigra) and seen in bands in 
the cerebellum that presumably correspond to the molecular layer. To determine the regional 
relative efficacy, SPM was then used to compare G-protein activity produced by the three 
cannabinoid agonists. WIN-stimulated G-protein activity was significantly greater than M-AEA 
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Agonist EC50 (µM) Emax (% Net Stim.) 
   
M-AEA 0.32 ± 0.08 89.2 ± 4.2 
CP55,940 0.005 ± 0.001 93.7 ± 3.4 
WIN55,212-2 0.04 ± 0.01 102.5 ± 4.8 
 
 
 
 
Figure 2.1. Concentration-effect curves for cannabinoid agonists in membranes prepared from 
whole mouse brain. Varying concentrations of drug were incubated in 0.1 nM [35S]GTPγS, 
0.125% BSA, 30 µM GDP for 2 hrs at 30°C. No significant differences were found in agonist-
stimulated [35S]GTPγS binding produced by M-AEA, CP, and WIN. [35S]GTPγS binding 
experiments (N=3-4) were performed in triplicate and data are reported as the mean %Net 
Stimulation [(agonist-basal)/basal x 100%] + S.E.M. Data were fit using Graphpad Prism 5. 
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Figure 2.2. 3D image reconstruction and volumetric rendering of average (N = 3) cannabinoid-
stimulated [35S]GTPγS binding (red) in naïve mouse brain using a maximally effective 
concentration of the full CB1 receptor agonist WIN55,212-2 (10 µM). A threshold was applied to 
show the spatial extent of highest WIN-stimulated G-protein activity in brain regions, including 
the molecular layer of the cerebellum, cortex, and basal ganglia. AO (Anterior olfactory 
nucleus), Ent (entorhinal cortex), GP (globus pallidus), MO (medial orbital cortex), Pir (piriform 
cortex), SN (substantia nigra). Agonist-stimulated [35S]GTPγS binding autoradiography was 
performed as described in Methods 
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Figure 2.3. SPM analysis showing the regional distribution of significant differences between 25 
µM M-AEA- (A), 3 µM CP55,940- (B), or 10 µM WIN55,212-2- (C) versus basal [35S]GTPγS 
binding (p < 0.01, ANOVA, N = 5) in CB1+/+ reconstructed naive mouse brains. Representative 
coronal sections with colored overlays (red to yellow) show significant differences 
corresponding to a p-value scale. Corresponding bregma coordinates from the left- to rightmost 
column are: 0.26 mm, -2.46 mm, -3.16 mm, -6.12 mm (Paxinos et al., 2008). AMYG 
(amygdala), CBLM (cerebellum), Cg (cingulate cortex), CPu (caudate-putamen), HIPP 
(hippocampus), SN (substantia nigra). 
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Figure 2.4. Regional comparison of agonist-stimulated [35S]GTPγS binding produced by the 
cannabinoid agonists WIN (10 µM), CP (3 µM), and M-AEA (25 µM) in CB1+/+ reconstructed 
naive mouse brains. Representative coronal sections illustrate Statistical Parametric Maps (p < 
0.05, ANOVA, n=5) of significant differences in receptor-mediated G-protein activation, 
between WIN and M-AEA (A), or WIN and CP (B). WIN stimulated significantly greater G-
protein activity than M-AEA in most CB1 containing regions, with the exception of the thalamus. 
In addition, WIN-stimulated [35S]GTPγS binding was greater than CP in globus pallidus, 
periaqueductal gray, and hypothalamus. Colored overlays (red to orange) correspond to 
significance level represented by a p-value scale. Corresponding bregma coordinates from the 
top left anterior-most to bottom right posterior-most slice are: 0.02 mm, -0.7 mm, -1.7 mm, -3.4 
mm, -4.16 mm, -6.12 mm (Paxinos et al., 2008). Au (auditory cortex), Hipp (hippocampus), CPu 
(caudate-putamen), GP (globus pallidus), Hyp (hypothalamus), M (motor cortex), PAG 
(periaqueductal gray), S (somatosensory cortex), SN (substantia nigra reticular), V (visual 
cortex), M-AEA, methanandamide; WIN, WIN55,212-2 
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in almost all regions examined, with exception of the thalamus (Fig. 2.4A). SPM provided a 
detailed anatomical comparison, as seen in the cortex (cingulate, somatosensory, and motor 
cortex) where WIN produced significantly greater G-protein activation than M-AEA in both 
superficial and deep laminae (Fig. 2.4A). A similar regional activation profile (data not shown) 
was seen comparing CP and M-AEA, where CP stimulated significantly greater G-protein 
activity than M-AEA. When comparing WIN and CP however, region-specific differences in the 
relative stimulation produced by these agonists were identified by SPM. For example, WIN 
stimulated significantly greater G-protein activity than CP in some CB1 containing regions 
including globus pallidus, hypothalamus and periaqueductal gray (Fig. 2.4B). In contrast, WIN- 
and CP-stimulated G-protein activity were equivalent in the caudate-putamen, hippocampus, 
amygdala, cerebellum and cortical regions including motor, somatosensory, and cingulate 
cortices (Fig. 2.4B). Overall, SPM revealed that in some regions, including globus pallidus, 
hypothalamus, and periaqueductal gray, the activity profile was WIN > CP > M-AEA. In 
contrast, for most regions including caudate-putamen, hippocampus, amygdala, cerebellum and 
cortex (motor, somatosensory, and cingulate cortices) the relationship was WIN = CP > M-AEA. 
Interestingly, a different relative efficacy profile was found in the thalamus compared to all other 
brain regions. SPM revealed that WIN-, CP-, and M-AEA-stimulated [35S]GTPγS binding did 
not significantly differ in thalamic nuclei, including ventral posteromedial and posterolateral, 
ventromedial, and ventrolateral thalamic nuclei. Subsequent ROI analyses substantiated almost 
all of the SPM findings, except in hypothalamus where WIN and CP did not differ in stimulating 
[35S]GTPγS binding. In this brain region, ROI analysis revealed similar qualitative differences 
between WIN and CP as determined using SPM analysis, but failed to reach significance at the p 
< 0.05 level. This could be explained by differences in the analytical technique, where 
84 
 
significance by SPM is based at the individual voxel-level as opposed to a user-defined region of 
interest, which contains the average of many image pixels or subnuclei.  
While the anatomical distribution of agonist-stimulated G-protein activity was similar for 
each of the three agonists compared to basal (no agonist), the relative magnitude of activity 
varied by brain region, as determined by an independent ROI analysis of cannabinoid-stimulated 
[35S]GTPγS binding for selected brain regions (Table 2.1). The relative efficacies of the three 
agonists were calculated by expressing net agonist-stimulated [35S]GTPγS binding produced by 
CP or M-AEA as percent of [35S]GTPγS binding stimulated by the full agonist WIN (Table 2.1). 
For example, the relative efficacy of M-AEA ranged from 32% of WIN in the PAG to 76% of 
WIN in thalamus. In addition, the relative efficacy of CP ranged from 60% of WIN in 
periaqueductal gray to 105% in thalamus. Due to the potential contribution of WIN acting at 
non-CB1 sites (see next section), [35S]GTPγS binding data is also reported as %CP (Table 2.2).  
A similar relative efficacy relationship was revealed when using CP as the standard agonist. The 
high relative efficacy of WIN in specific brain regions did not correlate with having non-CB1-
mediated activity, indicating that CB1 receptors contribute to the majority of the signal detected 
in WIN-stimualted [35S]GTPγS autoradiography. When normalized to the full CB1 agonist WIN, 
there was no significant correlation between the relative efficacies of M-AEA- and CP-
stimulated G-protein activation (Fig. 2.5) across the sampled brain regions of interest. In 
addition, a significant interaction of drug x region (p < 0.01) was found when analyzed by a two 
way repeated measures ANOVA. A significant interaction between the factors drug and region 
and lack of correlation in the relative efficacy profile, suggests that there may be regional 
differences in the relative efficacies of M-AEA and CP, which cannot be explained by receptor 
levels or G-protein abundance. These results thus indicate that the relative G-protein activity 
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produced by these cannabinoid agonists was region-dependent, as revealed by both SPM and 
ROI analysis of 3D reconstructed agonist-stimulated [35S]GTPγS autoradiographic data.  
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Table 2.1 
Regional differences in the relative efficacies of different cannabinoid agonists (25 µM M-AEA, 
3 µM CP, 10 µM WIN) were found by both SPM and ROI analysis of agonist-stimulated 
[35S]GTPγS autoradiographic images in CB1+/+ naïve mice. 
 
 
Net-stimulated binding (nCi/g) Net stimulation as %WIN 
Brain Region M-AEA CP WIN M-AEA CP WIN 
Motor cortex 263 ± 11Aa 470 ± 14Bb 494 ± 13Bb 53 ± 2 95 ± 3 100 ± 3 
Somatosensory cortex 146 ± 29Aa 272 ± 44Bb 264 ± 37Bb 55 ± 11 103 ± 17 100 ± 14 
Cingulate cortex 273 ± 17Aa 488 ± 16Bb 521 ± 30Bb 52 ± 3 94 ± 3 100 ± 6 
Hippocampus 170 ± 34Aa 313 ± 50Bb 377 ± 26Bb 45 ± 9 83 ± 13 100 ± 7 
Amygdala 200 ± 34Aa 384 ± 36Bb 457 ± 28Bb 44 ± 7 84 ± 8 100 ± 6 
Thalamus 59 ± 20Aa 81 ± 24Aa 77 ± 2Aa 76 ± 25 105 ± 30 100 ± 27 
Hypothalamus 83 ± 23Aa 203 ± 31Bb 235 ± 16Cb 35 ± 10 86 ± 13 100 ± 7 
Periaqueductal gray 100 ± 30Aa 188 ± 19Bb 313 ± 23Cc 32 ± 10 60 ± 6 100 ± 7 
Cerebellum 210 ± 45Aa 472 ± 39Bb 456 ± 37Bb 46 ± 10 103 ± 8 100 ± 8 
Substantia Nigra 597 ± 45Aa 801 ± 28Bb 863 ± 42Bb 69 ± 5 93 ± 3 100 ± 5 
Globus Pallidus 480 ± 28Aa 607 ± 16Bb 788 ± 38Cc 61 ± 4 77 ± 2 100 ± 5 
Caudate-Putamen 189 ± 9Aa 373 ± 15Bb 399 ± 26Bb 47 ± 2 94 ± 4 100 ± 7 
 
A, B, C & a, b, c Net-stimulated binding values labeled with different letters within a brain region are 
significantly different from each other based on SPM (upper case; p < 0.05 corrected, ANOVA, 
n=5) or ROI analysis (lower case; p < 0.05, n=5, ANOVA, Tukey’s post-hoc analysis) as 
described under Methods. Measurements in each column are mean net [35S]GTPγS binding 
values (nCi/g) ± SEM for M-AEA-, CP-, and WIN-stimulated conditions as determined by ROI 
analysis. Net values were calculated by subtracting basal from agonist-stimulated [35S]GTPγS 
binding. ROI anatomical boundaries are described in Section III: Methods.  
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Table 2.2 
Relative efficacies of different cannabinoid agonists (25 µM M-AEA, 3 µM CP, 10 µM WIN) 
from ROI analysis of agonist-stimulated [35S]GTPγS autoradiographic images in CB1+/+ naïve 
mice. 
 
 
Net stimulation as %CP 
Brain Region M-AEA CP WIN 
Motor cortex 56 ± 2 100 ± 3 105 ± 3 
Somatosensory cortex 54 ± 11 100 ± 16 97 ± 14 
Cingulate cortex 56 ± 3 100 ± 3 107 ± 6 
Hippocampus 54 ± 11 100 ± 16 121 ± 8 
Amygdala 52 ± 9 100 ± 10 119 ± 7 
Thalamus 72 ± 24 100 ± 29 95 ± 26 
Hypothalamus 41 ± 11 100 ± 16 116 ± 8 
Periaqueductal gray 53 ± 16 100 ± 10 167 ± 13 
Cerebellum 44 ± 10 100 ± 8 97 ± 8 
Substantia Nigra 75 ± 6 100 ± 3 108 ± 5 
Globus Pallidus 79 ± 5 100 ± 3 130 ± 6 
Caudate-Putamen 51 ± 2 100 ± 4 107 ± 7 
 
 
ROI measurements in each column are mean net [35S]GTPγS binding values (nCi/g) ± SEM for 
M-AEA-, CP-, and WIN-stimulated conditions expressed as %CP. Net values were calculated by 
subtracting basal from agonist-stimulated [35S]GTPγS binding. ROI anatomical boundaries are 
described in Section III: Methods. 
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Figure 2.5. Correlation analysis of regional relative efficacy in CB1+/+ naive mice. No significant 
correlation was found between the relative efficacies of M-AEA (25 µM) and CP (3 µM) in 
sampled brain regions, suggesting regional differences in their relative efficacies. The axes 
represent the net-stimulated [35S]GTPγS binding (basal activity subtracted) value of each agonist 
(CP or M-AEA) normalized to net-stimulation by WIN (10 µM). Error bars represent the 
standard error of the mean and each point represents a sampled brain region, which include: 
motor cortex, somatosensory cortex, cingulate cortex, hippocampus, amygdala, thalamus, 
hypothalamus, periaqueductal gray, cerebellum, substantia nigra, globus pallidus, and caudate-
putamen. Agonist-stimulated [35S]GTPγS binding autoradiography was performed as described 
in Methods. 
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2.2 WIN55,212-2 stimulates G-protein activity in a subset of brain regions of mice lacking CB1 
receptors 
Results in wild-type mice suggested that the relative efficacy of cannabinoid agonists 
varies by brain region. However, the interpretation of these findings is complicated by the 
possible contribution of non-CB1 binding sites to receptor-mediated G-protein activity. This 
question was addressed using SPM analysis of M-AEA-, CP-, and WIN-stimulated [35S]GTPγS 
binding in reconstructed CB1-/- mouse brain (N=8). SPM analysis showed that agonist-stimulated 
[35S]GTPγS binding produced by CP or M-AEA did not significantly differ from basal activity 
(in the absence of agonist) in any brain region from CB1-/- mice (Fig. 2.6). However, WIN-
stimulated [35S]GTPγS binding significantly differed from basal binding in a number of areas in 
CB1-/- mice as determined by SPM and subsequently confirmed by ROI analyses (Table 2.3, Fig 
2.6). As seen in Fig. 2.7, WIN-stimulated [35S]GTPγS binding was significantly greater than 
basal binding in regions that partially overlapped the distribution of CB1 receptors. SPM analysis 
revealed WIN-stimulated [35S]GTPγS binding in visual (V) and auditory cortices (Au) that 
appeared to be localized to deeper laminae. In the hippocampus, WIN-stimulated [35S]GTPγS 
binding was noted in the caudal, ventral CA1 and CA3, and to a lesser extent rostral, dorsal CA3. 
Although ROI analysis of the whole hippocampus showed a similar trend as in the SPM analysis, 
it failed to reach significance at the p < 0.05 criterion, possibly due to the heterogeneity of signal 
in this brain region as demonstrated in the SPM map (Fig. 2.7). WIN-stimulated [35S]GTPγS 
binding was widely distributed in the amygdaloid complex, and appeared to be distributed in 
areas that corresponded to anterior portions of the basomedial and basolateral, and medial, lateral 
and central nuclei. WIN-stimulated [35S]GTPγS binding was also found in the medial 
hypothalamus. Interestingly, the greatest magnitude of WIN-stimulated [35S]GTPγS binding in 
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CB1-/- mouse brains was found within the brain stem including tegmental nuclei that appeared to 
correspond to lateral and dorsal tegmentum, and areas adjacent to the fourth ventricle, which 
corresponds to the locus coeruleus (Table 2.3). Significant WIN-stimulated G-protein activity 
was also found in the cerebellum that appeared to correspond to the molecular layer. In contrast, 
no differences between WIN-stimulated G-protein activity and basal binding were detected in 
basal ganglia (globus pallidus, substantia nigra, caudate-putamen), brain areas that normally 
contain among the highest levels of CB1 receptors. It is important to note that the average 
magnitude of net WIN-stimulated G-protein activation in significant brain areas was 
approximately 4-5 fold less in CB1-/- mice compared to wild-type mice (Table 2.1 versus 2.3). 
For example, net WIN-stimulated G-protein activity (WIN stimulated – basal) in cerebellum was 
83 ± 20 nCi/g in CB1-/-, compared to 456 ± 37 nCi/g in wild-type mice. Thus, data from 
reconstructed CB1-/- mouse brains suggest that the aminoalkylindole WIN, but not the 
endocannabinoid analogue M-AEA or bicyclic CP, activates non-CB1 sites in a subset of brain 
areas that only partially overlaps with CB1 receptor containing regions. 
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Table 2.3 
WIN (10 µM) stimulated [35S]GTPγS binding in CB1-/- brains in regions partially overlapping 
CB1 receptors. 
 
 
[35S]GTPγS binding (nCi/g) 
 
Sig. Sig. 
Brain Region Basal WIN 
WIN 
Net %Stim SPM ROI 
Auditory cortex 455 ± 17 533 ± 18 77 ± 21 18 ± 5 v,c * 
Visual cortex 434 ± 20 494 ± 20 60 ± 30 16 ± 7 v,c n.s. 
Amygdala 763 ± 20 911 ± 34 148 ± 27 19 ± 3 v,c ** 
Hippocampus 429 ± 16 478 ± 18 49 ± 24 12 ± 6 p < 0.01 n.s. 
Thalamus 390 ± 17 397 ± 8 7 ± 14 3 ± 3 n.s. n.s. 
Hypothalamus 735 ± 29 863 ± 35 128 ± 40 19 ± 6 v * 
Dorsal Tegmental complex 483 ± 12 687 ± 21 205 ± 19 43 ± 4 p < 0.001 *** 
Locus Coeruleus 523 ± 23 720 ± 30 197 ± 29 39 ± 6 p < 0.001 *** 
Globus Pallidus 508 ± 19 488 ± 12 -19 ± 14 -3 ± 3 n.s. n.s. 
Substantia Nigra 404 ± 17 419 ± 13 16 ± 29 6 ± 8 n.s. n.s. 
Caudate-Putamen 509 ± 24 515 ± 24 6 ± 20 2 ± 4 n.s. n.s. 
Periaqueductal gray 758 ± 27 764 ± 16 6 ± 30 2 ± 4 n.s. n.s. 
Cerebellum 223 ± 11 306 ± 20 83 ± 20 39 ± 10 v,c ** 
 
 
Measurements in columns 1 and 2 are mean [35S]GTPγS binding values (nCi/g) ± SEM for basal- 
and WIN-stimulated conditions sampled within each brain region by ROI.  Net binding equals 
[WIN stimulated- basal binding].  Percent stimulation (%Stim) for each brain region is calculated 
as ([(WIN – basal)/basal]*100%). Column five shows significance (p < 0.05) at the voxel (v) or 
cluster (c) level (corrected for multiple comparisons, as described in Section III: Methods, 
ANOVA, n=8) or uncorrected p-value for each brain region as determined by SPM analysis. 
Column six shows results obtained by ROI measurement with subsequent analysis using repeated 
measures ANOVA, followed by Tukey’s post-hoc comparison. *, p < 0.05, **, p < 0.01, ***, p < 
0.001. ROI anatomical boundaries are described in Methods. WIN, WIN55,212-2; n.s. = not 
significant
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Figure 2.6. Agonist-stimulated [35S]GTPγS binding values measured and analyzed using regions 
of interest (ROI) from a subset of brain areas from naive CB1-/- mice (N = 8) using different 
cannabinoid agonists (25 µM M-AEA, 3 µM CP, 10 µM WIN). * p < 0.05, ** p < 0.01, *** p < 
0.001 compared to basal; # p < 0.05, ## p < 0.01, ### p < 0.001 compared to M-AEA; & p < 
0.05, && p < 0.01, &&& p < 0.001 compared to CP. All comparisons used a one-way repeated 
measures ANOVA followed by Tukey's Multiple Comparison Test. Agonist-stimulated 
[35S]GTPγS binding autoradiography was performed as described in Methods 
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Figure 2.7. SPM analysis showing the regional distribution of significant differences between 
WIN-stimulated (10 µM) and basal [35S]GTPγS binding (p < 0.05, ANOVA, n=8) in CB1-/- 
mouse brains. Representative coronal sections with colored overlays (red to yellow) show 
significant differences (WIN > basal) corresponding to a p-value scale. Corresponding bregma 
coordinate from top left anterior-most slice to bottom right posterior-most slice are: 1.34 mm, -
1.82 mm, -3.28 mm, -4.84 mm, -5.34 mm (Paxinos et al., 2008). Au (auditory ctx), BMA/BLA 
(basomedial and basolateral amygdala), CA1 (CA1 field of hippocampus), CBLM (cerebellum), 
CPu (caudate-putamen), DTg (tegmental nucleus, dorsal), LC (locus coeruleus), MH (medial 
hypothalamus), SN (substantia nigra), V (visual cortex), WIN, WIN55,212-2. Agonist-stimulated 
[35S]GTPγS binding autoradiography was performed as described in Methods 
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2.3 WIN55,212-2-stimulated G-protein activity in wild-type mice is blocked by SR141716.  
 The aminoalkylindole WIN activated G-proteins in CB1-/- mice, providing evidence for 
non-CB1 sites in a genetic model. To validate this finding, a pharmacological approach was 
applied by incubating wild-type mouse brain sections with WIN in the presence or absence of the 
CB1 antagonist SR141716A (SR1), and resulting G-protein activity was compared using SPM in 
the reconstructed CB1+/+ mouse brain (N=8). In CB1 antagonist studies 0.5 µM SR141716A was 
used, which is 1,000-fold greater than its KD value and at this concentration does not exhibit 
inverse agonism in [35S]GTPγS autoradiographic assays, as previously determined in our 
laboratory (Sim-Selley et al., 2001). 
 SR1 (0.5 µM) alone did not significantly stimulate or inhibit [35S]GTPγS binding 
compared to basal binding in any brain region (Fig. 2.8). WIN-stimulated G-protein activity was 
robust and widespread in CB1 receptor containing regions in the absence of SR1, as discussed 
above (Fig. 2.8). WIN-stimulated [35S]GTPγS binding in the presence of SR1 (WIN/SR1) was 
reduced in all brain regions and did not significantly differ from basal as determined by SPM. It 
is possible that WIN might exhibit lower potency and/or efficacy for putative non-CB1 sites 
(Breivogel et al., 2001). Therefore, a higher concentration of WIN (50 µM) was used in the 
presence or absence of 0.5 µM SR1 in select brain regions that demonstrated non-CB1 binding 
sites as determined in CB1-/- mice (Table 2.3, Fig. 2.7). WIN alone produced greater G-protein 
activation compared to basal in all regions, except for dorsal tegmentum where only an 
insignificant trend was observed (Fig. 2.9). Variability in measured signal in this particular 
region was probably due to the general difficulty in collecting representative sections at the same 
level of dorsal tegmentum from different animals. ROI analyses of all these regions, however, 
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showed no significant stimulation of [35S]GTPγS binding  in the presence of 50 µM WIN + SR1 
(Fig. 2.9). These findings suggest that SR1 might also bind to putative non-CB1 sites.  
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Figure 2.8. SPM analysis showing various comparisons between WIN (10 µM), WIN in the 
presence of the CB1 antagonist SR1 (WIN/SR1; 0.5 µM)), SR1 alone (0.5 µM), or basal (no 
agonist) (p < 0.01, ANOVA, n=8) in CB1+/+ mouse brains. Representative coronal sections are 
shown at the level of the striatum (A), hippocampus (B), substantia nigra (C), and cerebellum 
(D). Colored overlays (red to yellow) show significant differences corresponding to a p-value 
scale. Corresponding bregma coordinate from top- to bottom-most row are: -0.34 mm, -1.7 mm, 
-3.28 mm, -5.52 mm. WIN, WIN55,212-2; SR1, SR141716A. Agonist-stimulated [35S]GTPγS 
binding autoradiography was performed as described in Methods 
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Figure 2.9. SR141716A (0.5 µM) blocked 30 µM WIN-stimulated [35S]GTPγS binding 
(represented as the mean ± SEM) in naive CB1 +/+ mice (N = 7). * p < 0.05, ** p < 0.01, *** p < 
0.001 compared to basal. All comparisons used a one-way repeated measures ANOVA followed 
by Tukey's Multiple Comparison Test. Agonist-stimulated [35S]GTPγS binding autoradiography 
was performed as described in Methods  
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2.4 The inactive isomer WIN55,212-3 does not produce G-protein activation in cerebellum of 
CB1 -/- mice 
 To confirm the stereoselectivity of the aminoalkylindole WIN55,212-2 for putative non-
CB1 sites, we used its inactive stereoisomer WIN55,212-3 to stimulate [35S]GTPγS binding in 
CB1-/- mice. Compared to basal (354.5 ± 11.63 nCi/g), 10 µM of WIN55,212-3 produced no 
differences in receptor-stimulated [35S]GTPγS binding  (381 ± 14.1 nCi/g). The full CB1 agonist 
and active isomer WIN55,212-2, however, produced significantly greater G-protein activation 
(443.3 ± 14.06 nCi/g) when compared to either basal or WIN55,212-3 (Fig. 2.10). As a positive 
control, the synthetic µ opioid receptor agonist DAMGO (10 µM) stimulated greater [35S]GTPγS 
binding (1150 ± 9.2 nCi/g) compared to basal (686.2 ± 24.2 nCi/g) in the medial thalamus of 
CB1-/- mice (Fig. 2.10). These results suggest that putative non-CB1 sites in the cerebellum of 
CB1-/- mice show stereoselectivity to the active isomer WIN55,212-2 in regard to G-protein 
activation. This stereoselectivity also supports the fact that G-protein activation of non-CB1 sites 
is receptor-mediated. 
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Figure 2.10. Stereoselectivity of WIN55,212-2 in stimulating [35S]GTPγS binding in naive CB1-/- 
mice. WIN55,212-2 (10 µM) produced greater [35S]GTPγS binding (shown as the mean ± SEM) 
compared to either basal or its inactive isomer WIN55,212-3 (10 µM) in the cerebellum from 
naive CB1 -/- mice (N = 8). The synthetic µ opioid receptor agonist DAMGO (10 µM) was used 
as a positive control. *** p < 0.001 compared to basal. ## p < 0.01 compared to WIN55,212-3. 
Cerebellum analysis used a one-way repeated measures ANOVA followed by Tukey's Multiple 
Comparison Test and Medial Thalamus used a pair-wise t-test. Agonist-stimulated [35S]GTPγS 
binding autoradiography was performed as described in Methods 
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2.5 Discussion 
The primary goal of this study was to elucidate regional differences in the relative 
efficacy of receptor-mediated G-protein activity produced by cannabinoids differing in intrinsic 
efficacy and chemical structure. The potential contribution of non-CB1 sites to agonist-stimulated 
G-protein activity was then evaluated in the CB1-/- mouse model. This was accomplished using a 
novel approach, in which Statistical Parametric Mapping (SPM) was adapted for whole-brain 
analysis of 3D reconstructed agonist-stimulated [35S]GTPγS autoradiographic data. SPM 
revealed regional differences in the efficacy of cannabinoids to activate G-proteins in brains of 
wild-type mice and localized novel WIN-stimulated [35S]GTPγS binding sites in CB1-/- mouse 
brains. This approach provided the dual advantages of creating a functional map of receptor-
activated G-proteins in the reconstructed brain, with an unbiased statistical comparison of levels 
of G-protein activity, thereby providing new data on cannabinoid-mediated activity in the mouse 
brain.  
 SPM has previously been adapted for the analysis of reconstructed autoradiographic 
datasets mapping cerebral blood flow (Nguyen et al., 2004), and successfully applied to 
functionally map brain activity in small animals (Dubois et al., 2008; Holschneider et al., 2006; 
Soto-Montenegro et al., 2008; Yang et al., 2007). Applying SPM analysis to in vitro agonist-
stimulated [35S]GTPγS autoradiographic data offers unique advantages compared to conventional 
region of interest (ROI) analysis. ROI analysis is generally assessed within predefined 
anatomical boundaries, but effects of interest might not always conform to anatomically defined 
regions. For heterogenous distributions of receptor-mediated activity, the size and shape of ROIs 
and plane(s) of data might be difficult to define a priori in order to maximize signal detection.  In 
addition, if regions of receptor activity are substantially smaller than the defined ROI, 
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significance might be missed when signal is averaged with surrounding background that is 
included within the ROI. Moreover, the anatomical precision of this approach is illustrated in the 
motor and somatosensory cortices, where voxels with the most significant and greatest 
magnitude of cannabinoid-stimulated [35S]GTPγS binding in CB1+/+ mice were localized in 
specific cortical laminae (Fig. 2.4A) in a pattern consistent with previous reports showing the 
highest concentration of CB1 receptor protein in the superficial (II, III) and deep (VI) layers of 
cortex (Herkenham et al., 1991; Tsou et al., 1998). It is important to note that most of the 
significant differences between cannabinoid-stimulated [35S]GTPγS binding showed bilateral 
symmetry. This neuroanatomical property, in addition to the known expression profile of CB1 
receptor protein, further strengthens the validity of SPM for analyzing agonist-stimulated 
[35S]GTPγS binding autoradiographic data. 
Initial studies revealed regional differences in the relative efficacies of WIN-, CP-, and M-
AEA-stimulated [35S]GTPγS binding. SPM comparison identified an efficacy profile of WIN > 
CP > M-AEA in areas including globus pallidus, hypothalamus, and periaqueductal gray. 
However in other brain areas including caudate-putamen, cerebellum, hippocampus, amygdala, 
substantia nigra and cortex, the relative efficacy for cannabinoid-stimulated G protein activity 
was WIN = CP > M-AEA. A different finding emerged in the thalamus, where the profile WIN = 
CP = M-AEA was found. A previous study using membrane preparations from cerebellum, 
hippocampus, and hypothalamus also reported regional differences in the relative efficacy and 
potency of WIN, CP, and M-AEA (Breivogel and Childers, 2000). However, the relative 
stimulation of receptor-activated G-proteins for these cannabinoid agonists differed somewhat 
from the current study. This discrepancy could be due to differences in the anatomical resolution 
of autoradiography versus [35S]GTPγS binding in membranes prepared from grossly dissected 
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brain regions. While the mechanism(s) underlying regional differences in relative agonist 
efficacy are not known, CB1 receptors have been shown to exhibit domain selectivity for 
coupling to different subtypes of Gαi/o, and in various brain regions, activate different subtypes 
of G-proteins with varying efficacy and potency after agonist stimulation (Mukhopadhyay et al., 
2000; Prather et al., 2000). Cannabinoid-selective G-protein signaling has also been 
demonstrated using recombinant expression of CB1 receptors in situ with reconstitution of 
purified G-protein subunits (Glass and Northup, 1999). In that study, the relative efficacies of 
different cannabinoid agonists differed between Gαi versus Gαo activation. One can thus envision 
ligand- and region-specific CB1 receptor signaling based on the stoichiometric complement of 
various Gα subtypes.  
An alternative explanation for the higher efficacy of certain cannabinoids is the contribution 
of multiple receptors (e.g. CB1 + non-CB1 receptors) to the overall agonist-stimulated activity. 
To explore this question further, SPM was used to determine the extent to which WIN, CP, and 
M-AEA, would activate G-proteins in CB1-/- mouse brains. Of these cannabinoid agonists, only 
the aminoalkylindole WIN significantly stimulated [35S]GTPγS binding when compared to basal 
activity (absence of agonist). In this study, WIN stimulated [35S]GTPγS binding in a subset of 
brain regions in CB1-/- mouse brains that only partially overlapped the distribution of activity in 
CB1+/+ brains. The greatest magnitudes of WIN-stimulated G-protein activity were noted within 
the dorsal tegmental complex and locus coeruleus, which contain acetylcholine and 
norepinephrine producing neurons, respectively. Relatively high levels of G-protein activation 
were also found in the cerebellum, which appear to correspond to the molecular layer. Modest G-
protein activation was found in the cortex, amygdala, hippocampus, and hypothalamus. 
Interestingly, the hypothalamus was a brain region in which SPM analysis of brains from CB1+/+ 
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mice found significantly greater WIN- versus CP-stimulated [35S]GTPγS binding, suggesting a 
possible contribution of additional non-CB1 sites to the greater efficacy for WIN in G-protein 
activation. However, for other brain areas in CB1-/- mice with significant WIN-stimulated 
[35S]GTPγS binding, such as amygdala and cerebellum, there were no differences in efficacy for 
G-protein activation between WIN and CP in the CB1+/+ mice. For these brain areas, it is possible 
that differences in regional G-protein coupling may enhance the efficacy of CP in CB1+/+ mice. 
Interestingly, no significant WIN-stimulated [35S]GTPγS binding in CB1-/- mice was found in the 
nuclei of the basal ganglia, which normally contain the highest levels of CB1 receptors 
(Herkenham et al., 1991). In contrast, the brainstem contains relatively low to moderate levels of 
CB1 receptors (Herkenham et al., 1991) but the greatest magnitude of WIN-stimulated activity 
was detected in certain pontine nuclei. These findings are also consistent with previous reports 
that WIN stimulated [35S]GTPγS binding, but CP had no effect, in membrane homogenates 
prepared from CB1-/- mice (Breivogel et al., 2001). Although previous studies have also found 
that anandamide (AEA) stimulated G-protein activity in CB1-/- mice (Breivogel et al., 2001; Di 
Marzo et al., 2000), the stable analog M-AEA had no effect in this study. Brain areas with 
significant WIN-stimulated [35S]GTPγS binding compared to basal in this study (Table 2) were 
similar to those previously reported by Breivogel and colleagues (Breivogel et al., 2001). Both 
studies found WIN-stimulated G-protein activity in the brainstem, cortex, hypothalamus, and 
hippocampus, and no significant WIN-stimulated [35S]GTPγS binding in the basal ganglia. 
However, no significant WIN-stimulated [35S]GTPγS binding was found in the cerebellum by 
Breivogel and colleagues, whereas in this study significance was localized in bands that appear 
to correspond to the molecular layer of the cerebellum (Fig 4). The slight discrepancy in results 
could be due to differences in the analytical techniques, where SPM assesses changes at the 
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individual voxel-level in intact brain tissue sections versus the [35S]GTPγS binding assay for 
homogenized gross brain areas. 
Interestingly, non-CB1 WIN-stimulated [35S]GTPγS binding sites detected by SPM appeared 
to be distributed in certain functional systems. The localization of non-CB1 sites in the locus 
coeruleus (LC) and its projection regions including frontal cortex, amygdala, hypothalamus, 
hippocampus, and cerebellum, might suggest a possible neuromodulatory role of these non-CB1 
sites within the noradrenergic system. Noradrenergic projections from the LC to forebrain 
regions are especially relevant to regulation of cognition, attention and anxiety (Aston-Jones et 
al., 1999; Bremner et al., 1996; Foote et al., 1983). Previous studies by Van Bockstaele and 
colleagues have shown that systemic WIN administration increased cfos expression in tyrosine 
hydroxalase positive LC neurons, indicating that WIN was affecting the coeruleo-cortical 
pathway. In addition, administration of WIN systemically (Oropeza et al., 2005) or directly into 
the frontal cortex (Page et al., 2008) increased norepinephrine release in an SR1-sensitive 
manner. Interestingly, CB1 receptors are generally associated with presynaptic inhibition of 
neurotransmitter release (Schlicker and Kathmann, 2001) and inhibit NE release in the 
hippocampus (Schlicker et al., 1997). While it is possible that enhanced WIN-mediated NE 
release in the frontal cortex occurs via an indirect mechanism, it is also possible that NE release 
is regulated by both CB1 and non-CB1 receptors in this region. Approximately 30% of CB1 
receptor immunoreactive terminals in the frontal cortex also contain the catecholamine-
synthesizing enzyme dopamine-β-hydroxylase (Oropeza et al., 2007), and if non-CB1 WIN sites 
predominated in remaining terminals, the net result could be enhanced NE release. However, this 
question would need to be further examined in CB1-/- mice. Thus, the anatomical profile of non-
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CB1 WIN sites found in the current study could subserve a distinct modulatory function from the 
endogenous cannabinoid system that has yet to be fully characterized. 
Because WIN was active in CB1-/- mice, pharmacological studies were conducted in CB1+/+ 
mice to assess WIN-stimulated [35S]GTPγS binding in the presence of the CB1 receptor 
antagonist SR141716A (SR1). However, no significant G-protein activation was detected with 
WIN in the presence of SR1, nor did SR1 alone produce any change in [35S]GTPγS binding 
compared to basal activity. Thus, it is possible that SR1 might bind to both CB1 and non-
CB1/CB2 sites. In fact, previous studies have shown that certain non-CB1 mediated effects of 
WIN are inhibited by pretreatment with SR1 (Hajos et al., 2001; Hoffman et al., 2005; Pistis et 
al., 2004). It is further possible that multiple non-CB1 WIN-stimulated [35S]GTPγS binding sites 
exist, based on pharmacological and species specificity as defined in the literature (Hoffman et al 
2005). Although the molecular identity of non-CB1 WIN-binding sites in the current study is 
unknown, several conclusions can be reached regarding their pharmacology. WIN is an agonist 
of unknown efficacy, SR1 appears to be an antagonist or very low efficacy partial agonist, and 
CP and M-AEA are not agonists. Further, these sites are presumably coupled to inhibitory G-
proteins of the Gαi/o class because agonist-stimulated [35S]GTPγS autoradiography in brain does 
not appear to detect other classes of receptor-activated G-proteins due to the high abundance of 
Gαo in brain and the kinetics of binding under the conditions of the assay (Sim-Selley and 
Childers, 2002). Insensitivity to CP indicates that these sites are unlikely to be CB2 receptors 
(Govaerts et al., 2004), despite previous reports that CB2 receptors are expressed in brainstem 
(Van Sickle et al., 2005). These sites are also unlikely to be GPR55, which has been shown to 
activate Gq and G12 and does not respond to WIN in various in vitro assays (Ross, 2009).  Thus, 
the present results provide anatomical and functional evidence supporting the existence of a 
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novel non-CB1/CB2/GRP55 WIN-stimulated [35S]GTPγS binding site in defined regions of 
mouse brain. 
 In summary, Statistical Parametric Mapping (SPM) was used to assess and spatially map 
regional differences in cannabinoid-mediated G-protein activity in reconstructed mouse brain 
images derived from agonist-stimulated [35S]GTPγS binding autoradiography. SPM analysis, 
combined with conventional ROI analysis, demonstrated regional differences in the relative 
efficacies of various cannabinoid agonists, and showed that certain cannabinoid agonists activate 
functional non-CB1 sites, in addition to CB1 receptors. The unique pharmacology and functional 
neuroanatomical distribution of non-CB1 sites indicates that this novel system might have 
distinct physiological roles from the endogenous cannabinoid system that have yet to be 
characterized. Furthermore, the neuroanatomical distribution of these putative non-CB1 sites 
suggests that this system could be exploited therapeutically. Lastly, this study demonstrates SPM 
as a powerful tool for the neuroanatomical analysis and functional mapping of G-protein coupled 
receptors in 3D reconstructed mouse brain images derived from [35S]GTPγS autoradiography. 
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VI. Chapter 3: β-arrestin 2 regulation of the CB1 receptor following chronic administration 
of THC 
 In the previous chapter, whole brain analysis of CB1 receptor activity revealed region-
specific differences in the relative efficacy of different classes of cannabinoid agonists. Regional 
differences in the relative efficacy of receptor-mediated G-protein activation suggest unique 
signaling properties of the CB1 receptor that could result in differential receptor regulation by 
brain region. This hypothesis could have implications for the regulation of CB1 receptor 
adaptation during repeated cannabinoid administration, which could affect the magnitude and/or 
rate of tolerance development following repeated administration of cannabinoids. Chronic 
administration of THC and other cannabinoid agonists generally leads to the development of 
tolerance to its in vivo effects. Tolerance has also been demonstrated to various cannabinoid-
mediated effects including antinociception, hypothermia, catalepsy, spontaneous motor 
hypoactivity, and memory. Previous work in our laboratory demonstrated region-specific 
differences in the attenuation or desensitization of CB1 receptor activity following chronic 
administration of THC (McKinney et al., 2008; Sim-Selley and Martin, 2002; Sim-Selley et al., 
2006; Sim et al., 1996a). However, a mechanistic link between desensitization and tolerance has 
not been determined for cannabinoids. Studies in cell models have shown that β-arrestin 2 
(βarr2) regulates CB1 receptors in vitro (Jin et al., 1999; Kouznetsova et al., 2002), but evidence 
for involvement of βarr2 in regulation of CB1 receptors in brain is very limited. In this chapter, 
we will test the hypothesis that the regulatory protein βarr2 mediates the functional adaptation of 
CB1 receptors to chronic stimulation by THC in certain brain regions where the two are co-
distributed. Further, we propose that βarr2-mediated regulation of CB1 receptors contributes to 
the development of tolerance to THC-mediated in vivo effects. 
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3.1 β-arrestin 2 attenuates tolerance to specific THC-mediated effects in vivo 
 One study has reported the potential role of βarr2 in acute cannabinoid-mediated effects. 
Breivogel et al. (Breivogel et al., 2008) showed that loss of βarr2 enhanced THC-mediated 
antinociception and hypothermia in βarr2 knockout (KO) mice compared to wild-type (WT) 
mice. Similarly, Bohn et. al. reported enhanced and prolonged antinociception after morphine 
administration, as well as greater morphine-mediated hypothermia in mice lacking βarr2 
compared with their wild-type littermates (Bohn et al., 2000; Bohn et al., 2002; Bohn et al., 
1999). The role of βarr2 in cannabinoid-mediated effects following repeated cannabinoid 
administration has not been examined, but evidence from the µ opioid system suggests possible 
outcomes. In those studies, βarr2 KO mice did not develop tolerance to morphine-mediated 
antinociception as determined in the hot-plate test, but interestingly only delayed tolerance when 
assessed using the warm-water tail immersion test. These results suggest that βarr2 regulates 
nociceptive function through the µ opioid receptor and may have differential effects within 
various anatomical systems. Mu opioid receptors and CB1 receptors both belong to the 
superfamily of GPCRs and interact in certain physiological responses (reviewed in (Corchero et 
al., 2004)). However, it is unclear whether common mechanisms regulate these receptor classes. 
We therefore tested the hypothesis that βarr2 is involved in producing tolerance to various THC-
mediated effects. 
 To test this hypothesis, βarr2 KO mice and their WT littermates were treated twice daily 
for 6.5 days with an intraperitoneal (i.p.) administration of either vehicle (1:1:18, 
ethanol:cremaphor:saline) or 10 mg/kg THC. Drug dosing and in vivo tests were done in 
collaboration by Dr. Laura Bohn's laboratory (Scripps Research Institute, FL). On the morning of 
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the 7th day, 24 hrs following drug treatment, THC-mediated effects were assessed using a 
cumulative dosing paradigm (3, 7, 20, 26, 44 mg/kg for doses of 3, 10, 30, 56, 100 mg/kg i.p.) in 
40 minute intervals, in which behaviors were assessed 30 minutes after each injection. The 
following behaviors were assessed: 1) antinociception using the tail warm-water withdrawal 
assay at 52°C, 2) hypothermia using rectal temperature, and 3) catalepsy using the ring 
immobility test. In vivo procedures are outlined in Section III - Methods. 
 Results revealed that abrogation of βarr2 produced effect-specific alterations in both 
vehicle control and THC-treated mice. Interestingly in the vehicle treated groups, βarr2 KO 
animals displayed a greater sensitivity to the hypothermic effect of THC compared to WTs 
[F(1,84) = 7.39, p < 0.01].  In contrast, mice in the vehicle treated groups, showed no difference 
in antinociception or immobility between genotypes. Assessment of tolerance to these effects 
following repeated THC treatment also showed effect-specific alterations in tolerance in βarr2 
KO compared to WT mice. However in this case, only tolerance to antinociception was affected 
by loss of βarr2. Although both WT [F(1,84) = 92.45, p < 0.0001] and βarr2 KO [F(1,84) = 
14.72, p < 0.001] animals developed tolerance to the antinociceptive effects of THC (Fig. 3.1C), 
tolerance to antinociception was attenuated in the THC-treated βarr2 KO group, which was 
significantly less than the THC-treated WT group [F(1,84) = 13.25, p < 0.001]. When tested for 
catalepsy, both WT [F(1,84) = 18.13, p < 0.0001] and βarr2 KO [F(1,84) = 53.76, p < 0.0001] 
animals developed tolerance that was of similar magnitude (Fig. 3.1B). In contrast to acute 
results, both WT [F(1,84) = 51.15, p < 0.0001] and βarr2 KO [F(1,84) = 44.48, p < 0.0001] 
animals developed tolerance to THC-mediated hypothermia following the chronic THC dosing 
paradigm (Fig. 3.1A) and the tolerance was similar in magnitude. These results show that βarr2 
may be involved in the acute effects of THC-mediated hypothermia, whereas tolerance to 
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antinociception is attenuated in βarr2 KO mice. Therefore, attenuation in tolerance occurred in a 
behavior-specific manner, suggesting that βarr2 may regulate CB1 receptors in a region-specific 
manner as well in brain. 
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Figure 3.1. THC-mediated in vivo effects in βArr2 KO and WT animals following 6.5 day 
administration of 10 mg/kg THC or vehicle treatment (i.p.) given twice daily. THC-mediated 
effects including change in rectal temperature, percentage of time of ring immobility (catalepsy), 
and percent of maximum possible antinociceptive effect were measured. Both βArr2 KO and WT 
animals developed tolerance to THC-mediated hypothermia (A) and catalepsy (B). However, 
tolerance to THC-mediated antinociception (C) was significantly attenuated in βArr2 KO 
animals compared to WT. Data reflect the mean ± SEM (N = 8 per group) 
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3.2 β-arrestin 2 regulates CB1 receptor desensitization in mouse spinal cord following chronic 
administration of THC 
 
 Persistent exposure to an agonist leads to characteristic changes at the level of the GPCR 
in order to dampen its signaling capacity, and thereby maintain equilibrium. The mechanisms 
underlying the regulation of GPCRs, specifically receptor desensitization (uncoupling of G-
proteins) and downregulation (receptor degradation), have been studied extensively in cell 
models (Ferguson and Caron, 1998; Gainetdinov et al., 2004). In the classical sense, receptor 
desensitization occurs when a receptor is phosphorylated by a GPCR kinase (GRK), which leads 
to the binding of an arrestin protein and subsequent uncoupling of the G-protein from its cognate 
receptor. These same mechanisms appear to contribute to regulation of CB1 receptors in response 
to persistent stimulation by an agonist. Previous work by Mackie and colleagues has shown that 
co-expression of both GRK3 and βarr2, using a Xenopus Oocyte expression system, was required 
for the rapid desensitization of CB1-receptor mediated potassium currents following exposure to 
the full CB1 agonist WIN55,212-2 (Jin et al., 1999). In the current study, the attenuation in 
tolerance to THC-mediated antinociception, as measured by tail withdrawal in βarr2 KO mice, 
also suggests that βarr2 regulates CB1 receptors in anatomical circuits that may mediate this 
behavior. The tail withdrawal assay is largely a spinally-mediated reflex, suggesting that βarr2-
mediated  regulation of CB1 receptors in the spinal cord could contribute to this observation. To 
test this hypothesis, whole spinal cords were collected from mice 24 hours after the behavioral 
tests described above. Membrane preparations from homogenized spinal cord were then used to 
generate concentration-effect curves of cannabinoid-stimulated [35S]GTPγS binding to assess 
changes in CB1 receptor-mediated G-protein activity (conducted as described in Section III - 
Methods). No significant differences were found in basal (no agonist) [35S]GTPγS binding 
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between genotypes or drug treatment groups, thus indicating no gross alteration in constitutive 
G-protein coupling (Fig 3.2). These data also indicate that residual THC did not remain in the 
sample because it would stimulate [35S]GTPγS binding above basal levels seen in vehicle-treated 
mice. CP55,940 (CP)-mediated G-protein activity was first compared between vehicle-treated 
mice to determine whether loss of βarr2 altered baseline (e.g. no drug treatment) CB1 receptor 
activity. Results showed that CP-stimulated [35S]GTPγS binding did not differ between 
genotypes in vehicle-treated mice, with Emax values (expressed as %Net Stimulation, see 
Methods) of 45.04 ± 1.91% in WT and 46.41 ± 2.13% in βarr2 KO animals (Fig. 3.3A, Table 
3.1). Chronic treatment with THC lead to significant desensitization of receptor-mediated G-
protein activity in βarr2 WT mice, with an Emax value for CP-stimulated [35S]GTPγS binding of 
27.88 ± 3.64% in WT compared to 41.10 ± 1.80% in βarr2 KO animals, which represented an 
approximately 38% decrease in receptor-mediated activity (Fig. 3.3A, Table 3.1). Interestingly, 
CB1 receptor desensitization was attenuated in the βarr2 KO mice, where its Emax value for CP-
stimulated [35S]GTPγS binding was reduced by approximately 11% of its respective vehicle 
control. Further, this Emax value did not significantly differ from its respective vehicle control, 
but did differ from THC-treated WT mice. No differences were found in the EC50 values for CP-
stimulated [35S]GTPγS binding between treatment groups (Table 3.1). This important 
observation indicates that there was satisfactory washout of drug prior to performing in vitro 
studies. Similar results were obtained when using the full CB1 agonist WIN55,212-2 (WIN) to 
assess receptor-stimulated [35S]GTPγS binding (Fig. 3.3B). Again, WIN-stimulated [35S]GTPγS 
binding did not differ between genotypes in vehicle-treated mice, with Emax values of 75.46 ± 
6.82% in WT and 80.87 ± 11.55% in βarr2 KO animals (Fig. 3.3B, Table 3.1). Chronic treatment 
also led to significant desensitization of CB1 receptors βarr2 WT mice with an Emax value of 
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49.39 ± 4.41%, or an approximately 35% decrease in receptor-mediated G-protein activity, 
compared to no change in the βarr2 KO animals (Emax value of 72.53 ± 5.99%, or an 
approximately 10% decrease in receptor-mediated G-protein activity). When comparing Emax 
values between THC-treated βarr2 WT and KO mice, a close trending difference was also found 
(p = 0.052). Lastly, a significant interaction between Drug x Genotype was found [F(1,24) = 
5.68, p < 0.05], suggesting that βarr2 is involved in mediating CB1 receptor desensitization of G-
protein coupling following THC treatment in spinal cord. Thus βarr2  regulation of CB1 receptor 
desensitization may be one mechanism that contributes to THC-mediated antinociceptive 
tolerance.  
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Basal [35S]GTPγS Binding (nCi/g) 
 
WT Vehicle WT THC βarr2-/- Vehicle βarr2-/- THC 
214.7 ± 10.6 207.5 ± 17.9 221.3 ± 19.8 198 ± 14.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Basal [35S]GTPγS binding in spinal cord of βArr2 KO and WT animals following 
chronic THC or vehicle treatment. βArr2 KO and WT animals received 6.5 day administration of 
10 mg/kg THC or vehicle treatment (i.p.) given twice daily. No differences were found in basal 
(no agonist) [35S]GTPγS binding by genotype or drug treatment as determined by 2-way 
ANOVA. Binding values represent the mean ± SEM (N = 6).  
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Figure 3.3.  Desensitization of CB1 receptor-mediated G-protein activation was attenuated in 
spinal cords of βarr2 KO animals following chronic treatment of THC. βArr2 KO and WT 
animals received 6.5 day administration of 10 mg/kg THC or vehicle treatment (i.p.) given twice 
daily. Agonist-stimulated [35S]GTPγS binding curves using CP55,940 (A) or WIN55,212-2 (B) 
are shown and values are expressed as %Net stimulation [(agonist - basal)/basal x 100%]. Each 
point represents the mean ± SEM (N = 6-7 in each point) [35S]GTPγS binding value. Emax 
[35S]GTPγS binding values were calculated using non-linear regression analyses in Prism and are 
shown in the bar graphs (right). * p < 0.05, *** p < 0.001, compared to respective vehicle 
control; ### p < 0.001 versus KO THC (2-way ANOVA, Student-Newman Keuls post-hoc). 
Agonist-stimulated [35S]GTPγS binding curves were generated as described in Methods.  
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Table 3.1. Desensitization of CB1 receptor-mediated G-protein activation was attenuated in 
spinal cords of βarr2 knockout animals following chronic treatment of THC. βArr2 KO and WT 
animals received 6.5 day administration of 10 mg/kg THC or vehicle treatment (i.p.) given twice 
daily. Concentration-effect curves were constructed and analyzed for best-fit Emax and EC50 
values using Prism and described in Methods. Values represent the mean ± SEM (N = 6-7 in 
each point). Emax [35S]GTPγS binding values are expressed as %Net stimulation [(agonist - 
basal)/basal x 100%]. * p < 0.05, *** p < 0.001, versus respective vehicle control group; ### p < 
0.001 versus KO THC (2-way ANOVA, bonferroni post-test).  
 
Group EC50 (µM) Emax (% Net Stim.) % Vehicle 
CP55,940    
WT Vehicle 0.04 ± 0.01 45.04 ± 1.91 100 ± 4.25 
WT THC 0.02 ± 0.01 27.88 ± 3.64***,### 61.89 ± 8.08 
βarr2-/- Vehicle 0.02 ± 0.01 46.41 ± 2.13 100 ± 4.60 
βarr2-/- THC 0.01 ± 0.01 41.10 ± 1.80 88.56 ± 3.88 
WIN55,212-2    
WT Vehicle 0.08 ± 0.02 75.46 ± 6.82 100 ± 9.04 
WT THC 0.20 ± 0.04 49.39 ± 4.41* 65.45 ± 5.84 
βarr2-/- Vehicle 0.34 ± 0.19 80.87 ± 11.55 100 ± 14.28 
βarr2-/- THC 0.22 ± 0.07 72.53 ± 5.99 89.67 ± 7.41 
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3.3 β-arrestin 2 regulates CB1 receptor downregulation in mouse spinal cord following chronic 
administration of THC 
 βarr2 may also serve other physiological functions in the regulation of GPCR signaling. 
For example, βarr2 has previously been demonstrated as an adaptor protein, targeting 
phosphorylated β2 adrenergic receptors towards degradation via clathrin-mediated endocytosis 
(Lin et al., 1997). Reduction in cell surface receptor levels, or downregulation, could therefore be 
another mechanism contributing to drug tolerance. We therefore evaluated the effect of βarr2 
deletion on CB1 receptor downregulation in whole spinal cord following chronic THC 
administration. Receptor binding saturation curves were generated using the CB1 receptor 
antagonist SR141716A (SR1). No differences were found in [3H]SR141716A binding between 
genotypes in vehicle treated mice, with Bmax values (pmol/mg) of 0.47 ± 0.04 in WT and 0.54 ± 
0.04 in βarr2 KO mice (Fig. 3.4). Chronic THC treatment resulted in significant CB1 receptor 
downregulation in βarr2 WT mice (Bmax = 59.4% of vehicle control) that was attenuated in βarr2 
KO mice (Bmax = 82.3% of vehicle control) (Fig. 3.3). Furthermore, no differences in receptor 
affinity were found between groups (Fig. 3.3), indicating adequate washout of drug and that 
downregulation was due primarily to a reduction in bound CB1 receptor protein. It is important to 
note that SR1 recognizes both high and low affinity binding states of the receptor, and therefore 
is independent of receptor desensitization. These results thus indicate that βarr2 is also involved 
in regulating CB1 receptor downregulation within the spinal cord, thus contributing to the 
attenuation in THC-mediated antinociceptive tolerance.  
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Group KD (nM) Bmax (pmol/mg) % Vehicle 
    
WT Vehicle 1.03 ± 0.24 0.47 ± 0.04 100 ± 9.07 
WT THC 0.91 ± 0.11 0.28 ± 0.02**,# 59.40 ± 4.12 
βarr2-/- Vehicle 1.43 ±0.27 0.54 ± 0.04 100 ± 6.67 
βarr2-/- THC 1.51 ± 0.34 0.44 ± 0.07 82.30 ± 12.21 
 
 
 
 
 
 
 
Figure 3.4. Chronic administration of THC led to downregulation of CB1 receptors in spinal 
cords of WT animals, but was abolished in βarr2 KO mice. βArr2 KO and WT animals received 
6.5 day administration of 10 mg/kg THC or vehicle treatment (i.p.) given twice daily. CB1 
receptor binding curves (as described in Methods) were generated using [3H]SR141716A. Bmax 
(pmol/mg) and KD (nM) values were calculated with Prism using a one site hyperbola function 
and displayed as the mean ± SEM (N = 6-7 per point). ** p < 0.01, compared to respective 
vehicle control; # p < 0.001 versus KO THC (2-way ANOVA, Student-Newman Keuls post-hoc) 
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3.4 Method for 3D reconstruction of agonist-stimulated [35S]GTPγS and [3H]CP55,940 binding 
autoradiography 
 Results of in vivo studies showed that βarr2 deletion altered THC-mediated effects in a 
effect-specific manner. The attenuation in THC-mediated antinociceptive tolerance, but not 
tolerance to catalepsy or hypothermia, suggests that βarr2 may differentially regulate CB1 
receptor signaling within different neuronal populations. For example, cannabinoid-mediated 
antinociception is likely to be mediated by circuits that include the PAG and spinal cord 
(Lichtman et al., 1996). Results in membrane homogenates of spinal cord support a role for 
βarr2-regulated CB1 receptor desensitization/downregulation in this region in antinociceptive 
tolerance.  Based on in vivo findings, we predict that deletion of βarr2 would reduce 
desensitization in regions including PAG.  Conversely, we do not predict that βarr2 would affect 
desensitization in regions such as hypothalamus and basal ganglia that contribute to hypothermia 
and catalepsy, respectively. To test this hypothesis, we utilized Statistical Parametric Mapping 
(SPM) analysis to determine whether βarr2 regulates CB1 receptor function and levels following 
chronic THC treatment, using reconstructed images derived from agonist-stimulated [35S]GTPγS 
and [3H]CP55,940 binding autoradiography, respectively. 
 3D reconstructions of agonist-stimulated [35S]GTPγS binding were conducted as outlined 
in Chapters 1-2. CP55,940 (CP) was used to stimulate [35S]GTPγS binding, since we showed that 
it exhibits similar efficacy as the full CB1 agonist WIN55,212-2 (WIN) for G-protein activation 
in a number of CB1 receptor containing brain regions (see Chapter 2, Fig. 2.4) but does not 
activate non-CB1/CB2 sites as shown in mice lacking CB1 receptors (see Chapter 2, Fig. 2.7). 
[35S]GTPγS binding values in reconstructed images were expressed as net differences (agonist-
stimulated minus basal [35S]GTPγS binding). These reconstructions of net values were derived 
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by image subtracting basal images from their respective CP-stimulated images, both of which 
were spatially normalized to the same coordinate space. Estimation of spatial normalization 
parameters were derived from CP-stimulated images, as these provided the most contrast 
between anatomical structures. The image average of all CP-stimulated reconstructions from all 
treatment groups was used to create the template for estimation of spatial normalization of 
individual CP-stimulated reconstructions. These parameters were then applied to basal images 
that were coregistered to their respective CP-stimulated brain image. To remove artifactual 
binding values, such as negative numbers that result from inadequate overlap of basal and CP-
stimulated images, these values were set to zero. These occurred most frequently along the 
contour of sections, where artifacts related to slice preparation were predominately found. 
Setting negative voxel values to zero thus allows the SPM program to ignore these data points 
and view them as background, which by default has a voxel value of zero. 
 To quantitate CB1 receptor density, [3H]CP55,940 (3 nM) was incubated with brain 
sections, in the presence (non-specific binding) or absence (total binding) of 10 µM CP55,940. 
Images of total binding values (specific + non-specific) were used to reconstruct images derived 
from [3H]CP55,940 binding autoradiography. This was done because non-specific activity was 
low, therefore reconstructions derived from non-specific binding sections would be suboptimal 
given the extremely low contrast and poor structural information following image quantitation 
(Fig. 3.5B).  Average non-specific activity ranged from 0.49% to 3.6% of total binding across all 
sampled brain regions of interest (see next section). This would present a technical challenge for 
creating image reconstructions derived from specific binding values. Reconstructions of total 
[3H]CP55,940 binding used similar approaches as in agonist-stimulated [35S]GTPγS binding 
images (outlined in Chapter 2).   
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Figure 3.5. (A) CB1 receptor Bmax and KD values were determined in mouse cerebellum with 
[3H]CP55,940 using a one site hyperbola function in Prism. (B) [3H]CP55,940 autoradiographic 
images are shown for total (left column) and non-specific (right column) binding. [3H]CP55,940 
autoradiography and receptor-binding were conducted as described in Methods, Section III. 
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3.5 β-arrestin 2 regulates CB1 receptor desensitization in a region-specific manner 
 Previous studies from our laboratory demonstrated that CB1 receptors undergo 
desensitization following chronic THC administration, with regional differences in the 
magnitude of reduction in CB1 receptor-mediated G-protein activation (McKinney et al., 2008; 
Sim-Selley and Martin, 2002; Sim et al., 1996a). Based on in vivo results from this study and 
agonist-stimulated [35S]GTPγS binding results in spinal cord, one would postulate that βarr2 
could produce region-specific regulation of CB1 receptor desensitization in the CNS. To answer 
this question, CB1 receptor-mediated G-protein activity was assessed in the reconstructed mouse 
brain using SPM with subsequent region of interest (ROI) analyses in brains from vehicle- and 
THC-treated βarr2 WT and KO mice. 
 Under basal conditions with no agonist, there were no observed differences by genotype 
or drug treatment in all sampled brain areas in regards to basal [35S]GTPγS binding (Fig. 3.6). 
Within vehicle control groups, significant differences between genotypes in CP-stimulated 
[35S]GTPγS binding were found in certain sampled brain regions. The biggest difference was 
found in the piriform cortex where greater CB1 receptor-mediated G-protein activity was found 
in the βarr2 KO animals (380 ± 18 nCi/g) versus WT animals (225 ± 32 nCi/g) (Fig. 3.7). In the 
auditory/visual (A/V) cortex, significantly greater CB1 receptor-mediated G-protein activity was 
also found in the βarr2 KO animals (249 ± 26 nCi/g) versus WT animals (188 ± 20 nCi/g). 
Interestingly, intra-regional differences in the vehicle treated groups were found in the 
hippocampus, where significant differences in CB1 receptor-mediated G-protein activity were 
only noted in the caudal extent. In the caudal sub-region of the hippocampus, CP-stimulated 
[35S]GTPγS binding was 362 ± 27 nCi/g in βarr2 KO animals versus 279 ± 31 nCi/g in the WT 
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Figure 3.6. Basal [35S]GTPγS binding values in βArr2 KO and WT animals following chronic 
administration of THC or vehicle. No differences in basal [35S]GTPγS binding were found by 
either genotype or drug treatment in various brain regions as determined by 2-way ANOVA. 
Binding values represent the mean ± SEM in various sampled brain regions from βarr2 WT and 
KO  mice following 6.5 day chronic administration of either vehicle or 10 mg/kg THC (N = 8 per 
group) twice daily.  
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Figure 3.7. Net (agonist - basal) CP55,940-stimulated [35S]GTPγS binding values (mean ± SEM) 
in sampled brain regions from βarr2 WT and KO  mice following 6.5 day treatment with vehicle 
twice daily (N = 8 per group). *** p < 0.001, * p < 0.05; Two way ANOVA, Student-Newman 
Keuls Post-hoc. CG CTX, cingulate cortex; CPU, caudate-putamen; GP, globus pallidus; PIR 
CTX, piriform cortex; HIPP, hippocampus; AMYG, amygdala; HYPO, hypothalamus; THAL, 
thalamus; SS CTX, somatosensory cortex; SN, substantia nigra; A/V CTX, auditory/visual 
cortex; PAG, periaqueductal gray; CBLM, cerebellum   
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animals. Similar non-significant trends of greater CB1 receptor-mediated G-protein activity were 
also noted in the cingulate cortex (p = 0.051), somatosensory cortex (p = 0.078), and amygdala 
(p = 0.058) of βarr2 KO animals versus WT (Fig. 3.7). Overall, these results showed regionally 
restricted differences in agonist-stimulated [35S]GTPγS binding between genotypes that were 
generally small in magnitude. 
 SPM with subsequent ROI analyses was then applied to assess agonist-stimulated 
[35S]GTPγS binding in vehicle- and THC-treated βarr2 WT and KO mice to compare the 
regional profile and magnitude of desensitization between genotypes. Comparing volumetric 
reconstructions derived from the image average of all subjects within each group, visual 
decreases in CB1 receptor-stimulated [35S]GTPγS binding can be appreciated in brain areas 
including the hippocampus, amygdala, and rostral periaqueductal gray (PAG), within both βarr2 
WT and KO animals following THC treatment (Fig. 3.8-3.9). Overall, SPM analysis revealed 
region-specific receptor desensitization in CB1 receptor-mediated G-protein activity (Fig. 3.10) 
with a similar regional relationship in magnitude of desens as previously reported: hippocampus 
> cerebellum > striatum/basal ganglia (McKinney et al., 2008; Sim et al., 1996a). Also, the 
distribution of receptor desensitization coincided with regions known to contain CB1 receptors 
(Herkenham et al., 1991), as well as the anatomical distribution of CB1 receptor activity (Chapter 
2).  
 A subset of regions showed a similar response as seen in spinal cord and were consistent 
with the prediction that βarr2 regulates CB1 receptor desensitization. The clearest example of this 
was in the cerebellum. SPM detected moderate desensitization in WT animals (Fig. 3.10), where  
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Figure 3.8. Net cannabinoid-stimulated [35S]GTPγS binding reconstructions derived from the 
image average of all subjects within each group (N = 8). βarr2 WT and KO  mice were treated 
for 6.5 day administration of either vehicle or 10 mg/kg THC twice daily. Original 
autoradiographic images are shown in grayscale and correspond to the scale (bottom right). CG 
CTX, cingulate cortex; CPU, caudate-putamen; GP, globus pallidus; PIR CTX, piriform cortex; 
HIPP, hippocampus; AMYG, amygdala; HYPO, hypothalamus; THAL, thalamus; SS CTX, 
somatosensory cortex; SN, substantia nigra; A/V CTX, auditory/visual cortex; PAG, 
periaqueductal gray; CBLM, cerebellum.  
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Figure 3.9. Net cannabinoid-stimulated [35S]GTPγS binding reconstructions derived from the 
image average of all subjects within each group (N = 8). βarr2 WT and KO  mice were treated 
for 6.5 day administration of either vehicle or 10 mg/kg THC twice daily. Images are shown in 
pseudocolor and correspond to the color scale (bottom right). Anatomical reference labels are 
shown in Fig. 3.8. 
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Figure 3.10. SPM analysis revealed both region- and genotypic-specific differences in 
desensitization of CB1 receptor-mediated G-protein activation in the reconstructed mouse brain 
of βarr2 WT and KO mice following 6.5 day chronic administration of either vehicle or 10 
mg/kg THC (N = 8 per group) twice daily. Brain regions within each genotype demonstrating 
significant desensitization (p < 0.05, 2-way ANOVA, N = 8) are colored in blue/green and 
correspond to the significance scale (bottom). AMYG, amygdala; A/V CTX, auditory/visual 
cortex; CBLM, cerebellum; CG, cingulate cortex; CPU, caudate-putamen; GP, globus pallidus; 
HIPP, hippocampus; HYPO, hypothalamus; PAG, periaqueductal gray; PIR, piriform cortex; SN, 
substantia nigra; SS, somatosensory cortex; THAL, thalamus; V, visual cortex;.  
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Figure 3.11. Region- and genotypic-specific differences were found in the magnitude of CB1 
receptor desensitization following chronic 6.5 day THC treatment twice daily in both βarr2 WT 
and KO  mice (N = 8 per group). CP55,940-stimulated [35S]GTPγS binding values are shown 
normalized to vehicle and represent the mean ± SEM (N = 8). * p < 0.05, Student's two-sample t-
test. CG CTX, cingulate cortex; CPU, caudate-putamen; GP, globus pallidus; PIR CTX, piriform 
cortex; HIPP, hippocampus; AMYG, amygdala; HYPO, hypothalamus; THAL, thalamus; SS CTX, 
somatosensory cortex; SN, substantia nigra; A/V CTX, auditory/visual cortex; PAG, 
periaqueductal gray; CBLM, cerebellum.  
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Figure 3.12. Net CP55,940-stimulated [35S]GTPγS binding values (mean ± SEM) in sampled 
brain regions (N = 8 per group) of βarr2 WT and KO  mice following 6.5 day chronic 
administration of either vehicle or 10 mg/kg THC twice daily. *** p < 0.001, ** p < 0.01, * p < 
0.05 versus respective vehicle; ### p < 0.001, # p < 0.05 versus WT vehicle; $ versus KO THC 
(Two way ANOVA, Student-Newman Keuls Post-hoc). A/V, auditory/visual; SS, somatosensory 
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Table 3.2 
Net CP55,940-stimulated [35S]GTPγS binding values in brain tissue sections from βarr2 WT and 
KO  mice following 6.5 day chronic administration of either vehicle or 10 mg/kg THC (N = 8 per 
group) twice daily 
 
Brain sections were incubated with 0.04 nM [35S]GTPγS, 3 µM CP55,940, and 2 mM GDP as 
described under III. Methods. [35S]GTPγS binding values represent the mean ± SEM. ). *** p < 
0.001, ** p < 0.01, * p < 0.05 versus respective vehicle; ### p < 0.001, # p < 0.05 versus WT 
vehicle; $ versus KO THC (N = 8 per group, two way ANOVA, Student-Newman Keuls Post-
hoc) 
 
 Vehicle THC 
Region WT βarr2-/- WT βarr2-/- 
NAc 150 ± 20 189 ± 24 136 ± 24 163 ± 33 
CPu 256 ± 23 282 ± 24 230 ± 17 252 ± 25 
GP 726 ± 36 751 ± 47 631 ± 41 593 ± 43* 
CG CTX 221 ± 39 318 ± 36 176 ± 29 235 ± 29 
HIPP (rostral) 248 ± 17 242 ± 32 147 ± 32* 146 ± 23* 
HIPP (caudal) 279 ± 31 362 ± 27# 203 ± 12* 212 ± 14*** 
PIR CTX 225 ± 32 380 ± 18### 195 ± 29 229 ± 25*** 
A/V CTX 188 ± 21 249 ± 26 165 ± 23# 169 ± 9* 
SS CTX 226 ± 25 281 ± 22 168 ± 15 169 ± 20** 
AMYG 321 ± 17 385 ± 27 209 ± 26** 228 ± 19*** 
HYPO  216 ± 21 238 ± 32 169 ± 35 136 ± 20* 
THAL 90 ± 15 90 ± 15 79 ± 12 110 ± 21 
SN 814 ± 26 856 ± 30 776 ± 58 733 ± 24* 
PAG (rostral) 146 ± 19 171 ± 28 81 ± 16* 88 ± 9** 
PAG (caudal) 207 ± 26 189 ± 22 100 ± 12**,$ 158 ± 12 
LEnt CTX 350 ± 16 393 ± 19 252 ± 23** 277 ± 23*** 
CBLM 440 ± 19 437 ± 23 314 ± 32* 434 ± 38 
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ROI analysis showed that CB1 receptor-mediated G-protein activity in THC-treated WT mice 
was 71 ± 7% of vehicle levels. In contrast, CB1 receptor desensitization was nearly abolished in 
βarr2 KO mice following chronic treatment with THC, and CB1 receptor-mediated G-protein 
activity was comparable in βarr2 KO and WT mice. A significant interaction of Drug treatment 
X Genotype was also found [F(1,28) = 4.51, p < 0.05], suggesting that βarr2 is involved in 
mediating CB1 receptor desensitization within the cerebellum following this treatment paradigm. 
Interestingly, intra-regional differences in the magnitude of CB1 receptor desensitization were 
revealed by SPM analysis, which underscores an advantage of using a whole-brain approach to 
assess the regulatory role of βarr2 in mediating CB1 receptor desensitization in highly different 
neuroanatomical systems and brain regions. In these regions, βarr2 attenuated desensitization in 
certain aspects of the nucleus, whereas desensitization was similar between genotypes in other 
subregions.  For example, initial ROI examination of the caudal sub-region of the PAG showed 
that chronic THC lead to a greater reduction in CB1 receptor-mediated activity in the WT 
animals (48 ± 5% of respective vehicle) versus βarr2 KO animals (84 ± 6% of respective vehicle) 
(Fig. 3.8). However, in more rostral portions of the PAG, SPM analysis revealed significant 
desensitization within the βarr2 KO animals (51 ± 5% of respective vehicle). Subsequent ROI 
analysis substantiated these findings, demonstrating significant desensitization within both βarr2 
WT and KO mice (Fig. 3.12, Table 3.2). 
 Other regions showed no difference between βarr2 KO and WT mice either because both 
genotypes exhibited desensitization (i.e. amygdala) or neither genotype exhibited desensitization 
(i.e. striatum).  Consistent with previous reports using similar dosing paradigms (McKinney et 
al., 2008; Sim-Selley and Martin, 2002; Sim et al., 1996a), there were no differences in CB1 
receptor-mediated G-protein activity in the caudate-putamen and nucleus accumbens within 
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either genotype, as determined by both SPM and ROI analyses. Interestingly, different results 
were found in the striatal/basal ganglia output nuclei, as discussed below. In the thalamus, a 
brain area with relatively sparse concentrations of CB1 receptors (Herkenham et al., 1991), there 
were also no differences in CP-stimulated [35S]GTPγS binding following THC treatment in 
either genotype. Similar magnitudes of desensitization were found in the amygdala region within 
both genotypes, where there was slightly greater desensitization in βarr2 KO (59 ± 5% of 
respective control) versus WT animals (65 ± 8% of respective control). Among all sampled 
cortical regions in this study, including cingulate, somatosensory, piriform, and auditory/visual 
cortex, CB1 receptor G-protein activity in the WT mice was apparently reduced following THC 
treatment, ranging between 74-87%, but did not differ from vehicle-treated mice. Significant 
desensitization however was found in the lateral entorhinal cortex within WT THC-treated 
animals. Interestingly, there was a trend towards greater desensitization in the βarr2 KO mice, 
particularly in the piriform (60 ± 6% of vehicle) and auditory/visual cortex (68 ± 3% of vehicle), 
as demonstrated by SPM analysis and subsequently confirmed by an independent ROI analysis 
(Fig. 3.10, Fig. 3.11). This appeared to result from the slightly higher, but insignificant 
difference from WT level of CP-stimulated [35S]GTPγS binding in vehicle-treated βarr2 KO 
mice. As noted above, the piriform cortex was also a brain region where CP-stimulated 
[35S]GTPγS binding in the vehicle treated groups was greater in the βarr2 KO versus WT mice 
(Fig. 3.7).  
  Unexpectedly, SPM analysis identified enhanced desensitization in certain regions of 
βarr2 KO mice. SPM showed significant desensitization of CB1 receptor-mediated G-protein 
activation in the hypothalamus of βarr2 KO animals (57 ± 8% of vehicle), but not in WT mice 
(79 ± 16% of vehicle) This was subsequently confirmed by ROI analysis, which showed no 
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difference in CP-stimulated [35S]GTPγS binding between vehicle- and THC-treated WT animals. 
The basal ganglia output nuclei, including the substantia nigra and globus pallidus, contain the 
highest concentrations of CB1 receptors (Herkenham et al., 1991) and are relatively insensitive to 
changes in CB1 receptor activity following THC treatment. Although WT animals exhibited no 
changes in CB1 receptor-mediated G-protein activity after THC treatment, βarr2 KO animals 
interestingly displayed a significant reduction in the substantia nigra (85 ± 3% of respective 
vehicle) and a trend in the globus pallidus (79 ± 6%, p = 0.053). Subregional differences in 
desensitization were also found in the hipocampus. In this region, desensitization was more 
robust in the caudal extent of βarr2 KO mice (Fig. 3.10). This was confirmed by a subsequent 
ROI analysis, which showed significantly greater desensitization in the caudal aspects of the 
hippocampus in βarr2 KO mice (58.6 ± 4% of vehicle), compared to WT mice (72.6 ± 4% of 
vehicle). Significant reductions in CP-stimulated [35S]GTPγS binding were also found in the 
rostral hippocampus of βarr2 KO and WT animals, where both exhibited about a 40% reduction 
following chronic THC treatment.  
 Increases in the apparent efficacy of CP-stimulated [35S]GTPγS binding in various brain 
regions in βarr2 KO mice appeared to be associated with the enhancement or unmasking of CB1 
receptor desensitization in the these same brain regions following chronic administration of 
THC. Interestingly, the relative magnitude of desensitization of βarr2 KO when normalized to 
WT animals was positively correlated with the relative efficacy of CP-stimulated [35S]GTPγS 
binding in βarr2 KO mice when normalized to WT animals (p = 0.0101, R2 = 0.5; Fig. 3.13). For 
example, a 1.5 fold increase in the relative efficacy of CP-stimulated [35S]GTPγS binding in 
βarr2 KO mice was equal to about a 2 fold increase in the relative magnitude of desensitization 
in βarr2 KO mice.  This suggests that increases in the apparent efficacy of cannabinoid agonists 
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in βarr2 KO mice may enhance other regulatory pathways thus producing greater CB1 receptor 
desensitization. 
 Together, these results suggest a regional-specificity in the regulation of CB1 receptors by 
βarr2 at the level of G-protein coupling.  However, it is unclear whether βarr2 may regulate other 
mechanisms of CB1 receptor adaptation, such as receptor downregulation or degradation of 
proteins. 
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Brain Region Desensitization Ratio Relative efficacy 
Cingulate cortex 1.44 ± 0.16 1.26 ± 0.44 
Somatosensory cortex 1.24 ± 0.10 1.53 ± 0.27 
Auditory-Visual cortex 1.33 ± 0.14 2.65 ± 0.30 
Piriform cortex 1.69 ± 0.08 3.01 ± 0.49 
Lateral Enthorhinal cortex 1.12 ± 0.05 1.06 ± 0.21 
Amygdala 1.20 ± 0.08 1.16 ± 0.14 
Hippocampus (rostral) 0.98 ± 0.13 0.97 ± 0.24 
Hippocampus (caudal) 1.30 ± 0.10 1.51 ± 0.14 
Periaqueductal gray (rostral) 1.17 ± 0.19 1.10 ± 0.12 
Caudate Putamen 1.10 ± 0.09 1.00 ± 0.85 
Hypothalamus 1.10 ± 0.15 2.01 ± 0.38 
Nucleus Accumbens 1.26 ± 0.16 1.44 ± 1.91 
 
Figure 3.13. Relative efficacy of CP-stimulated [35S]GTPγS binding is positively correlated with 
the relative magnitude of CB1 receptor desensitization in βarr2 KO mice following chronic THC 
administration (top graph). βArr2 KO and WT animals received 6.5 day administration of 10 
mg/kg THC or vehicle treatment (i.p.) given twice daily. Each point in the graph represents a 
brain area (listed in the table above) corresponding to its mean Desensitization Ratio and mean 
Relative efficacy. The Desensitization Ratio was calculated by normalizing the magnitudes of 
desensitization in βarr2 KO mice to the mean magnitude of desensitization in βarr2 WT mice. 
The Relative efficacy was calculated by normalizing the magnitudes of CP-stimulated 
[35S]GTPγS binding in vehicle treated βarr2 KO mice by the mean magnitude of CP-stimulated 
[35S]GTPγS binding in vehicle treated βarr2 WT mice. Calculated ratios in the table represent the 
mean ± SEM (N = 8). Linear regression analysis was performed in Graphpad Prism 5. 
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3.6 β-arrestin 2 is involved in CB1 receptor downregulation in the cerebellum 
 βarr2 targeting of GPCRs towards internalization and subsequent degradation represents 
another mechanism by which GPCRs respond to persistent stimulation by agonists. To 
investigate whether there were changes in CB1 receptor levels within the brain following THC 
treatment, SPM and ROI analyses of [3H]CP55,940 binding were performed. Results in sampled 
brain regions showed that [3H]CP55,940 binding did not differ between genotypes in vehicle-
treated mice (Fig. 3.14). Comparing volumetric reconstructions derived from the image average 
of all subjects within each group, visual decreases in [3H]CP55,940 binding can be seen in the 
cortex, hippocampus, and PAG (Figs. 3.15-3.16). Again, striatal regions including the caudate-
putamen and basal ganglia output nuclei (globus pallidus, substantia nigra), demonstrated 
minimal changes in [3H]CP55,940 binding. 
 In the cerebellum, CB1 receptors were significantly downregulated (55 ± 10% of vehicle) 
and this response was virtually abolished in βarr2 KO mice. In addition, a significant interaction 
of Drug treatment X Genotype was found in the cerebellum [F(1,28) = 4.277, p < 0.05], 
suggesting that βarr2 is involved in mediating CB1 receptor downregulation in this particular 
brain area (Fig 3.18, Table 3.3).  
 In general, there were no significant differences in CB1 receptor levels according to SPM 
analysis (data not shown) and in all sampled brain regions using ROI, within βarr2 KO mice 
following chronic THC treatment. Within WT mice, only an insignificant trend towards 
decreased receptor levels were found following THC treatment in the hypothalamus (71 ± 20% 
of respective vehicle), hippocampus (75 ± 17% of respective vehicle), and PAG (68 ± 15% of 
respective vehicle) (Fig. 3.17). Collectively, these results suggest that βarr2 may be involved in 
mediating receptor downregulation in the cerebellum. 
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Figure 3.14. [3H]CP55,940 binding values (mean ± SEM) in sampled brain regions from βarr2 
WT and KO  mice following 6.5 day chronic administration of either vehicle or 10 mg/kg THC 
twice daily (N = 8 per group). CG CTX, cingulate cortex; CPU, caudate-putamen; GP, globus 
pallidus; HIPP, hippocampus; AMYG, amygdala; HYPO, hypothalamus; THAL, thalamus; SS 
CTX, somatosensory cortex; SN, substantia nigra; PAG, periaqueductal gray; CBLM, cerebellum. 
[3H]CP55,940 autoradiography was performed as described in Methods 
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Figure 3.15. [3H]CP55,940 receptor binding reconstructions derived from the image average of 
all subjects within each group (N = 8 per group). βarr2 WT and KO  mice were treated 6.5 day 
with either vehicle or 10 mg/kg THC twice daily. Original autoradiographic images are shown in 
grayscale and correspond to the scale of binding values (bottom right). CG CTX, cingulate 
cortex; CPU, caudate-putamen; GP, globus pallidus; PIR CTX, piriform cortex; HIPP, 
hippocampus; AMYG, amygdala; HYPO, hypothalamus; THAL, thalamus; SS CTX, 
somatosensory cortex; SN, substantia nigra; A/V CTX, auditory/visual cortex; PAG, 
periaqueductal gray; CBLM, cerebellum. [3H]CP55,940 autoradiography was performed as 
described in Methods 
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Figure 3.16. [3H]CP55,940 receptor binding reconstructions derived from the image average of 
all subjects within each group (N = 8 per group). βarr2 WT and KO  mice were treated 6.5 day 
with either vehicle or 10 mg/kg THC twice daily. Images are shown in pseudocolor and 
correspond to the color scale of binding values (bottom right). Anatomical reference labels are 
shown in Fig. 3.15. [3H]CP55,940 autoradiography was performed as described in Methods 
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Figure 3.17. [3H]CP55,940 binding values normalized to vehicle (mean ± SEM) in sampled 
brain regions from βarr2 WT and KO  mice following 6.5 day chronic administration of either 
vehicle or 10 mg/kg THC twice daily (N = 8 per group). ** p < 0.05, Student's two-sample t-test. 
CG CTX, cingulate cortex; CPU, caudate-putamen; GP, globus pallidus; PIR CTX, piriform 
cortex; HIPP, hippocampus; AMYG, amygdala; HYPO, hypothalamus; THAL, thalamus; SS CTX, 
somatosensory cortex; SN, substantia nigra; PAG, periaqueductal gray; CBLM, cerebellum. 
[3H]CP55,940 autoradiography was performed as described in Methods 
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Figure 3.18. [3H]CP55,940 binding values (mean ± SEM) in sampled brain regions (N = 8 per 
group) from βarr2 WT and KO  mice treated 6.5 day with either vehicle or 10 mg/kg THC twice 
daily.. * p < 0.05 versus respective vehicle (Two way ANOVA, Student-Newman Keuls Post-
hoc). SS, somatosensory. [3H]CP55,940 autoradiography was performed as described in Methods 
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Table 3.3 
[3H]CP55,940 binding values in brain tissue sections from βarr2 WT and KO  mice treated 6.5 
day with either vehicle or 10 mg/kg THC twice daily (N = 8 per group). 
 
Brain sections were incubated with 3 nM [3H]CP55,940 as described under Methods. 
[3H]CP55,940 binding values represent the mean ± SEM. p < 0.05 versus respective vehicle 
(Two way ANOVA, Student-Newman Keuls Post-hoc). CG CTX, cingulate cortex; CPU, 
caudate-putamen; GP, globus pallidus; PIR CTX, piriform cortex; HIPP, hippocampus; AMYG, 
amygdala; HYPO, hypothalamus; THAL, thalamus; SS CTX, somatosensory cortex; SN, 
substantia nigra; PAG, periaqueductal gray; CBLM, cerebellum. 
 
 Vehicle THC 
Region WT βarr2-/- WT βarr2-/- 
CPU 2.39 ± 0.36 2.10 ± 0.43 1.76 ± 0.46 2.05 ± 0.38 
CG CTX 1.63 ± 0.29 1.41 ± 0.22 1.22 ± 0.24 1.14 ± 0.13 
GP 5.51 ± 0.86 5.29 ± 0.89 4.90 ± 1.11 4.88 ± 0.72 
HIPP 1.66 ± 0.29 1.48 ± 0.21 1.24 ± 0.28 1.43 ± 0.19 
HYPO 1.75 ± 0.42 1.67 ± 0.23 1.25 ± 0.35 1.27 ± 0.29 
THAL 1.12 ± 0.16 1.17 ± 0.18 1.17 ± 0.26 1.24 ± 0.12 
AMYG 1.77 ± 0.40 1.72 ± 0.24 1.20 ± 0.30 1.64 ± 0.22 
SS CTX 1.57 ± 0.27 1.57 ± 0.25 1.23 ± 0.22 1.23 ± 0.16 
SN 5.66 ± 0.80 5.52 ± 0.82 5.28 ± 1.09 5.15 ± 1.07 
PAG 1.76 ± 0.37 1.47 ± 0.21 1.21 ± 0.27 1.51 ± 0.30 
CBLM 3.18 ± 0.46 2.63 ± 0.40 1.74 ± 0.32* 2.80 ± 0.36 
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3.7 Discussion 
 The overall finding of this study is that βarr2-mediated CB1 receptor adaptation following 
chronic THC treatment occurs in a region-specific manner, which was also reflected in 
differential effects on tolerance. Deletion of βarr2 resulted in the loss of desensitization in the 
cerebellum, rostral PAG, and spinal cord. In addition, CB1 receptor downregulation occurred in 
only the spinal cord and cerebellum, and was attenuated in βarr2 KO animals following chronic 
THC treatment. Whole-brain analysis using SPM revealed that other brain regions retained the 
ability to desensitize in βarr2 KO animals following chronic THC treatment, suggesting other 
potential regulatory mechanisms either compensating for the absence of βarr2 or serving as the 
primary mediator of desensitization in these specific populations of neurons. For example, the 
hippocampus, amygdala, and rostral PAG retained the ability to desensitize to chronic THC 
treatment despite the absence of βarr2. Interestingly, desensitization was found in the 
hypothalamus and almost all examined cortical regions of βarr2 KO, but not WT animals. 
Further, a greater magnitude of desensitization was noted in the caudal hippocampus and 
amygdala of βarr2 KO animals. Regional differences in βarr2-mediated CB1R adaptation were 
associated with differential effects on tolerance, where THC-mediated antinociception, but not 
catalepsy or hypothermia, was attenuated in βarr2 KO mice. These results demonstrate not only 
inter-regional, but intra-regional differences in the involvement of βarr2-mediated regulation of 
CB1 receptor signaling.  
 Deletion of βarr2 resulted in a region-specific loss in desensitization of CB1 receptor-
mediated G-protein activity after chronic administration of THC. This occurred in the 
cerebellum, caudal aspects of the PAG, and spinal cord of βarr2 KO animals. This is consistent 
with previous reports in cell models demonstrating that desensitization of CB1 receptor-mediated 
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activation of Kir3 channels is dependent on both G-protein receptor kinase 3 (GRK3) and βarr2 
(Jin et al., 1999). In addition, other reports have shown decreases in the rate and extent of 
desensitization of various GPCRs in cells with reduced concentrations of β-arrestin (Mundell and 
Benovic, 2000; Mundell et al., 1999), and conversely augmentation of desensitization following 
overexpression of β-arrestin (Pippig et al., 1993). Results from studies in cell models thus 
demonstrate that when in proximity with other important components of the desensitization 
machinery (i.e. GRKs), βarr2 plays an important regulatory role in the desensitization of 
receptors following persistent stimulation with an agonist. Mechanistically, this may also have 
important implications regarding the development of tolerance. In this study, βarr2 KO mice 
exhibited an attenuation in tolerance to THC-mediated antinociception, which is related to the 
loss in CB1 receptor desensitization in the spinal cord and caudal PAG and loss of 
downregulation in the spinal cord. These are two brain areas that serve important functions in 
modulating the perception of pain (Lichtman et al., 1996).  
 The hippocampus, amygdala, rostral PAG, and lateral entorhinal cortex, were brain areas 
where desensitization occurred in both genotypes following chronic THC treatment. The finding 
that desensitization of CB1 receptor-mediated G-protein can still occur despite deletion of βarr2, 
suggests that other mechanisms may be present. One possibility is the involvement of the other 
non-visual arrestin isoform, βarr1, which shares structural similarity (78% amino acid homology) 
and has a very similar anatomical distribution as βarr2 (Attramadal et al., 1992; Gurevich et al., 
2002). In addition, the expression of βarr1 exceeds βarr2 by two to three fold in the CNS 
(Gurevich et al., 2002). Knockout of either βarr1 or βarr2 results in a viable phenotype, whereas 
the deletion of both isoforms is embryonic lethal (Kohout et al., 2001). This suggests that either 
isoform can substitute for the other, however emerging data (reviewed in (DeWire et al., 2007)) 
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and results in this study indicate that they may not completely substitute, since CB1 receptor 
desensitization was not present in all examined brain regions.  
  Unexpectedly, CB1 receptor-mediated G-protein activity was desensitized in the 
hypothalamus and cortical regions, including the cingulate, piriform, auditory/visual, and 
somatosensory cortex, of βarr2 KO animals but not WT animals. In some instances, 
desensitization was greater in magnitude in particular brain regions in βarr2 KO compared to 
WT, such as the caudal extent of the hippocampus and amygdala. Thus it appears that deletion of 
βarr2 enhanced CB1 receptor desensitization in these particular brain areas. It's interesting to note 
that the relative abundance of βarr2 is highest and overlaps the expression profile of CB1 
receptors in areas such as the hypothalamus, amygdala, and cortex (Gurevich et al., 2002), 
suggesting a potential association between deletion of βarr2 and the observed enhancement of 
desensitization. One possible explanation is that under normal conditions, βarr2 may shift the 
population of CB1 receptors toward an inactive state, such that in its absence, the available pool 
of functional CB1 receptors are increased. In fact, studies in HEK-293 cells showed that 
constitutively active CB1 receptors undergo constitutive endocytosis and recycling to the 
membrane, with a substantial proportion of CB1 receptors localized in intracellular vesicles 
(Leterrier et al., 2004). A subsequent report later showed that this constitutive endocytosis was 
required for the proper axonal targeting of CB1 receptors in hippocampal neurons (Leterrier et 
al., 2006), indicating an important functional role for the constitutive endocytosis and recycling 
of CB1 receptors. In other GPCRs, constitutively active mutant isoforms of the 5HT2C serotonin 
receptor also displayed constitutive endocytosis that was βarr2 dependent (Marion et al., 2004).  
 If deletion of βarr2 results in an overall increase in the population of functional CB1 
receptors, this may possibly increase the apparent efficacy of an agonist. Potential increases in 
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the apparent efficacy of cannabinoids in βarr2 KO animals suggest an involvement of βarr2 in 
the acute regulation of CB1 receptor signaling. Such increases in the apparent efficacy of an 
agonist may result in an increase in the magnitude of desensitization. Interestingly, Breivogel et. 
al. found that acute treatment with THC produced greater decreases in body temperature and 
antinociception in βarr2 KO versus WT mice (Breivogel et al., 2008). This enhancement in the 
sensitivity of THC was not replicated by other structurally different classes of cannabinoids, 
including the bicyclic analogue CP55,940, metabolically stable synthetic endocannabinoid 
derivatives methanandamide and O-1812, and the aminoalkylindole JWH-073. This suggests a 
possible ligand-specific sensitivity to some cannabinoid in vivo effects. Similarily, previous 
reports utilizing βarr2 KO mice showed greater morphine-mediated hypothermia and enhanced 
analgesia, with associated increases in µ-opioid receptor-mediated G-protein activation produced 
by the selective µ-opioid receptor agonist [D-Ala2, MePhe4, Gly5-ol]enkephalin (DAMGO) 
(Bohn et al., 1999). Follow up studies also found ligand-specific prolonged and enhanced 
antinociceptive responses in βarr2 KO mice upon administration with equipotent doses of 
morphine and the structurally similar agonist heroin, but not upon administration with etorphine, 
fentanyl, or methadone (Bohn et al., 2004). Paradoxically, the lower efficacy µ-opioid receptor 
agonists morphine and heroin generally do not promote receptor internalization yet produces 
rapid development of tolerance (Finn and Whistler, 2001; Zhang et al., 1998). Similarily, low 
efficacy cannabinoid agonists such as anandamide and THC induce little internalization 
compared to higher efficacy cannabinoid agonists such as WIN, CP, HU210, and 2-AG, which 
promote more rapid and greater internalization (Hsieh et al., 1999; Wu et al., 2008). In the 
current study, although both genotypes displayed relatively equal degrees of tolerance to THC-
mediated hypothermia, significant differences between the genotypes were found within the 
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vehicle treated groups. Specifically, vehicle treated βarr2 KO animals produced a greater 
decrease in body temperature compared to WT animals when tested with THC, consistent with 
results by Breivogel and colleagues (Breivogel et al., 2008). This may also be related to the 
observation of desensitization in βarr2 KO but not WT animals in the hypothalamus, which is a 
brain area that likely mediates the hypothermia effects of THC. One possibility is that the 
increase in apparent efficacy of cannabinoid agonists within the hypothalamus of βarr2 KO mice 
may unmask desensitization in this brain region, whereas in the wild-type animals reduction in 
stimulated G-protein activity was only moderate following the current treatment paradigm. 
Vehicle treated βarr2 KO animals also had greater CP-stimulated G-protein activity compared to 
WT animals in other brain regions including the hippocampus and cortex, indicating that deletion 
of βarr2 had enhanced the apparent efficacy of CP in stimulating G-protein activity in these 
particular brain areas. 
  Other mechanisms involving second-messenger dependent kinases may also mediate 
CB1 receptor desensitization and contribute towards the development of tolerance. In one study, 
inhibiting cAMP-dependent kinase (PKA) or Src family tyrosine kinase inhibitor reversed THC-
induced antinociceptive tolerance (Lee et al., 2003). Further, no effects were seen when 
inhibiting other kinases, including protein kinase C (PKC), cGMP-dependent protein kinase 
(PKG), GRK inhibitor, and phosphatidylinositol-3 kinase (PI3-K), indicating involvement of 
specific kinases in the development of THC-mediated antinociception. The  involvement of PKA 
in mediating antinociceptive tolerance is supported by the fact that there is an enhanced 
activation of the cAMP pathway in brain regions of animals tolerant to the analgesic effect of 
THC (Rubino et al., 2000). In a related study, inhibition of PKA reversed tolerance to THC-
induced antinociception, catalepsy, and hypoactivity, but not hypothermia (Bass et al., 2004). 
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The differential effects on cannabinoid tolerance from PKA inhibition suggests involvement of 
distinct signaling pathways in different neuronal populations. Interestingly, reversal of tolerance 
to hypoactivity occurred as early as after 1.5 day treatment with THC, whereas for 
antinociceptive tolerance reversal was apparent after the 6.5 day treatment time point (Bass et al., 
2004). The differences in the time course of these two behavioral measures indicate that the 
relative contribution of PKA in mediating tolerance may vary among different neuronal 
populations. For example, brain regions involved in pain sensation may predominately involve 
PKA at a later time point compared to regions subserving motor function in the development of 
tolerance. Other studies have noted increased basal levels of cAMP and PKA activity in 
membrane homogenates of striatum, cortex, and cerebellum following chronic administration of 
THC (Rubino et al., 2000), further suggesting an involvement of PKA during the development of 
cannabinoid tolerance. 
 Emerging evidence suggests that phosphorylation-independent mechanisms may also 
contribute to the regulation of GPCR function (reviewed in (Ferguson, 2007)). In a recent report, 
GRK2-mediated desensitization and internalization of mGluR5 in striatal neurons occurred 
independently of receptor phosphorylation, and rather via GRK2 RH domain interactions with 
Gαq/11 binding (Ribeiro et al., 2009). GRK2 is highly abundant throughout the CNS and is the ost 
highly expressed GRK isoform in the brain (Arriza et al., 1992). The anatomical co-distribution 
of CB1 receptors and GRK2, as well as the subcellular localization of GRK2 in the cytoplasm 
and presynaptic axon terminals (Arriza et al., 1992), suggest that these two proteins may 
colocalize and that GRK2 may serve a function in the regulation of CB1 receptor signaling. This 
is supported by evidence demonstrating that presynaptic expression of a dominant negative 
GRK2 reduced desensitization of WIN55,212-2-induced presynaptic inhibition of glutamatergic 
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neurotransmission in rat hippocampal neurons (Kouznetsova et al., 2002). Further, GRK2 
expression is particularly high in regions such as the hippocampus (Murga et al., 1998), which in 
the current study was a brain region that demonstrated desensitization of CB1 receptor-mediated 
G-protein activity (particularly pronounced in the more caudal extent) despite the absence of 
βarr2. In addition, GRK2 is also abundant throughout the cortex (Arriza et al., 1992). Although 
the THC treatment paradigm used in this study did not produce desensitization in almost all 
cortical regions examined (except lateral entorhinal cortex) in WT animals, desensitization was 
apparent in βarr2 KO animals. It is possible that GRK2-dependent regulatory mechanisms 
become more prominent following THC treatment in the absence of βarr2. 
 In this study we have demonstrated region-specific differences in the involvement of 
βarr2 in the regulation of CB1 receptor adaptations following chronic administration of THC. In 
the absence of βarr2, CB1 receptors in βarr2 KO animals still retained the ability to desensitize 
and downregulate in specific brain areas, suggesting that additional signaling pathways may also 
contribute towards its regulation. Moreover, deletion of βarr2 did not attenuate any acute effects 
of THC, suggesting that it does not mediate THC-induced effects including antinociception, 
hypothermia, and catalepsy. Involvement of multiple regulatory pathways in different neuronal 
populations illustrates the complexity and fine tuning of CB1 receptor signaling. Diverse 
regulation of CB1 receptor signaling among highly distinct anatomical brain regions, further 
support the importance of performing an anatomically inclusive analysis of CB1 receptor 
signaling and the power of utilizing a whole-brain unbiased analytical approach. Investigating 
the complete regulation of CB1 receptor signaling within various anatomical contexts will further 
facilitate our understanding of the neuromodulatory role of CB1 receptors as well as provide 
153 
 
exciting therapeutic avenues in the design of drugs for the selective enhancement and/or 
attenuation of tolerance development of specific cannabinoid-mediated effects. 
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VII. Conclusion and Perspectives 
 
 In the preceding studies we proposed that regional-differences in the acute and chronic 
signaling of CB1 receptors reflect differences in its regional regulation, and that this specificity 
would be revealed using a novel whole-brain unbiased approach. This was successfully 
accomplished by adapting Statistical Parametric Mapping (SPM) to study CB1 receptors in 
reconstructed mouse brain images derived from autoradiographic data, which previously has not 
been described. Using this approach to investigate the acute signaling properties of CB1 
receptors, regional differences in the relative efficacy of cannabinoid agonists were 
demonstrated. In addition, the aminoalkylindole WIN55,212-2 (WIN), activated G-protein 
coupled non-CB1/2/GPR55 sites in specific brain regions that partially overlapped with CB1 receptor 
containing regions. Moreover, the presence of these putative novel sites in brainstem nuclei, 
including the lateral dorsal tegmental nuclei and locus coeruleus, suggest a possible role in 
regulating the release of neurotransmitters such as acetylcholine and norepinephrine, 
respectively. Regional differences in the relative efficacy of cannabinoid agonists to produce 
CB1 receptor-mediated G-protein activation suggests unique signaling properties of the CB1 
receptor within various brain areas. This may have important implications regarding the chronic 
regulation of CB1 receptors, as well as the development of cannabinoid tolerance, particularly if 
the contribution of different regulatory mechanisms has regional-specificity. Another possible 
explanation for regional differences in CB1 receptor regulation is the co-localization of CB1 
receptors with specific signaling or regulatory proteins. This question was investigated by 
examining the role of  β-arrestin-2 (βarr2) on CB1 receptor adaptation using a βarr2 knockout 
(KO) mouse model. Interestingly, studies using βarr2 KO animals showed that involvement of 
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βarr2 in the regulation of CB1 receptor adaptations, including desensitization of receptor-
mediated G-protein activity and downregulation of CB1 receptors, have regional-specificity as 
well. Deletion of βarr2 resulted in a loss of desensitization in the cerebellum, caudal PAG, and 
spinal cord, with a corresponding attenuation in THC-mediated antinociception. However in 
regions such as the amygdala and rostral hippocampus, desensitization was found in both 
genotypes and did not differ in magnitude. Unexpectedly, in regions such as the hypothalamus, 
caudal hippocampus, and cortex, desensitization appeared to be enhanced in βarr2 KO mice. CB1 
receptor downregulation was found only in the cerebellum and spinal cord of wild-type mice 
after chronic treatment with THC, and this was lost in βarr2 KO mice. Tolerance to THC-
mediated catalepsy and hypothermia were further unaffected in the absence of βarr2.. 
Collectively, these results in βarr2 KO mice suggest that βarr2 may play a role in the regulation 
of CB1 receptor signaling in specific brain areas, whereas in other brain regions different 
mechanisms of regulation may exist with anatomical and perhaps temporal specificity.  
 Regional differences in the signaling and regulation of CB1 receptors is not perhaps 
surprising, given the highly diverse cellular architecture, and its co-localization and interaction 
with various signaling components. From a biological and signaling perspective, this might be 
expected for a highly abundant GPCR in the CNS that has an important neuromodulatory 
function in the fine tuning and physiological action of other receptor systems. Due to the high 
degree of interaction of CB1 receptors with other functionally distinct receptor systems, complex 
and overlapping pathways likely exist to regulate and fine-tune cannabinoid-mediated signaling.  
 Studies in CB1 KO mice demonstrated that non-CB1/2/GPR55 sites exhibited a unique 
pharmacology and neuroanatomical localization. One important question is the functional 
relevance of non-CB1 sites. For example, given the anatomical localization and systems 
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connectivity of non-CB1/2/GPR55 sites in the cortex and its afferent projections from the locus 
coeruleus and amygdala, one hypothesis is that these putative novel cannabinoid sites may 
modulate behaviors such as attention or emotional learning. Another unanswered question is the 
potency and efficacy of WIN at non-CB1/2/GPR55 sites revealed by SPM analysis. Thus, full 
concentration-effect curves using WIN or structurally similar agonists in these specific regions is 
needed. Perhaps most important would be the molecular identification and cloning of this 
putative novel cannabinoid receptor, which might be assisted by results in this dissertation 
mapping the functional distribution of non-CB1/2/GPR55 sites. Identification of "WIN-binding" 
sites, which is probably one of several apparently distinct novel cannabinoid sites, may reveal 
unique physiological roles of the endocannabinoid system and its therapeutic exploitation. 
 SPM analysis revealed a number of interesting observations from chronic THC studies 
using βarr2 KO mice, and results have generated multiple questions regarding the regulation of 
CB1 receptor signaling. For example, to what extent is βarr1 involved in mediating CB1 receptor 
adaptations to chronic THC treatment? Do second-messenger dependent kinases contribute to the 
development of tolerance of some THC-mediated effects, and if so can it be reversed in βarr2 
KO mice if we disrupted these kinase-dependent pathways? What is the time course of action for 
adaptation through other putative regulatory mechanisms in βarr2 KO mice and how does it vary 
by brain region? Interestingly, deletion of βarr2 resulted in an enhancement of desensitization in 
areas such as the hippocampus. What role does βarr2 play in learning and memory? These are a 
few important and exciting questions that will further our understanding of the regulation of CB1 
receptor signaling. 
 Whole-brain based analytical approaches are not only important to the study of CB1 
receptor signaling, but other receptor systems as well. Voxel-based analyses provide an 
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unprecedented level of anatomical precision, which is highly suitable for answering questions 
and investigating the nature of receptor signaling among various distinct populations of neurons. 
Doing so may potentially give important insight as to the physiological function and role of 
receptors and/or their signaling proteins. This is particularly advantageous for the cannabinoid 
system due to its neuromodulatory role and widespread abundance throughout the CNS. In 
addition, this paradigm allows an important translation of knowledge gained from mechanistic 
studies in well defined cellular systems into different anatomical contexts within the brain. Such 
an approach can be termed "Functional Anatomics", inspiring the next step in the study of 
biological systems. Fundamentally speaking, this concept is similar to other large-scale data 
mining paradigms including proteomics, functional genomics, lipidomics, bioinformatics, etc. 
One interesting idea would be the integration of gene expression databases, such as the Allen 
Brain Atlas, to identify potential interactions or involvement of specific proteins, for example 
based on their overlapping subcellular localization in different brain regions. 
 Understanding the relationship between structure and function within the human brain as 
well as the integration of distinct neuronal populations has historically been a challenging effort. 
Yet, accumulating evidence of receptor functional selectivity further points to the importance of 
understanding the regulation of signal transduction within various anatomical contexts. Studies 
in this dissertation demonstrated regional specificity in the acute and chronic signaling and 
regulation of CB1 receptors in the reconstructed mouse brain. These results not only highlight the 
importance of performing an anatomically inclusive analysis, but suggest that mechanisms of 
CB1 receptor signaling and regulation are diverse among different neuronal populations. This has 
extremely important implications in regard to understanding the cannabinoid system in relevance 
to human health and disease, as well as the potential design of cannabinoid-based therapeutics to 
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maximize clinical efficacy and minimize their side effects. It is important to note that repeated 
use of cannabinoids for management of chronic clinical conditions, such as multiple sclerosis, 
pain, etc., is susceptible to the development of tolerance, and possibly dependence and addiction. 
Because of diverse CB1 receptor regulatory mechanisms among various brain regions, tolerance 
is likely to develop differentially for various cannabinoid-mediated effects with respect to 
relative magnitude, and to its onset and duration following cessation of cannabinoid 
administration. Lastly, understanding the regional regulation of CB1 receptor signaling may 
allow better insight into the possibility of thwarting tolerance to the desired therapeutic effects of 
cannabinoids. 
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VIII. Appendix 
 
This section contains supplementary thesis data from various collaborative studies. The reader is 
referred to the primary reference of each study for further details when appropriate. Supporting 
information for thesis chapters are also included.  
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Figure A1. Regional changes in cannabinoid agonist-stimulated [35S]GTPγS binding following  
chronic disruption of MAGL by the MAGL inhibitor JZL 184. (Top) Representative 
autoradiograms showing CP55,940-stimulated [35S]GTPγS binding in coronal brain sections 
following either chronic vehicle (left column) or JZL 184 (right column) treatment. Pseudocolor 
images indicate levels of receptor-mediated G-protein activity and highlight significant decreases 
in CB1 receptor activation in the cingulate cortex (CG CTX, row 1), hippocampus (HIPP, row 2) 
and periaqueductal gray (PAG, row 3), while no differences are apparent in the caudate-putamen 
(CPU, row 1) or cerebellum (CBLM, row 4). Colors correspond to a quantitative scale depicting 
[35S]GTPγS binding values (nCi/g). Line cartoons in the rightmost column are shown for 
anatomical reference and areas shaded in gray are sampled regions of interest (Bottom) 
Densitometric analysis of CP55,940-stimulated [35S]GTPγS binding in selected brain regions, 
including: cingulate cortex (CG CTX), caudate putamen (CPU), globus pallidus (GP), preoptic 
area of the hypothalamus (POA), hippocampus (HIPP), amygdala (AMYG), hypothalamus 
(HYPO), somatosensory cortex (SS CTX), substantia nigra (SN), periaqueductal gray (PAG), & 
cerebellum (CBLM). Data are presented as means ± SEM (N = 8 per group, sampled in triplicate 
slices for each targeted region). * p < 0.05, ** p < 0.01, *** p < 0.001 versus vehicle treatment 
for specific region (Student's t-test). 
Work in collaboration with Dr. Liu’s laboratory (Medical College of Wisconson), Dr. 
Lichtman’s laboratory (Virginia Commonwealth University), and Dr. Cravatt’s laboratory 
(Scripps Research Institute).  
Source: Chronic monoacylglycerol lipase blockade causes functional antagonism of the 
endocannabinoid system. J.E. Schlosburg, J.L. Blankman, J.Z. Long, D.K. Nomura, B. Pan, S.G. 
Kinsey, P.T. Nguyen, D. Ramesh, L. Booker, J.J. Burston, E.A. Thomas, D.E. Selley, L.J. Sim-
Selley, Q. Liu, A.H. Lichtman, B.F. Cravatt. 2010. In press, Nature Neuroscience. 
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Figure A2. Statistical Parametric Mapping (SPM) reveals greater CB1 receptor-mediated activity 
in epileptic animals versus controls in discrete forebrain regions.  SPM analysis illustrates 
regions with significantly greater net WIN55,212-2-stimulated [35S]GTPγS binding in epileptic 
rats when compared to control.  Representative coronal sections (top panel) and volumetric 
rendered images (bottom panel) illustrate the spatial extent of differences in magnitude of G-
protein activation shown as colored overlays (red to yellow) that correspond to significance 
level.  Fr1-3 (frontal cortex, areas 1-3), I (insular cortex), Cg1-2 (cingulate gyrus, areas 1-2), 
CPu (caudate putamen), FL (forelimb cortex), S (septum), Par (parietal cortex), HL (hindlimb 
cortex), LD (laterodorsal thalamic nucleus), VL/M (ventrolateral/medial thalamic nuclei), Te 
(temporal cortex), hippocampal area CA3, DLG (dorsal lateral geniculate nucleus), VLG (ventral 
lateral geniculate nucleus), MG (medial geniculate nucleus), VPM/L (ventral 
posterolateral/medial thalamic nuclei). 
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Figure A3. Statistical Parametric Mapping (SPM) reveals increases in CB1 receptors in discrete 
forebrain regions of epileptic animals versus controls.  SPM analysis illustrates regions with 
greater total [3H]WIN55,212 binding in epileptic rats when compared to control.  Representative 
coronal sections and volumetric rendered saggital and transverse images illustrate the spatial 
extent of differences in magnitude of CB1 receptor binding shown as colored overlays (red to 
yellow) that correspond to significance level.  Fr1-3 (frontal cortex, areas 1-3), I (insular cortex), 
Cg1-2 (cingulate gyrus, areas 1-2), CPu (caudate putamen), FL (forelimb cortex), S (septum), 
Par (parietal cortex), HL (hindlimb cortex), LD (laterodorsal thalamic nucleus), VL/M 
(ventrolateral/medial thalamic nuclei), Te (temporal cortex), hippocampal area CA3, DLG 
(dorsal lateral geniculate nucleus), VLG (ventral lateral geniculate nucleus), MG (medial 
geniculate nucleus), VPM/L (ventral posterolateral/medial thalamic nuclei). 
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Table A1. Region of interest (ROI) analysis reveals increases in specific [3H]WIN55,212 
binding and net WIN55,212-stimulated [35S]GTPγS binding in forebrain regions of epileptic 
animals.  ROI analysis was conducted and compared to SPM to evaluate increases in [35S]GTPγS 
binding observed in epileptic animals.  Overall, several regions were confirmed using ROI 
analysis, such as the stratum radiatum of the hippocampus, whole thalamus, and caudate 
putamen. * p < 0.05, Student’s two-sample t-test. 
 [3H]WIN binding (nCi/mg) Net [35S]GTPγS binding (nCi/g) 
Region Control Epileptic Control Epileptic 
Whole Hippocampus 2.10 ± 0.35 2.80 ± 0.23 290 ± 39 370 ± 26 
Stratum Radiatum 1.92 ± 0.32 3.33 ± 0.35* 366 ± 38 513 ± 28* 
Whole Thalamus 0.50 ± 0.15 1.04 ± 0.18* 130 ± 21 239 ± 28* 
Cerebellum Mol Layer 4.30 ± 0.72 4.38 ± 0.42 409 ± 43 436 ± 24 
Substantia Nigra 5.20 ± 1.00 5.04 ± 0.67 789 ± 43 754 ± 50 
Caudate Putamen 1.37 ± 0.20 2.40 ± 0.32* 293 ± 46 436 ± 19* 
Globus Pallidus 4.39 ± 0.84 5.70 ± 0.87 969 ± 55 736 ± 51* 
Cingulate Cortex 1.52 ± 0.23 2.33 ± 0.27* 354 ± 44 236 ± 53 
Periaqueductal Gray 0.62 ± 0.15 0.80 ± 0.11 173 ± 31 58 ± 15* 
Deep (HL) Cortex 1.30 ± 0.29 3.55 ± 0.28* 396 ± 45 506 ± 42 
Entorhinal Cortex 0.86 ± 0.10 1.53 ± 0.21* 464 ± 72 329 ± 51 
 
 
 
Data presented in Figures A2 and A3, and Table A1 were done in collaboration with Dr. 
Falenski in Dr. DeLorenzo’s laboratory (Virginia Commonwealth University).  
Source: Statistical Parametric Mapping of the Regional Alterations in Cannabinoid CB1 Receptor 
Expression, Binding, and G-Protein Activation in the 3D Epileptic Rat Brain. Falenski KW, 
Nguyen PT, Sim-Selley LJ, DeLorenzo RJ. 2010. Manuscript in preparation.  
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Table A2. Internet links to downloadable analytical software and resources on brain imaging 
 
Software  
ImageJ http://rsbweb.nih.gov/ij/ 
ImageJ is a multi-operating system (MAC, PC, Linux) image analysis 
suite with an online library of plugins that are created and updated by an 
extensive user base. 
MRIcro/MRIcron http://www.cabiatl.com/mricro/ 
MRIcron (MRIcro is the original older name) is a free brain imaging 
viewer that has 3D rendering capabilities, region/volume of interest 
creation, and image header viewing/editing functions. MRIcron can also 
overlay results from SPM analyses (i.e. SPM statistical maps) onto 
reference brain images 
Spamalize http://brainimaging.waisman.wisc.edu/~oakes/spam/spam_frames.htm 
Image viewer that has 3D volumetric rendering capabilities. Requires 
the program IDL 
SPM http://www.fil.ion.ucl.ac.uk/spm/ 
Statistical Parametric Mapping (SPM) homepage also includes 
documentation, bibliography, and links to download the free software 
(requires the program Matlab). 
Documentation  
Brain imaging wikis http://imaging.mrc-cbu.cam.ac.uk/imaging/CbuImaging 
Wiki on image preprocessing, SPM beginner tutorials and 
documentation 
 
http://en.wikibooks.org/wiki/SPM 
Another SPM wiki 
SPM Forum https://www.jiscmail.ac.uk/cgi-bin/webadmin?A0=spm 
SPM community forums 
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